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The Nuclear Export of DNA Topoisomerase IIα as a  
Function of Drug Resistance in Human Myeloma Cell Lines:  
Clinical Implications and Mechanisms for Overcoming Drug Resistance 
Roxane Engel 
ABSTRACT 
 The focus of this investigation is about DNA topoisomerases, the molecular 
targets of clinically important chemotherapy, and mechanisms of drug resistance in 
human myeloma and leukemia cell lines.  The ultimate goal of this investigation was to 
identify mechanism(s) of drug resistance to anticancer agents so that a strategy to 
overcome drug resistance could be conceived.  We established an in vitro cell model by 
using human leukemia and myeloma cell lines to investigate possible mechanisms of 
drug resistance that are observed in confluent cells.  Plateau cell densities demonstrated 
de novo drug resistance to commonly used chemotherapeutic agents that was independent 
of altered drug transport.  We established that cellular drug resistance in these cells is a 
function of topo IIα subcellular localization and further demonstrate that topo IIα 
translocates to the cytoplasm in a cell-density dependent manner.  We provide 
experimental data that supports the nuclear export of topo IIα as the most likely event 
contributing to drug resistance to topoisomerase II inhibitors, which occurs when 
transformed cells transition from log to plateau cell density.  We provided a plausible 
nuclear export pathway for topo IIα, by identifying two 
 xv
Leptomycin B sensitive nuclear export signals, which are homologous to the binding sites 
recognized by the nuclear export receptor, exportin-1.  Thus, topo IIα is likely to be 
exported from the nucleus at plateau cell densities when exportin-1 binds topo IIα.  We 
confirmed that the nuclear export signals identified in topo IIα are functional when 
expressed in human myeloma cells transfected with an epitope-tagged topo IIα gene.  
Furthermore we demonstrate that the nuclear export signals can be abolished by site-
directed mutagenesis of specific amino acids residues found in the nuclear export signal.  
Our data may have clinical relevance because plasma cells obtained from bone marrow 
aspirates of patients with multiple myeloma contain a cytoplasmic distribution of topo 
IIα.   The potential implications of a functioning nuclear enzyme located in the cytoplasm 
of cells and theoretical mechanisms for overcoming the observed drug resistance are 
considered. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 1
Chapter One 
Introduction 
 
1.1 Cancer Trends and Statistics. 
 Cancer is the second leading cause of death in the United States, exceeded only 
by heart disease (American Cancer Society, 2005).  Increased life expectancy, 
environmental factors, genetics, and socio-economic issues can all contribute to the 
emergence of cancer around the world (Knudson, 2002; Doll, 1996).  According to the 
American Cancer Society (ACS), approximately 1,368,030 new cancer cases will have 
been diagnosed in the year 2004 and 563,700 Americans are expected to have died of 
cancer, more than 1500 people per day.  The ACS anticipates the trend in further cancer 
cases to continue for the year 2005.  The National Institutes of Health also estimate that 
medically related cancer costs will exceed the initial 2004 projection of 200 billion 
dollars (National Institute of Health, 2005).  Preventive measures have been insufficient 
at reducing the incidence of cancer, thus driving numerous medical researchers to seek 
new drugs and drug combinations for more effective cancer treatment.  The sum of these 
investigations has lead to the development of new treatment strategies, promising anti-
cancer agents, and improved quality of life for many cancer patients.  Consider, for 
instance, the recent advancements in the clinical management of multiple myeloma, a 
mostly incurable hematologic malignancy (Morgan and Davies, 2005; Rajkumar et al., 
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2002). For example, the administration of melphalan plus prednisone has been the 
conventional chemotherapy given for the treatment of multiple myeloma (Rajkuman et 
al., 2002).  The overall response rate with this regimen is approximately 50%, but the 
complete response rate is less than 10% and the median survival is approximately 3 years 
(Rajkumar et al., 2002).  High-dose therapy followed by autologous stem cell 
transplantation is a newer treatment strategy for multiple myeloma with improved 
response rates. Response rates with this strategy exceed 75% to 90% and complete 
response rates range from 20% to 40% (Rajkuman et al., 2002).  Despite these 
improvements however, multiple myeloma remains to be a mostly incurable plasma cell 
malignancy with a median survival of 3-4 years (Terpos et al., 2005).  Even when 
conventional therapy or high-dose chemotherapy is administered with autologous stem 
cell transplantation, myeloma patients continue to relapse (Rajkuman et al., 2002). These 
findings can be attributed in large part to unresponsive or drug resistant cellular 
phenotypes at the time of diagnosis or relapse (Yang et al., 2003).  In these instances, a 
detailed understanding of the mechanisms of drug action and a rationale for their 
effective application is required before effective cancer therapy can be delivered.  Thus, 
medical and scientific investigators have combined efforts to analyze the molecular basis 
of cellular drug resistance in the laboratory to improve clinical outcome, often referred to 
as translational or “bench-to-bedside” medicine (Horousseau et al., 2004; Goessel, 2003; 
Fishman and Sullivan, 2001).  A group of enzymes that regulate DNA topology, called 
DNA topoisomerases (topos), are at the center of many of the translational studies that 
are addressing cellular drug resistance in hematological malignancies.  
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 DNA topoisomerases are a key subject in cancer research because these proteins 
are the molecular targets of some of the most commonly used chemotherapy agents in the 
treatment of human cancers.  Topo targeted agents have been used in the effective 
treatment of leukemias, lymphomas, multiple myeloma, breast cancer, and other 
malignancies.  However, their clinical effectiveness is often limited by acquired (after 
drug exposure) or intrinsic cellular drug (before drug exposure) resistance, especially in 
the treatment of multiple myeloma (Valkov and Sullivan, 1997).  Thus, researchers are 
investigating acquired and intrinsic mechanisms of drug resistance at the molecular level, 
to circumvent drug resistance observed in myeloma patients.   
 The focus of this investigation is about DNA topoisomerases, their roles as 
molecular targets of chemotherapy, and mechanisms of cellular drug resistance to 
topoisomerase targeting agents.  The ultimate goal of this investigation was to identify 
mechanism(s) of drug resistance so that a strategy to overcome drug resistance could be 
conceived.  We established an in vitro cell model that demonstrated de novo drug 
resistance to commonly used chemotherapeutic agents.  We determined that the observed 
drug resistance was specific to topoisomerase targeting agents.  We provide experimental 
data that supports the nuclear export of topo IIα as the most likely event contributing to 
drug resistance in our cell model.  We established a plausible nuclear export pathway for 
topo IIα by identifying two Leptomycin B sensitive nuclear export signals, and then 
demonstrate that these signals are functional in human myeloma cells transfected with a 
FLAG tagged topo IIα gene.  Hematological cell lines are used throughout this discussion 
as a cell model for elucidating the role that topoisomerases impart on intrinsic cellular 
drug resistance to anti-cancer agents.  
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1.2 Discussion Points.  
 To appreciate the mechanisms of cellular drug resistance to topo targeting 
cytotoxic agents, several concepts are reviewed.  First, the fundamental concepts for the 
molecular basis of cancer pathogenesis are covered in chapter two followed by a review 
of human DNA topoisomerases, including but not limited to, their structure, function, and 
mechanisms of catalysis.  Chapters four and five depicts the physical biochemistry of 
commonly used anti-cancer agents with particular attention to cytotoxic agents that target 
DNA topoisomerase I and II.  These chapters detail how specific anti-cancer agents exert 
their cytotoxic effects, a subject that is necessary to realize how cells evade drug 
cytotoxicity.  Chapters six and seven cover our current understanding of in vitro and in 
vivo mechanisms of de novo cellular drug resistance related to multiple myeloma.  These 
chapters illustrate many of the challenges that clinicians must overcome for therapy to 
become more effective.  The mechanisms of nuclear-cytoplasmic transport of proteins are 
discussed in chapter eight because the subcellular distribution of proteins between the 
nuclear and cytoplasmic compartments has recently been established as another 
mechanism of regulating protein function.  Finally, the nuclear-cytoplasmic transport of 
topo is revealed as a novel mechanism of cellular drug resistance in human myeloma cell 
lines in chapters eleven through thirteen.  The significance of these findings in the 
clinical environment is assessed and future projections are deliberated. 
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Chapter Two 
Molecular Basis of Cancer Pathogenesis 
 
2.1 What is Cancer? 
 Cancer is not a single disease but rather a group of diseases characterized by the 
proliferation of cells that bypass regulatory checkpoints of the cell-cycle and/or escape 
induction of apoptosis (reviewed in Bocchetta and Carbone, 2004; Bertram, 2000).  In 
general, the proteins responsible for maintaining DNA and the cell cycle can be divided 
into six categories that include: (1)  cytokines/growth factors; (2) growth factor receptors; 
(3)  intracellular signaling molecules; (4) transcription factors; (5) cell-cycle/apoptotic 
regulatory proteins; and (6) proteins that regulate DNA topology and metabolism (i.e., 
DNA topoisomerases).  There is a high degree of cross-talk between proteins of the same 
class and between different classes of proteins, resulting in a network of highly 
synchronized events often referred to as a signal transduction cascade.  Malignant cells 
usually acquire DNA mutations in one or more of these cell cycle or DNA regulatory 
proteins, which gives them growth or proliferative advantages over other cells.  Since 
proteins function as part of a coordinated network with other proteins, even a single gene 
mutation can result in the propagation of additional gene mutations (i.e., if a gene 
mutation occurs in a DNA repair protein) or proliferative advantages (i.e., if a gene 
mutation occurs in a growth factor receptor).  These genetic advantages disrupt the 
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balance between cell proliferation and cell death.  For example, the retinoblastoma 
protein (pRb) is encoded by the RB tumor suppressor gene and regulates the cell cycle by 
arresting DNA replication when DNA damage is present (Sellers, 1997).  Mutations in 
the RB gene occur in 30 to 40% of all human cancers, thus permitting cells with DNA 
damage to divide endlessly (Merck, 2004).  In addition to genetic mutations, tumor cells 
can also influence their microenvironment to favor their survival.  For example, tumor 
cells secrete or promote the secretion of cytokines and growth factors to stimulate 
angiogenesis (Sivridis et al., 2003).  The new blood vessels supply nutrients and 
additional cytokines that continue to activate cell signaling pathways that further tumor 
sustenance. To better illustrate some of the points described above, let us take a closer 
look at one type of cancer, multiple myeloma.  
 
2.2 Cancer Biology of Multiple Myeloma: 
Multiple myeloma is a type of B-cell neoplasm characterized by the slow 
proliferation of well-differentiated plasma cells in the bone marrow (Bhawna, 2003; Ho 
et al., 2002).  Although mature plasma cells are the predominant type of cell found in 
multiple myeloma, pre-B, myeloid and T-cells are coexpressed with the mature plasma 
cell (Barlogie, 1989).  The population of malignant cells is collectively referred to as 
myeloma cells.   
 Multiple myeloma tumor progression is a multistep process that can be described 
to occur in three distinct phases: immortalization, unchecked cell proliferation, and 
dissemination of the malignant plasma cells (Pratt, 2002; Shain et al., 2000). The disease 
may first present as a monoclonal gammopathy of undetermined significance (MGUS), a 
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clinical term used to describe a single plasma cell that has formed a limited number of 
clones (Tricot, 2002; Dalton et al., 2001).  The precise cellular origin is not well 
understood, but is believed to be an immature B-cell that has been repeatedly exposed to 
antigen in the germinal centers of the lymphoid tissue.  The disease advances when the 
transformed cells clonally expand and grow in the bone marrow (intramedullary 
myeloma) (Van Riet et al., 1998).  During this time, the disease is usually chemosensitive 
and may enter a dormant phase (Pratt, 2002).  The myeloma cells receive growth and 
anti-apoptotic signals that facilitate their survival through interactions with the bone 
marrow microenvironment (Dalton, 2003; Shain, et al., 2000).  For example, expression 
of the adhesion receptors, very late antigen-4 (VLA-4) and very late antigen-5 (VLA-5) 
(Hata et al., 1993), permits myeloma cells to bind fibronectin, whereas the expression of 
the β2 integrin lymphocyte function associated antigen-1 allows for cell-cell aggregation 
(Asosingh et al., 2003; Kawano et al., 1991).  Such interactions stimulate the secretion of 
various cytokines from myeloma and stromal cells in the bone marrow microenvironment 
(Klein et al., 2003).  IL-6, the main plasma cell activating factor, stimulates cell 
proliferation via the Ras/Mitogen-activated kinase (Ras/MAPK) signaling cascade 
(Kawano et al., 1988; Ogata et al., 1997).  IL-6 also induces myeloma cell migration and 
angiogenesis via vascular epithelial growth factor (VEGF) induction (Dankbar et al., 
2000).   Advanced disease is distinguished by independence from growth factors in the 
bone marrow microenvironment and proliferation to extramedullary sites (extramedullary 
myeloma) (Pratt, 2002).  Throughout this time, advanced myeloma is characterized by 
resistance to apoptosis and chemotoxic agents (Dalton, 2003).  Understanding the bone 
marrow microenvironment in multiple myeloma disease pathogenesis has had a role in 
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the development of new cytotoxic agents.  For example, bortezomib is the first 
proteasome inhibitor to be evaluated in clinical trials for the treatment of hematological 
malignancies (Adams, 2004; Adams and Kauffman, 2004). 
 
2.3 Conclusions. 
In summary, cancer is a multifaceted disease that is propagated by multiple DNA 
mutations that are acquired via hereditary and natural means.  The gene mutations can 
result in altered cellular homeostasis and confer growth and proliferative advantages.  In 
turn, the collection of proteins that are involved in regulating the cell cycle and DNA 
replication/topology are the frequent targets of anti-cancer drugs (Damiens, 2000).  Thus, 
understanding the proteins involved in the intracellular cell signaling pathways, DNA 
replication/topology, and cell cycle regulation are the cornerstones of cancer research.  
 The focus of this investigation is about DNA topoisomerases, enzymes that 
regulate DNA topology.  We focus on the role of DNA topoisomerases as molecular 
targets of anti-cancer agents and mechanisms of drug resistance.  Although the complete 
family of human DNA topoisomerases is reviewed, the focus of this work centers around 
type II enzymes, topo IIα and topo IIβ, the current targets of cancer chemotherapy.  
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Chapter Three 
Biochemistry of DNA Topoisomerases 
 
3.1 General Introduction to the DNA Topoisomerase Family of Enzymes. 
The human genome consists of approximately 3.2 billion base pairs and would be 
about 2 meters in length, if stretched out from end to end (Porter et al., 2004).  
Nevertheless, DNA squeezes into the nucleus, which is approximately 6 µM in diameter 
(Porter et al., 2004).  For example, the smallest human chromosome is 14 mm long but is 
compacted to just 2 µM in length (Ball, 2003; Greeley, 1978).  Thus, DNA exists in a 
tightly compacted and dense form.  Conversely, DNA must also allow itself to become 
accessible to numerous transcription factors and regulatory proteins to allow gene 
transcription and DNA replication to occur (Khorasanizadeh, 2004).  The ability of DNA 
strands to separate and/or unwind, however, is limited by the torsional constraints of a 
double helix.  DNA topoisomerases are a family of nuclear enzymes that regulate the 
topological state and relieve the torsional stress of the DNA that arise during gene 
transcription, DNA replication, and cell division (Champoux, 2001; Wang, 1996).  DNA 
can become tangled into knots, supercoiled, and form interlocked circles that must be 
resolved by topo action (Figure 1) (Pulleyblank, 1997).  To regulate DNA topology, all 
topo enzymes introduce single- or double strand breaks in DNA to allow another strand 
of DNA or duplex DNA to pass through the newly generated gap (Champoux, 2001).  
Topo activity has been shown to be important during DNA replication, transcription, 
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genetic recombination, sister chromatid segregation, and chromosome condensation and 
decondensation.  For example, the human type I and II topoisomerases relax positive 
supercoils that are generated in front of the moving replication fork. This is significant 
because RNA polymerase generates tension in the DNA that must be relieved for gene 
transcription to occur.  Topo II also has an essential role in the proper execution of DNA 
replication and cell division.  Newly synthesized DNA strands must be completely 
unlinked from the parent strand and every replicated chromosome must be disentangled 
from each other to allow proper segregation of the chromosomes into daughter cells.   
"Molecular Houdini's" and enzymes with a "double-edged sword" are two terms 
that are used to describe DNA topoisomerases because the integrity of DNA is 
susceptible to topo cleavage activity (Osheroff, 1998; Anderson and Berger, 1994).  To 
ensure the integrity of DNA, all DNA breaks generated by topo are accompanied by the 
Figure 1.  Topological Configurations in DNA that are Resolved by Topo. (a)  
Twisting of DNA about its axis results in either positive or negatively supercoiled 
DNA, (b) DNA knots, and  (c) catenated DNA is when two or more circles of 
DNA interlock.  Although the family of topoisomerase enzymes are required for 
DNA replication, recombination, transcription and chromosome segregation, each 
type of enzyme makes different contributions to each process. For example, 
human topo I and II are able to relax supercoiled DNA, but only topo II is 
proficient knotting/unknotting and catenation/decatenation reactions.  This figure 
was reproduced from reference Pulleyblank, 1997.
a. Supercoiled b. Knotted c. Catenated DNA 
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formation of a covalent phosphotyrosine bond that tethers topo to the broken strand of 
DNA while DNA strand passage occurs (Tse et al., 1980).  The covalent topo-DNA 
intermediate, called a "cleavage complex" or a "cleavable complex", is transient and 
freely reversible (Roca and Wang, 1992).  Some anticancer agents exploit the DNA 
cleavage activity of topo to turn these enzymes into molecular toxins (Nitiss and Wang, 
1996).  Thus, there has been considerable interest in topo because they have become the 
molecular targets of some clinically important anticancer agents.   
In summary, DNA topoisomerase enzyme activity is essential for maintaining the 
topology of DNA during many DNA processes, including DNA replication, transcription, 
and chromosome segregation.  DNA topoisomerases have also emerged as important 
molecular targets of anti-cancer agents, especially in hematological malignancies (Wang, 
1987; Zijlstra et al., 1990).  The next topic to be covered describes the nomenclature and 
classification system for the family of DNA topoisomerases.  This will be followed by a 
complete description of each type of human topoisomerases. 
 
3.2 Classification of Mammalian DNA Topoisomerase. 
To date, six different DNA topoisomerases have been identified in humans and 
mice (referred to as topo I, topo II, and topo III, etc) and are classified as either type I or 
II enzymes (Champoux, 2001; Wang, 1996).  The human type I, type II, and type III topo 
enzymes have been distinguished by differences in their gene locus, molecular weights, 
catalytic requirements, mechanism of catalysis, and biological roles (table 1) (Champoux, 
2001; Wang, 1996). Type I enzymes include topo III, topo I, and mitochondrial DNA 
topo I (topo Imt).  All type I enzymes are active as monomers and catalyze transient 
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single strand DNA breaks without ATP.  The type I enzymes can be further distinguished 
as IA or IB enzymes based on more specific differences in their reaction mechanisms.  
For example, the type IA enzymes covalently bind to the 5’-end of the cleaved DNA 
strand while type IB enzymes bind to the 3’-end of the cleaved DNA strand.  
 In contrast to type I enzymes, type II enzymes form dimers and couple double-
strand DNA breaks with ATP hydrolysis.  Type II enzymes have two known isoforms 
referred to as topo IIα and topo IIβ.  Several monoclonal and polyclonal antibodies have 
been used to detect the different enzymes by Western blot and immunohistochemistry. 
Monoclonal antibodies are available for human topo I (Beidler and Cheng, 1995), 
whereas several monoclonal (Kellner et al., 1997; Negri et al., 1993) and polyclonal 
antibodies are available for human topo IIα (Sullivan et al., 1993) and topo IIβ (Austin et 
al., 1995).  One monoclonal antibody has been used to detect topo IIIα expression by 
immunohistochemistry (Lodge, 2000).   
A review covering human type I and type II enzymes ensues.  The type I enzymes 
(i.e., topo Imt, topo I, and topo III) are discussed first, followed by a discussion of the 
type II enzymes (topo IIα and topo IIβ).  The type II enzymes are the focus of the work 
presented here and thus, are discussed in greater detail than the type I enzymes. 
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Table 1.  Characteristics of Human DNA Topoisomerases I, II, and III*  
 Topo I Topo Imt** Topo IIα Topo IIβ  Topo IIIα Topo IIIβ 
Type IB IB IIA IIA IA IA 
Chromosome 20q12-13.2 8q24.3 17q21-22 3q24 17p11.2-12 22q11 
Molecular Weight 
(kDa) 91 60-70  170 180 ~110 ~96 
mRNA (kb) 4.2 nda 6.2 6.5 4.0-7.2 2.8-3.8 
DNA strand 
cleavage single nd
a double double single single 
Covalent 
Intermediate 3' nd
a 5' 5' 5' 5' 
ATP dependence no no yes yes no no 
Cell cycle 
dependence no nd
a yes, maximal in G2/M no nda nda 
Knockout mouse  early embryonic lethal nda presumed lethal perinatal death early embryonic lethal shortened mean life span 
Active site Tyr-723 predicted Tyr-559 Tyr-805 Tyr-821 
predicted  
Tyr-337 
predicted  
Tyr-336 
Location nucleolus nucleoplasm mitochondria 
nucleoplasm 
nuclear matrix 
nucleoplasm 
nucleolus 
nucleusd 
mitochondriad 
isoform I: 
nucleoplasmee 
 
isoform II: 
cytoplasmee 
Intracellular 
Targeting Signal(s) 
1. basic NLSb 
2. acidic NLSc 
3. nucleolarc 
1. mitochondrial* 
 
1. bipartite NLSf 
2. LMB sensitive NESg 
   (in vitro/in vivo) 
1. bipartite NLSf 
2. LMB sensitive NESh,  
    (in vitro, only) 
1. mitochondriald,   
   (in vitro/in vivo) nd
a 
Inhibitors 
topotecan, karenitecin, 
9-nitrocamptothecin, 
camptothecin, CPT-11 
CPT sensitive; 
potential molecular 
target 
VP-16, VM-26, mitoxantrone, m-AMSA, doxorubicin, 
merbarone, daunomycin, ICRF-193, ICRF-187, ICRF-
159, and XK469 (beta specific) 
potential molecular 
target 
potential molecular 
target 
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3.3 Type IB: Human Mitochondrial DNA Topoisomerase I (Topo Imt). 
There are approximately 1000 mitochondria in every mammalian cell (Zhang et 
al., 2004a). Each human mitochondrion contains 5-10 copies of closed circular 
mitochondrial DNA (mtDNA) that has16, 569 base pairs (Moraes, 2001; Anderson, 1981; 
Bibb, 1981).  Human mtDNA encodes 22 tRNAs, 13mRNAs, 12S and 16S rRNA 
(Anderson, 1981).  DNA topo enzyme activity resolves the topological constraints of 
DNA within the mitochondria (Wang et al., 2002).  The human TOP1mt gene is located 
on chromosome 8q24.3 and encodes for a 601 amino acid polypeptide that is highly 
homologous to DNA topo I (Zhang et al., 2001). The protein was identified as 
mitochondrial DNA topo I (topo Imt) because it contains a mitochondrial targeting 
sequence and lacks a nuclear localization signal (Zhang et al., 2001). Topo Imt also has 
different biochemical properties from those of the nuclear enzyme, DNA topo I (Zhang et 
al, 2001).  A MegaBlast search of all National Library of Medicine databases was 
conducted and indicated that only vertebrates contain both mitochondrial and nuclear 
topo I gene (Zhang et al., 2004a).  These results raise the question of how non-vertebrates 
perform mitochondrial DNA metabolic functions. It is possible that one gene encodes 
two polypeptides that are targeted either to the nucleus or to the mitochondria (Zhange et 
al., 2004a).  Current investigations are underway to elucidate gene mutations in 
mitochondrial topo I that could potentiate human disease.  Thus, topo Imt could evolve as 
a new molecular target in the future.  Unless otherwise noted, this discussion will focus 
on nuclear DNA topo I, the current molecular target of anticancer drugs.  
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3.4  Type IB: Human DNA Topoisomerase I (Topo I). 
Eukaryotic topo I was first described in mammalian cells in 1972 (Champoux and 
Dulbecco, 1972).  Although topo I gene knockouts are lethal in mouse models, yeast topo 
I gene knockouts are viable (Champoux, 2001).  The gene for human DNA topo I was 
cloned in 1988 and the complete amino acid sequence of topo I protein is shown in 
Appendix A on page 270 of this manuscript (Juan et al., 1988).  The structure topo I 
includes four functional domains (Figure 2): a highly charged N-terminal domain, a 
conserved core domain and an essential C-terminal domain (Redinbo et al., 1999; Stewart 
et al, 1996).  The C-terminal domain contains the active site tyrosine residue (Tyr723) 
(Eng et al., 1989) and is essential for DNA binding and relaxation in vitro, whereas the 
amino terminal region may have an important role in regulating the cellular localization 
of topo I because it contains the nuclear localization signal (NLS) and nucleolin binding 
site.  Amino acids 150-156 have been shown to be sufficient for nuclear localization 
1 215 636 
COOH 
N-terminal  
domain Core domain Linker domain C-terminal  domain 
Poorly conserved 
Highly charged 
Protease sensitive 
Nuclear Targeting 
Highly conserved 
DNA binding 
Enzyme activity 
Poorly conserved 
Dispensable in vitro 
Conserved 
Active site Tyr-723
H2N 
Figure 2. Structural Domains of Human DNA Topoisomerase I. Topo I has four 
domains: an N-terminal domain ( ) (amino acids 1-215), a core domain ( ) (amino 
acids 215-636), a linker domain ( ) (amino acids 636-713), and a C-terminal domain 
( ) (amino acids 713-765). The most significant properties are described below each 
domain. Figure reproduced from reference (Champoux, 2001). 
713 765
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(D’Arpa et al, 1988), but a second NLS has been identified within amino acids 117-146 
(Mo et al., 2000).  Topo I shows a stable expression throughout the cell cycle (Heck et 
al., 1988).  Topo I is post-translationally modified by phosphorylation (D’Arpa and Liu, 
1995) and ubiquitination (Desai et al., 1997), which may be important for regulating its 
activity, localization or degradation.  Topo I has an important role in transcription, rRNA 
synthesis, DNA replication and transcription initiation and is the specific target for 
camptothecin (CPT) and its derivatives (topotecan and CPT-11) (D’Arpa, 1990).  
 DNA topo I catalyzes transient single strand DNA breaks to relax DNA supercoils 
(reviewed in Wang, 2002).  Topo I is capable of relaxing both negatively and positively 
supercoiled DNA without the presence of a cofactor, but metal cations such as Mg2+ 
stimulate topo I activity (Liu and Miller, 1981).  Figure 3 illustrates the catalytic cycle of 
topo I.  To cleave DNA, topo I catalyzes the transesterfication of the active site tyrosine 
(Tyr-723) to form a 3'-phosphotyrosine covalent enzyme DNA intermediate (D'Arpa et 
al., 1988).  The 3'-phosphotyrosine bond is formed when the O-4 oxygen of tyrosine at 
position 723 (Tyr723) completes a nucleophilic attack on the scissile phosphate in the 
DNA backbone (D'Arpa e al., 1988).  The formation of the 3'-phosphotryosine bond is 
significant because it forms a "proteinaceous" bridge between topo I and DNA, and thus 
ensures the integrity of DNA. The covalent topo-DNA intermediate is also referred to as 
a "cleavage complex" (Pommier, 2003) or "cleavable complex" (Tewey et al., 1984).   
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After DNA unwinding, the reaction reverses when the 5' OH of the cleaved DNA strand 
reattacks the phosphotyrosine residue in a secondtransesterfication reaction.  Under 
normal cellular conditions, topo I cleavage complexes are transient and usually 
undetectable. The steady-state concentration of the covalent 3' phosphotyrosine 
intermediate is kept low because the rate of DNA religation is faster than the rate of 
cleavage (Pommier et al., 2003).  However, topo I cleavage complexes are also produced 
by other endogenous and exogenous factors, such as UV-induced base modifications, 
DNA oxidation by oxygen free radicals, mismatch repair deficiencies, DNA alkylating 
agents, and some anticancer agents (Pommier., 2003; Pourquier and Pommier, 2001).  
Such topo I cleavage complexes can result in DNA damage and cell death, if left 
unrepaired. The objective of some cancer chemotherapy, however, is to capture topo I 
cleavage complexes by administering a drug (ie, a DNA topo I inhibitor) that traps topo I 
on DNA in a cleaved form (Nitiss and Wang, 1996).   
 
3.5  Type IA: DNA Topoisomerase III. 
 The gene for eukaryotic DNA topo III was discovered in 1989 (Wallish et al., 
1989) and later identified in humans on chromosome 17p11.2-12 (Hanai et al., 1996).  
There are two topo III homologues that are expressed in mammalian cells, topo IIIα and 
topo IIIβ, and each of these has isoforms generated by alternative mRNA splicing (Seki 
et al., 1998).  Human topo IIIα has a putative mitochondrial targeting sequence and 
localizes to both the nucleolus and mitochondria (Wang et al, 2002).  In contrast, human 
DNA topo IIIβ is found only in the nucleus (Kobayashi and Hanai, 2001).  Both topo IIIα 
and IIIβ can relax negatively supercoiled DNA, but the biological functions of the 
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different topo III enzymes have not been determined (Goulaouic et al., 1999).  Yeast 
studies demonstrate that Top3 gene mutants grow very slowly, display 
hyperrecombination and have defects in meiotic recombination (Gangloff et al., 1999).  
Furthermore, targeted disruption of the mouse topo IIIα gene shows that topo IIIα 
expression is essential in early embryogenesis (Li and Wang, 1998).  Topo III gene 
expression occurs in multiple somatic tissues and is differentially regulated during 
different developmental stages, which is associated with binding of the upstream 
stimulatory factor-2 (USF-2) to an E-box element located in the topo III gene promoter 
(Han et al., 2001).  The YY1 transcription factor may also have a role as a cell type 
specific topo III transcriptional activator (Park et al., 2001).  
Both topo IIIα and IIIβ interact with the RecQ/SGS1 family of DNA helicases, 
which has been shown to occur in yeast and Escherichia coli (Kim et al., 1998).  It has 
been suggested that RecQ helicases may function to recruit two molecules of topo III to 
DNA structures during genetic recombination to facilitate the cleavage and passage of 
double strand DNA (Park et al., 2001).  Human topo IIIα is shown to associate with the 
Bloom syndrome protein (BLM), another member of the RecQ family of DNA helicases, 
in somatic and meiotic human cells (Shimamoto et al., 2000).  A mutation in the BLM 
gene is associated with Bloom’s syndrome, a rare genetic disorder that is associated with 
hyperrecombination between sister chromatids and increased propensity for cancer (Ellis 
et al., 1995).  An association of human topo IIIα with BLM could be significant in 
regulating the frequency and fidelity of recombination events by either disrupting nascent 
joint molecules or by regulating the migration of Holiday structures (Harmon et al, 1999).  
Thus, topo III may have a role as a tumor suppressor gene, but additional investigations 
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are necessary to further elucidate its role in recombination and suppression of cancer. 
Furthermore, defining the physiological roles of topo III enzymes could lead to the 
development of new anti-cancer agents that specifically target these enzymes. 
 
3.6 Conclusions to Topoisomerase I.  
 In summary, type I enzymes cleave single strand DNA in an ATP independent 
manner. Topo Imt and topo III are two of the most recent type I enzymes to be identified 
in humans and these enzymes could be the future molecular targets of anti-cancer drugs.  
However, topo I is the current molecular target of chemotherapeutic agents.  In chapter 4, 
we will learn more about how drugs, called camptothecins, target topo I and exert their 
cytotoxic effects in cancer cells.  Before that, however, a discussion of the type II 
enzymes must be covered because these too are the molecular targets of commonly used 
anti-cancer agents. 
 
3.7 General Introduction to the Type II Enzymes. 
 In the preceding section, we reviewed the type I topoisomerases that are 
expressed in humans.  Now, we will turn our attention to topo II, a type II enzyme.  In 
humans, topo II has two isoforms, topo IIα and topo IIβ that share many similar 
properties. Although many difference in structure, tissue distribution, and gene 
expression have been described for topo IIα and topo IIβ , differences in their functional 
roles, drug action, and relative contributions to cancer chemotherapy are less clear 
(Austin and Marsh, 1998).  Topo IIα has been the most extensively investigated isoform, 
whereas the role of topo IIβ is drug resistance is not well understood (Beck et al., 1999).  
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Immediately following in section 3.8, is a description of common principles and 
biochemical properties that are generally applied to both topo IIα and topo IIβ.  Then, in 
section 3.9, the features that distinguish the two isoforms are given.   
 
3.8 Type IIA: Similarities between Topo IIα and Topo IIβ. 
 The type II enzyme, called DNA gyrase, was isolated from Escherichia coli and 
was the first type II topoisomerase to be characterized (Gellert et al., 1976).  Bacterial 
DNA gyrase is unique because it can introduce negative supercoils in DNA or convert 
positive supercoils into negative supercoils (Wang, 1996).  DNA gyrase is the target for 
clinically important quinolone antimicrobial agents, such as Ciproflaxin (Hooper et al., 
1993).  However, DNA gyrase should not be confused with mammalian topo II enzymes, 
the current molecular targets of anticancer agents.   
 In contrast to bacterial DNA gyrase, eukaryotic topo II is unable to generate 
supercoils in vitro (Liu et al., 1983).  Topo II activity is required to separate replicated 
chromosomes prior to cell division, and unlike topo I and topo III, is able to decatenate 
intertwined double strand DNA molecules (Marini et al., 1980).  All type II 
topoisomerases form dimers (Champoux, 2001) and each topo II monomer can be 
divided into three domains (Jensen et al., 1996), an N-terminal domain that contains the 
ATP-binding region (Bjerbaek et al., 2000; Gardiner et al., 1998), the central domain 
containing the active site tyrosine residue (Okada et al., 2000) and the C-terminal domain 
that contains the nuclear localization sequences (Figure 4) (Mirski et al., 1997, 1999).  
The C-terminal domain has also been shown to be important for interactions with other 
proteins (Messenger et al., 2002; Kroll, 1997). 
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All topo II enzymes share common mechanisms for DNA-cleavage and religation 
reactions (Champoux, 2001; Wang, 1996).  A description of the catalytic cycle of topo II 
is important in understanding how drugs target topo II.  The catalytic cycle of topo II 
involves several distinct stages including: DNA binding, strand cleavage, strand passage, 
religation, and enzyme turnover (Figure 5) (Champoux, 2001; Wang, 1996).  Topo II 
dimers first bind to double strand DNA, and then each monomer cleaves opposite DNA 
strands to generate a 4-base stagger.  Topo II mediated DNA breaks occur through. 
Figure 4. Structural Domains Shared by DNA Topo IIα (shown in A) and topo IIβ 
(shown in B). Topo IIα and topo IIβ have three domains as shown. The ATPase 
domain (white box) is at the amino terminus and contains the ATP binding site. The 
DNA domain (grey box) contains the active site Tyr residues and the carboxyl 
terminus (dark grey box) is important for intracellular localization because it 
contains the nuclear localization(NLS) and nuclear export signals (NES).  
H2N COOH ATPase DNA Binding Carboxyl terminus
Active site NLS NES
H2N ATPase COOH DNA Binding Carboxyl 
terminus 
Active site NES     
A. Topo IIα  
B. Topo IIβ 
NLS 
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Figure 5.Catalytic Mechanism of DNA Topo II. The "two-gate model" of topo II catalysis is 
shown. According to this model, topo II has two lobes called A' (colored red) and B' (colored 
blue).  The DNA strand that is cleaved is called the "gate DNA" or "G-segment". The DNA 
strand that is transported is called the "transport DNA" or "T-segment".  (1) Topo II binds gate 
DNA (orange rod) and undergoes conformational changes. (2) Topo binds ATP (yellow star) and 
the transport DNA molecule (green rod). (3) The ATPase domains on topo II dimerize and topo 
II cleaves the gate DNA. The presence of a metal cation is required.  (4) The transport DNA is 
transported through the break and into the central cavity of the B' lobe.  Gate DNA is held within 
the A' lobe. (5) Following DNA strand passage the transport DNA is released from the enzyme 
through a gate formed in the B' lobe.  The gate DNA is resealed.  (6) ATP is hydrolyzed and 
ADP and inorganic phosphate (Pi) are released to complete enzyme turnover.  This figure was 
reproduced from references Champoux, 2001 and Wang, 1996.
Cleavable complex Cleavable complex 
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transesterfication reactions, in which a DNA phosphoester bond is transferred to the 
active site tyrosine residue in each monomer.  Thus, each monomer remains covalently 
attached to the 5' end of DNA through a phosphotyrosine bond.  A conformational 
change in the enzyme pulls the cleaved DNA duplex apart to create an opening that is 
called, "the gated or G-segment DNA".  Strand passage occurs either from the same DNA 
molecule (relaxation, knotting, or unknotting) or different molecules 
(catenation/decatenation).  The DNA segment that is passed through the opening is called 
the "transported or T-segment DNA".  Enzyme turnover requires ATP hydrolysis and 
divalent cations (Mg2+) (Osheroff, 1987).  The mechanism of topo II enzyme catalysis is 
an important concept for understanding how topo poisons and catalytic inhibitors target 
topo II.    
Topo II can also catenate/decatenate interlocked circles of DNA (Champoux, 
2001).  Topo II decatenation activity is essential at the end of DNA replication for the 
proper separation of daughter chromosomes.  Cells lacking topo II are unable to 
decatenate sister chromatids or carry out chromosome condensation reactions prior to 
mitosis, which results in non-disjunction and chromosome breakage (Holm et al., 1989).  
Topo II catalytic activity is measured in vitro by the decatenation of kinetoplast DNA 
(kDNA) isolated from the mitochondria of Crithidia fasiculata.  kDNA consists of 
numerous interlocked minicircles and maxicircles.  Unlike the type I enzymes, topo II is 
able to decatenate the interlocked circles to generate free mini- and maxi- circles that can 
be separated from the network of kDNA by centrifugation (Sahai and Kaplan, 1986; 
Marini et al., 1980).  Thus, the ability to decatenate kDNA is an important distinction 
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between topo I and topo II enzymes because it allows us to estimate topo II enzyme 
activity independent of topo I activity in vitro.  
 
3.9 Differences between DNA Topoisomerase IIα and Topo IIβ. 
 Topo II has two isozymes, topo IIα and topo IIβ, with different molecular masses 
and gene loci (Lang et al., 1998; Drake et al., 1987) (Table 1, page 13).  The presence of 
two different gene loci suggests that these isoforms may be differentially regulated at the  
level of transcription.  The tissue distribution of topo IIα and topo IIβ mRNA and protein 
have been determined in mouse, rat, and humans (Bauman et al., 1997).  Topo IIα mRNA 
is highest in many proliferating cells such as thymus, spleen, bone marrow, intestine, and 
testis.  Topo IIβ mRNA is detectable in a wider range of tissue types; including those 
with few proliferating cells (Carpanico et al., 1992).  Topo IIβ is 90 amino acids longer 
than topo IIα and the two isoforms are 68% homologous in amino acids (Austin and 
Marsh et al., 1998).  The greatest variability in amino acids between topo II α and IIβ 
occurs in the C-terminal domain, and thus the C-terminus may impart specific differences 
in the functional roles of these isozymes.   
 Topo IIα is expressed in a cell cycle dependent manner with peaks in the S-phase 
and G2/M-phase of the cell cycle and is the target of ubiquitin-mediated proteolysis 
(Meyer et al., 1997; Nakajima et al., 1996).  Topo IIβ protein expression is more uniform 
throughout the cell cycle, suggesting that it may have a role as a "housekeeping gene" 
(Drake et al., 1989).  Topo IIα is also highly expressed in many rapidly proliferating 
human tumors (Holden et al, 1990, Turley, et al, 1997), thus making topo IIα a frequent 
molecular target of anti-cancer drugs.  In contrast, topo IIβ expression is constant 
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throughout the cell cycle with limited fluctuations in the amount or stability of the protein 
in either highly replicating or non-replicating cells (Woessner, 1991).  Topo IIβ is 
emerging as a new molecular target in tumors that are refractory to cytotoxic agents that 
target topo IIα (Gatto and Leo, 2003).   
 Both topo IIα and topo IIβ are differentially phosphorylated throughout the cell 
cycle with maximal phosphorylation occurring at G2/M phase (Burden et al, 1993; 
Burden and Sullivan, 1994).  Thus, maximum topo II phosphorylation correlates with 
chromosome condensation and segregation.  As cells transition from M phase to G1 phase 
of the cell cycle, 75% of topo IIβ becomes dephosphorylated, whereas 25% of topo IIα is 
dephosphorylated (Wells and Hickson, 1995; Burden and Sullivan, 1994) 
The kinases known to phosphorylate topo IIα in vitro include protein kinase C (PKC) 
(Wells et al., 1995), casein kinase 2 (CK2) (Ishida et al., 1996; Alghisi et al., 1994), and a 
proline directed kinase (Wells and Hickson, 1995).  The phosphorylation of precise 
amino acid residues by specific kinases have not been mapped in topo IIβ.  
 The expression of the different topo II isoforms seems to be necessary to fulfill 
distinct physiological roles, but what those roles are remains unclear (Wang, 1991; 
Wang, 2002).  Both enzymes are able to unknot DNA, relax supercoiled plasmid DNA, 
and catalyze ATP-dependent DNA strand passage activity in vitro (Austin and Marsh, 
1998).  Topo IIα has a significant role in cell proliferation, whereas topo IIβ is suggested 
to have a role in cell differentiation (Aoyama et al., 1998).  Topo IIα has an essential role 
in chromosome condensation and segregation during mitosis (Uemura et al., 1987). 
Recent findings, however, suggest that topo IIβ is able to substitute for topo IIα in 
chromosome condensation and segregation, but that topo IIα has a crucial role in 
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shortening of chromosome axes (Sakaguchi and Kikuchi, 2004).  Distinguishing the 
physiological roles of topo IIα from those of topo IIβ could lead to a better understanding 
of the molecular mechanisms conferring differences in drug sensitivity.  A transgenic cell 
line lacking topo IIβ was recently established and may lead to a better understanding of 
the differential roles between topo IIα and IIβ (Errington et al., 1999).  To date, there are 
no established cell lines that lack topo IIα. 
 I searched PubMedCentral, the U.S. National Institutes of Health free digital 
archive of biomedical and life sciences journal literature, and identified several proteins 
that have been reported to interact with topo IIα in vitro and/or in vivo (PubMedCentral, 
2005).  I have included a brief description of the protein partners that interact with topo 
IIα and speculated on the potential implication(s) of such protein-protein interactions in 
conferring drug resistance.  The protein partners that associate with topo IIα spans a 
variety of protein classes with roles in various cellular processes, including chromatin 
remodeling, apoptosis, mRNA splicing, RNA export, and proteasome-mediated protein 
degradation.  A complete discussion of each protein interaction identified in table 2 is 
beyond the scope of this investigation.  Briefly however, the data presented in this 
investigation suggests that the nuclear export of topo IIα may be regulated by the export 
receptor, exportin-1.  Our laboratory has also collaborated with other laboratories to 
investigate topo IIα interactions with HDAC (Tsai et al., 2000) and 14-3-3 proteins.  For 
example, histone deacetylases (HDAC) modifies protein histones and has a role in 
regulation of gene transcription. Topo II was shown to complex with HDAC1 and 
HDAC2 in vivo (Tsai et al, 2000).  Histone deacetylase activity coupled with topo II 
DNA cleavage has been implicated in etoposide induced apoptosis.  We also investigated 
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a potential interaction between 14-3-3 epsilon with topo IIα in human myeloma and 
leukemia cell lines at different cell densities because we thought that 14-3-3 may 
modulate the subcellular localization of topo IIα in these cells.  However, we did not 
observe 14-3-3- colocalization with topo IIα by confocal microscopy (data not 
published).  The 14-3-3 protein, however, has been shown to interact with topo IIα in 
HL-60 and CCRF human leukemia cells (Kurz et al., 2000).  This interaction was shown 
to abrogate topo IIα cleavable complex formation in the presence of the topo II poison, 
etoposide.  
 Although several protein-protein interactions have been described for topo IIα, 
specific protein-protein with topo IIβ have not been described.  The only observation of a 
protein interaction with topo IIβ has been the observation that topo IIβ can 
heterodimerize with topo IIα.  Although topo II usually forms homodimers, a 
subpopulation of α/β heterodimers has been reported to occur, but the biological 
significance of this interaction is not clearly established (Gromova et al., 1998; Biersack 
et al., 1996).   
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Table 2. DNA Topoisomerase IIα Protein Interactions 
Name 
In vitro 
or 
In vivo 
Function(s) of 
Protein Partner 
 Function(s) of    
 Topo-Protein Interaction 
(Observed or Predicted) 
 Role of Topo-Protein Interaction in  
Cellular Drug Sensitivity or Resistance 
(Observed or Predicted) 
References 
Topo IIβ In vitro DNA topology Possible role in DNA metabolism; potential therapeutic target 
Potential molecular target for new drugs that 
inhibit the topo IIα/β heterodimer 
Biersack et al., 1996 
Gromova et al., 1998 
p53 In vivo In vitro 
Tumor suppressor 
protein; regulation of 
G2/M transition 
Interaction with topo IIα protein may be 
necessary for detection/repair or 
activation of apoptotic response 
following DNA damage. p53 mediated 
topo II gene suppression blocks cells in 
G2/M, allowing cells to repair damaged 
DNA. 
p53 has been reported to have both pro- and anti-
apoptotic effects depending on the cell type and 
cytotoxic agent investigated. For example, mouse 
fibroblasts expressing wild-type p53 are more 
sensitive to etoposide and doxorubicin, but less 
sensitive to UV light and alkylating agents when 
compared to p53 deficient mouse fibroblasts. 
These results are in contrast to lymphoblastoid 
cells that are more sensitive to UV light and 
alkylating agents than their p53 mutant 
counterparts. 
Cowell et al., 2000 
Bernd, K. 2003 
Caspase activated 
DNase (CAD) In vitro 
Deoxyribonuclease 
involved in apoptosis 
and nuclear 
disassembly 
CAD enhances topo IIα decatenation 
activity in vitro. CAD may initiate at or 
near topo IIα binding sites to initiate 
chromosomal condensation and nuclear 
disassembly during apoptosis. 
Could be involved in apoptotic response to drug-
induced DNA damage Durrieu et al., 2000 
Interleukin enhancer 
binding factor 2 In vivo 
Transcription factor; 
also associated with 
pre-mRNA splicing 
complex 
May be involved in regulating IL-2 gene 
transcription during T-cell activation 
To date, there is no literature to describe ILF2-
topo IIα effects on cellular drug sensitivity. 
Ajuh et al., 2000 
Marcoulatos et al., 
1996 
Peptidyl-prolyl 
isomerase (Pin1) In vitro 
An isomerase that 
interacts with several 
phosphoproteins 
during the cell cycle 
Inhibits casein kinase II (CK2) 
phosphorylation of Thr1342 on topo IIα, 
but especially during G2/M; may 
regulate CK2 phosphorylation of topo 
during the cell cycle. 
Alterations in the phosphorylation status of topo 
IIα could regulate topo IIα enzyme activity, 
protein degradation, or subcellular localization and 
confer alterations in drug sensitivity. 
Messenger et al., 
2002 
Table 2 continued on next page. 
 
 30
 
Table 2 continued. 
Name 
In vitro 
or 
In vivo 
Function(s) of 
Protein Partner 
 Function(s) of    
 Topo-Protein Interaction 
(Observed or Predicted) 
 Role of Topo-Protein Interaction in  
Cellular Drug Sensitivity or Resistance 
(Observed or Predicted) 
References 
RNA helicase A 
(RHA) In vivo 
Unwinds double-
stranded DNA and 
RNA; nuclear export 
of retroviral RNA 
RHA may facilitate the access of topo 
IIα to chromatin and work together to 
maintain chromatin structure during 
transcription. RHA may be a 
transcriptional co-activator  
(i.e. topoIIα may activate RNA 
polymerase when complexed with 
RHA) 
Sumoylation could signal RHA to interact with 
topoIIα to initiate transcription of  specific genes 
in response to cellular demands (i.e. during 
apoptosis or when DNA damage is present) 
Lee et al., 2004 
Zhou et al., 2003 
SUMO1/Ubc9 In vivo In vitro 
An E2-type 
ubiquitin-conjugating 
enzyme involved in 
sumoylation (SUMO) 
and proteasome 
mediated 
degradation;  
SUMO could regulate topo IIα 
degradation, subcellular localization 
and/or enzyme activity. Ubc9 is also 
necessary for the assembly of RNA 
helicase-A topo IIα complexes to form.  
Sumoylation may alter drug sensitivity by 
modifying  the amount, location or activity of 
topo IIα. Sumoylation may be a step in 
chromosome condensation or DNA cleavage 
during apoptosis. SUMO-topo IIα is observed 
after teniposide induced DNA damage; SUMO-
topo IIβ is observed after exposure to the catalytic 
inhibitor ICRF-193. 
Mao et al., 2000 
Isik et al., 2003 
Argasinska et al., 
2004 
Histone deacetylase-
1  Histone 
deacetylase -2 
In vivo 
In vitro 
Chromatin 
remodeling 
Regulation of chromatin structure and 
gene transcription. 
The histone deacetylase inhibitor, sodium 
butyrate (NaB) results in a 2-fold increase in topo 
IIα protein and increased sensitivity to etoposide 
in human leukemic cells. 
Tris et al., 2000 
Johnson et al., 2001 
Kurz et al., 2001 
14-3-3- epsilon In vivo 
Adapter molecule 
involved in signal 
transduction 
pathways 
Interaction with 14-3-3 may modulate 
topo IIα protein activity or subcellular 
localization. 
14-3-3 epsilon abrogates topo IIα cleavable 
complex formation to etoposide as a result of 
reduced DNA binding activity. 
Kurz et al., 2000 
Exportin 1 In vivo In vitro 
Protein receptor for 
nuclear export 
Export topo IIα from the nucleus to the 
cytoplasm  
Decreased drug sensitivity to etoposide has been 
associated with a subcellular distribution of topo 
IIα from the nucleus to the cytoplasm in human 
myeloma cell lines. 
Engel and Turner et 
al.,  2004 
Mirski et al., 2003 
c-Jun In vivo Transcription factor; proto-oncogene 
c-Jun stimulates topo IIα decatenation 
activity 
Etoposide induces c-jun gene expression in HL-
60 and U-937 myeloid leukemia cell lines and 
may be an apoptotic event in etoposide-induced 
DNA damage  
Kroll et al., 1993 
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3.10 Conclusions. 
 Thus far, cancer pathogenesis and the family of DNA topoisomerases have been 
reviewed.  Some key points to remember are that topo I and topo II are the major nuclear 
enzymes that regulate DNA topology during DNA replication, transcription, and cell 
division.  Topo I catalyzes single-strand DNA breaks in an ATP-independent manner and 
is not expressed in a cell-cycle dependent manner, whereas topo II enzymes cleave 
double-strand DNA in an ATP-dependent manner.  Topo II has two isoforms, topo IIα 
and topo IIβ.  Topo IIα protein expression is cell cycle dependent, whereas topo IIβ 
expression is more constant throughout the cell cycle.  Topo I and topo II are the 
molecular targets of clinically important chemotherapeutic agents, especially in the 
treatment of hematological malignancies.  Next, the drugs that target topo I and topo II 
are reviewed. 
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Chapter Four 
DNA Topoisomerase Targeted Cytotoxic Agents 
 
4.1  Introduction to Topo Targeting Agents.  
 Topo proteins are the molecular targets of commonly used anti-cancer agents 
(Topcu, 2001).  Cytotoxic agents that target topo can be classified as poisons, catalytic 
inhibitors, or suppressors (Pommier et al., 1998; Andoh and Ishida, 1998).  Some poisons 
are specific to topo II (i.e., etoposide and teniposide), whereas other poisons target topo I 
(i.e., topotecan and irinotecan).  The poisons are further subclassified as either DNA 
intercalators or non-intercalators, but several drugs have multiple mechanisms of action, 
and thus do not fit discreetly into one specific drug category (Table 3) (Ross et al., 1984).  
DNA intercalators are able to bind to DNA, whereas the non-intercalators do not bind to 
DNA.  Some drugs, such as Actinomycin D, can act as a poison against both topo I and 
topo II, and yet other compounds can act as a poison against one class of topo enzymes, 
but as a catalytic inhibitor of another class of topo enzymes (van Hille et al., 1999).  The 
mechanism of drug action of the poisons is distinctly different from that observed with 
the catalytic inhibitors and suppressors.  The main difference between catalytic inhibitors 
and suppressors is their molecular target. Catalytic inhibitors inhibit topo II activity, 
whereas the suppressors inhibit topo I activity.  The topo I and topo II poisons are 
described in a separate section from the catalytic inhibitors and suppressors. 
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4.2 Topo I and Topo II Poisons. 
 To comprehend how anti-cancer agents target DNA topoisomerases, it is 
important to recall that, when all topo enzymes cleave DNA, they remain bound the 
cleaved DNA via a phosphotyrosine bond.  In this manner, topo bridges the gap between 
the cleaved DNA strands, thus ensuring that the correct strands of DNA are resealed back 
together.  Under normal physiological conditions, the complex between topo and the 
cleaved DNA strands, called a "cleavage" or "cleavable complex", is transient and freely 
reversible.  Some anti-cancer agents, however, stabilize the form of topo that is bound to 
cleaved DNA and are called, topoisomerase poisons.  Topo II poisons include the 
epipodophyllotoxins (i.e., etoposide, teniposide) and anthracyclines (i.e., doxorubicin), 
whereas the topo I poisons include the camptothecins (i.e., topotecan, irinotecan).  The 
topo poisons act by increasing the steady-state concentration of covalently bound DNA-
topo cleavage complexes by blocking the religation of cleaved DNA and stabilizing the 
DNA-drug-enzyme intermediate (Osheroff et al., 1994).  However, it is not clear why 
cells die, since the topo II-DNA covalent complexes trapped by topo poisons are freely 
reversible so that removal of the drug allows the DNA to return to an undamaged state 
(Nitiss and Wang, 1996).  It is possible that cells accumulate DNA damage to a point of 
no return, such that apoptotic pathways are triggered and cell death occurs even if DNA 
damage is repaired.  It is generally believed that the drug stabilized cleavage complexes 
become lethal when either DNA helicases (Howard et al., 1994) or an advancing 
replication fork collides with the drug-topo-DNA ternary complex (Hsiang et al., 1989).  
Such collisions are believed to be lethal because they disrupt the proteinaceous bridge 
between topo and the cleaved DNA, and thus the transient single- or double- strand DNA 
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break that was being held together by topo becomes a permanent double-stranded break 
(Osheroff, 1995; Chen and Liu, 1994).  The double-stranded DNA break becomes a 
target for gene recombination and repair pathways (Osheroff, 1998), resulting in sister 
chromatid exchanges, large insertions and deletions, and chromosomal translocations 
(Chen and Liu, 1994; Anderson and Berger, 1994; Corbet and Osheroff, 1993).  
Therefore, at least some of the double-strand breaks that are generated by collision with 
the replication fork can not be repaired by the enzyme (Nitiss and Beck, 1996; Zhang et 
al., 1990).  So, although the covalent topo-DNA complex is transient and freely 
reversible, collision with the replication fork can produce DNA lesions that persist after 
the drug is removed (Nitiss and Beck, 1996).  Though not well understood, these cellular 
events eventually trigger cell death pathways (Gupta et al., 1995, Pommier, 1993).  One 
additional caveat is that generation of a lethal collision is dependent on the orientation of 
the cleavable complex relative to the advancing replication fork.  Collision is lethal only 
if the cleavable complex is formed on the lagging-strand of DNA (Pourquier et al., 1999l 
Tsao et al., 1993). 
 
4.3 Topo I Suppressors and Topo II Catalytic Inhibitors. 
 In contrast to the topo poisons, the suppressors of topo I and catalytic inhibitors of 
topo II do not stabilize DNA-enzyme complexes, but rather work at another step of 
enzyme catalysis (Pommier et al., 1998).  The catalytic inhibitors include the topo II 
targeting agents, merbarone and the bisioxopiperazines (ICRF-193, ICRF-187).   
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 Class Drug Poisons 
Catalytic 
Inhibitors 
DNA 
Intercalators 
Free Radical 
Formation 
Epipodophyllotoxi
ns 
etoposide (VP-16), 
teniposide (VM-26) +++ - - + 
Isoflavinoids genistein ++ - - - 
Anthracyclines doxorubicin, daunomycin ++ + ++ + 
Actinomycins actinomycin D +++ - - - 
Anthracenediones mitoxantrone ++ + + - 
Acridines m-AMSA +++ + + - 
Topo II Agents 
Miscellaneous 
fostriecin, merbarone, 
ICRF-193, ICRF-187, 
ICRF-159 
- +++ - - 
Topo I Agents Alkaloids 
topotecan, camptothecin 
(CPT), irinotecan (CPT-
11), 9-nirocamptothecin 
(9-NC), karenitecin 
+++ - - - 
Table 3. DNA Topoisomerase I and II Inhibitors 
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Topo suppressors and catalytic inhibitors may inhibit binding between DNA and 
topoisomerase, stabilize noncovalent DNA topoisomerase complexes, or inhibit ATP 
binding (Larsen et al., 2003; Burden and Osheroff, 1998).  For example, catalytic 
inhibitor, called ICRF-193, has been shown to lock the enzyme in a closed form on DNA, 
preventing DNA cleavage (Roca et al., 1994, Fortune et al., 1998).  Recall that topo IIα 
cleavage activity is described to occur in a two-gate model.  The enzyme undergoes two 
forms, open and closed, in the absence or presence of ATP, respectively.  ATP binding 
triggers a conformational change in topo II, resulting in topo II gate closure around DNA.  
ATP hydrolysis results in opening of the topo II gate.  Therefore, ICRF-193 stabilizes 
topo II in a closed formation around DNA and prevents topo from opening again.  In 
general, the drugs that target topo IIα come from a range of classes with differing 
structures and mechanism of action.  Conversely, most of the antitumor agents that target 
topo I are poisons (refer to Table 3), and thus are the focus of this investigation. 
 A summary of the mechanisms of drug action of topo II targeting agents are 
illustrated in figure 7.  In general, topoisomerase poisons can be distinguished from 
catalytic inhibitors by their cytotoxic profiles (Froelich-Ammon and Osheroff, 1995 
Nitiss, 1994).  Increased cellular content of topo protein corresponds with cellular 
hypersensitivity to topo poisons, but decreased drug sensitivity to catalytic inhibitors 
(Bjornsti et al., 1989; Ishida et al., 1995).  Conversely, decreased cellular content of topo 
protein corresponds with decreased sensitivity to topo poisons but hypersensitivity to 
catalytic inhibitors (Bjornsti et al., 1989; Ishida et al., 1995; Nitiss and Wang, 1988).  
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Figure 6.The Mechanism of DNA Topo I Poisons. (1) Topo I monomer 
binds to supercoiled DNA (2) Topo I cleaves single strand of DNA .The 
cleavable complex is stabilized in the presence of  topo I poison (shown as 
orange box) (3) Advancing replication fork collides with cleavage complex, 
resulting in double strand DNA break. 
1 2
3
Supercoiled 
DNA 
Cleavable 
Complex 
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Figure 7.  The Mechanism of DNA Topo II Poisons and Catalytic Inhibitors. This is the same figure 
illustrated on page 23, but now the steps of enzyme inhibition by topo II poisons and catalytic inhibitors are 
indicated. Briefly, (1) Topo II binds DNA (orange rod)  (2) Topo II binds as second DNA strand, and then 
binds ATP (yellow star) (3) The ATPase domains on topo II dimerize, and then topo II cleaves DNA.(4) 
Strand passasge occrs through the gap (5) transport DNA is released, and then gate DNA is resealed.  (6) 
ATP is hydrolyzed and ADP and inorganic phosphate (Pi) are released to complete enzyme turnover.  Topo  
poisons act on the cleavable complex (forms d and e) and prevent reaction 4 from proceeding forward. The 
catalytic inhibitors act on any other step of the catalytic cycle (forms a, b, c, and f).  Catalytic inhibitors 
prevent topo binding to DNA, ATP binding, and ATP hydrolysis. This figure was modified from references 
Champoux, 2001 and Wang, 1996. 
a. b. 
c. 
d. e. 
f. 
Cleavable complex Cleavable complex
Poisons 
Catalytic 
Inhibitors 
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4.3 DNA Topoisomerase I Targeting Agents. 
 Camptothecin (CPT) (Figure 8.) is a plant alkaloid isolated from Camptotheca 
acuminata (Wall et al., 1986). Initial studies 
showed that CPT displayed potent antitumor 
activity against a wide range of tumors, but the 
drug was discontinued because of toxic side 
effects (Pommier, 2005).  There was a 
renewed interest in CPT when subsequent findings identified topo I as the main 
molecular target (Hsiang et al., 1985). Since CPT was the only known drug to target topo 
I, finding less toxic and more water soluble CPT derivatives became a subject of 
numerous investigations 
(Kollmannsberger, et al., 1999; Wani et 
al., 1987, 1986; Kunimotto et al., 1987). 
Topotecan (TPT) (Figure 9.) and 
irinotecan (CPT-11) are two water 
soluble CPT derivatives that are 
currently being used for the treatment of human cancers (Lackey et al., 1996; Luzzio et 
al., 1995). CPT-11 has been used in the treatment of colon, breast, gastric and small-cell 
lung cancers as well as leukemia (Rosen, 1998), whereas topotecan has been used against 
recurrent small cell lung cancer, ovarian cancer and endometrial cancer (Treat et al., 
2004; Ahmad and Gore, 2004; Traina et al., 2004).  CPT-11 must be converted to the 
active compound, SN-38 (7-ethyl-10-hydroxycamptothecin B-glucuronide) by 
carboxylesterase (Satoh et al., 1994).  Thus, increased drug sensitivity to irinotecan 
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Figure 8. Camptothecin (CPT)
Figure 9. Topotecan (TPT) 
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correlates with carboxylesterase expression and activity (Wierdl et al., 2001).  Cisplatin is 
also a substrate of the ABC drug transport protein, multidrug resistance related protein-3 
(MRP3).   
 CPT and its derivatives interact reversibly with a DNA-enzyme complex and 
usually have no detectable binding to isolated topo I or DNA (Fan et al., 1998; Hsiang et 
al., 1985).  However, the x-ray crystal structure of human topo I-DNA-topotecan ternary 
complex shows that topotecan can mimic a DNA base pair (Staker et al., 2002).  These 
findings may partially explain how topotecan can intercalate in DNA in the absence of 
topo enzyme in some instances. In the presence of camptothecins, topo I is unable to 
reseal nicked DNA because the drug blocks the active site of the covalently bound 
enzyme (Woo et al., 2002). However, single strand DNA breaks alone are not sufficient 
for cell death to occur and instead must be converted into permanent DNA double strand 
breaks by collision with the moving replication fork (Mosseso, 2000). Conversely, it has 
also been reported that CPT induced DNA strand-breaks can occur in unstimulated 
leukocytes where little or no replication is occurring (Daza et al., 2002), and thus other 
cellular events besides the collision of cleavable complexes with replication forks may 
have a role in CPT induced DNA damage.  The molecular basis of CPT induced cell 
death is not completely understood, since topo I cleavable complexes are readily 
reversible after drug removal (Pommier, 2005). It is generally accepted that collision of 
the moving replication fork with the topo I cleavable complexes leads to three 
biochemical events: formation of a double-strand DNA break, irreversible arrest of the 
replication fork, and formation of an irreversible topo I-linked DNA break  (Tsao et al., 
 41
1993; Hsiang et al., 1989).  It is thought that one or more of these events initiates S-phase 
cell death and G2 phase cell cycle arrest.  
  
4.4 DNA Topoisomerase II Targeting Agents: Etoposide and Mitoxantrone. 
 
 In contrast to the limited number of drug classes that target topo I, topo II is the 
molecular target for a number of diverse drug classes, 
including the epipodophyllotoxins, isoflavinoids, 
anthracyclins, actinomycins, anthracenediones and 
acridines (Table 3).    Etoposide (VP-16) and 
teniposide (VM-26) are two semi-synthetic 
epipodophyllotoxins.  Etoposide and teniposide are 
derived from 4'-demethylepipodophyllin benzylidene 
glucoside (DEPG), a naturally occurring compound 
synthesized by Podophyllum peltatum, the North 
American May Apple Mandrake (Figure 10) (Imbert, 
1998; Hande, 1998; Sinkule, 1984).  The May Apple 
was first described in 1731 and can be found growing from the coasts of Northern Florida 
to Maine (Catersby, 1731).  Native American Indians and American pioneers reportedly 
used the plant for medicinal purposes, such as for the treatment of skin cancer (Hande, 
1998).  In 1844 the first alcohol extraction of the plant was reported and the isolated resin 
was called podophyllin (King, 1844). For over twenty years, numerous isolation 
procedures were conducted, fronting an intense search for the active compound.  These 
Figure 10. Podophyllum peltatum, 
also known as the May Apple 
Mandrake. The plant shown here is 
bearing fruit, the richest source of 
podophyllotoxins. This photograph 
was reproduced with written 
permission from the Maryland 
Conservation Council. 
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Figure 11. Etoposide (VP-16)
investigations lead to the development of VP-16 and VM-26, which were renamed, 
etoposide and teniposide, respectively (Stahelin and Von Wartburg, 1989).  
 Unlike topo I targeting agents, topo II targeting drugs are able to kill cells at all 
points in the cell cycle (Dubrez et al., 1995). Topo II inhibitors such as VP-16 (Figure 11) 
and mitoxantrone (Alberts et al., 1980; 
Koeller and Eble, 1988) (Figure 12) stabilize 
the complex formed by topo II and the 5’ 
cleaved ends of the DNA, thus forming stable 
protein-linked double strand DNA breaks 
(Meresse et al., 2004).  VP-16 and 
mitoxantrone inhibit topo II DNA religation 
activity, leading to an increase in DNA scission (Liu, et al., 1983). The DNA breaks are 
believed to interfere with the progress of the moving replication fork (Qiu et al., 1996).  
Cells recognize drug-induced DNA damage and eliminate the damaged cells by 
apoptosis, but the pathway from DNA damage to cell death remains uncertain (Valkov 
and Sullivan, 2003).  Etoposide mediated cell death is reported to occur when DNA-
dependent protein kinase (DNA-PK) recognizes an accumulation of DNA double strand 
breaks and then phosphorylates p53 (Karpinich et al., 2002).  Activated p53 then results 
in increased transcription of the pro-apoptotic protein Bax, which then translocates into 
the mitochondria and induces the release of cytochrome c.    
 Mitoxantrone (MTX) is a synthetic anthracenediones that was developed as an 
analogue of doxorubicin (Fox, 2004).  Mitoxantrone has been shown to have multiple 
mechanisms of action. In addition to being a topo II inhibitor (as previously described 
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Figure 12. Mitoxantrone (MTX)
above), mitoxantrone also interferes with 
RNA synthesis, and intercalates with 
DNA.(Duff, 1984; Isabella et al., 1993)  
DNA intercalation results in aberrant 
DNA-protein crosslinks and DNA strand 
breaks (Hagemeister et al.,  
2005). Mitoxantrone has also been shown to inhibit antigen presentation and decrease the 
secretion of proinflammatory cytokines, which has important roles in modulating the 
immune response (Fox, 2004).  MTX has also been shown to alter prostaglandin 
biosynthesis and calcium release (Ehninger et al., 1990).  In summary, MTX has been 
shown to have multiple biological effects but, the drug's antitumor activity is mainly 
attributed to its interaction with DNA topoisomerase (Koeller and Eble, 1988).  However, 
it is possible that these other cellular events could contribute to drug sensitivity to MTX.  
Mitoxantrone was approved by the Food and Drug Administration for the treatment of 
adult acute myeloid leukemia and symptomatic hormone-refractory prostate cancer.  
Mitoxantrone also has demonstrated beneficial activity in preclinical lymphoma models 
and appears clinically active against both aggressive and follicular lymphomas 
(Hagemeister e., 2005). Topo II targeting agents have been used effectively in the 
treatment of non-Hodgkin’s lymphoma, leukemias, small-cell lung cancer and soft-tissue 
sarcomas.  However, cancer cells have many mechanisms for evading topo II mediated 
drug cytotoxicity.  Mechanisms of drug resistance to topo II targeting agents are reviewed 
in chapter six.  .  
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4.5  Dual Inhibitors of DNA Topoisomerase. 
 Dual inhibitors of topo I and topo II are emerging as a new class of cytotoxic 
agents with promising anti-tumor activity (Denny and Baguley, 2003).  The dual topo 
inhibitors have activity against both topo I and topo II enzymes and can be classified into 
three groups: DNA intercalators, non-DNA intercalators, and hybrid molecules (Denny 
and Baguley, 2003).  The DNA intercalators physically intercalate between DNA bases, 
whereas the non-DNA intercalators recognize structural motifs present in topo I and II 
proteins.  Two examples of dual topo I and II DNA intercalating agents include are        
N-[2-(dimethylamino) ethyl] acridine-4-carboxamide dihydrochloride (DACA) and the 
benzophenazine referred to as XR11576 (Mistry et al., 2002).  In vitro experiments using 
purified topo and DNA substrates show that DACA induces DNA breakage by both topo 
I and II (Finlay et al., 1996).  However, the mechanism of DACA inhibition on topo I and 
II is still in question. The data suggests that DACA may act as a topo poison at a low 
drug concentration (0.5-5 µM) and as catalytic inhibitor at a higher drug concentration (≥ 
10µM) (Spicer et al., 2000; Bridewell et al., 1999).  Thus, topo-DNA cleavage complexes 
are not observed at the higher drug concentrations. This may be possible, if the 
intercalation of DACA into DNA at higher drug concentrations inhibits the binding of 
topo to DNA.  DACA has completed phase I and II clinical trials (Dittrich et al., 2003; 
Caponigro et al., 2002; Twelves et al., 1999) and has been shown to overcome 
mechanisms of in vitro drug resistance in several multidrug resistant cell lines that 
express drug efflux pumps (i.e., P-glycoprotein, multidrug resistance protein, and 
multidrug resistance related protein) (Davey et al., 1997).  DACA has also been shown to 
be active against solid tumors in mice (Bridewell et al., 1999).   
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 Four examples of non-DNA intercalating agents have been described and include 
NK109, acetyl Boswellic acid, BN 80927, and F-11782.  Acetyl-Boswellic acid (acetyl-
BA) is  isolated from the gum resin of Boswellia serrata, a tree that grows in Asia.  
Acetyl-BA inhibits topo I and IIα by binding directly to topo enzymes, rather than DNA-
topo complexes, and is believed to compete with DNA for binding sites on topo 
(Syrovets et al., 2000).  BN 80927 is a camptothecin analogue that has a seven-membered 
β-hydroxylactone ring, in contrast to other camptothecins that have a six membered            
α-hydroxylactone ring (Huchet et al., 2000, Demarquay et al., 2000).   The                       
α-hydroxylactone ring in BN 80927 is modified by the insertion of methylene (-CH2) 
group.  When compared to camptothecin, topotecan, and irinotecan, BN 80927 has 
improved plasma stability because the additional methylene group undergoes slow and 
irreversible hydrolytic ring-opening (Demarquay et al., 2000).  In vitro and in vivo 
experiments show that BN 80927 inhibits topo-I mediated supercoiled-DNA relaxation 
because it stabilizes topo I- cleavage complex (Lavergne et al., 1999).  BN 80927 was 
also shown to inhibit topo II mediated supercoiled-DNA relaxation and DNA 
decatenation activity (Demarquay et al., 2000).  In contrast to etoposide, BN 80927 does 
not stabilize topo II-DNA cleavage complexes (Demarquay et al., 2000).  Thus, BN 
80927 is a topo I poison and a topo II catalytic inhibitor.  The fourth example of a non-
intercalating dual topo I and II inhibitor mentioned above was F11782.  Treatment of 
P388 murine leukemia cells with F11782 results in dose-dependent DNA fragmentation 
and activation of apoptotic pathways through a caspase 3/7 dependent mechanism.  
F11782 has also been shown to have improved in vivo anti-tumor activity, relative to 
three other cytotoxic agents (Kruczynski et al., 2004). 
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 The third group of dual topo inhibitors is known as "hybrid molecules" because 
they consist of a topo I inhibitor biochemcially linked with a topo II inhibitor.  The 
hybrid molecules are still in early stages of drug development and have not been formally 
reported in the literature (Denny and Baguley, 2003).  The dual topo inhibitors are 
promising new drugs because they may evading toxicity by compensating one enzyme 
for another enzyme.  
 
4.6  Conclusions. 
 Topo I and topo II are the molecular targets of several antitumor agents used for 
the treatment of hematological malignancies (Wang, 1996).  Topo I is the major 
molecular target of the camptothecins (i.e., topotecan and irinotecan).  The camptothecins 
are topo I poisons, and thus stabilize topo I-DNA cleavage complexes  Topo II poisons, 
such as VP-16 and VM-26, stabilize topo II cleavable complexes, whereas the catalytic 
inhibitors of topo II do not stabilize cleavable complexes.  The catalytic inhibitors 
prevent topo binding to DNA, or trap topo II in a closed formation.  Dual inhibitors of 
topo I and topo II are promising new cytotoxic agents, but the focus of this investigation 
is on topo I and topo II poisons and topo II catalytic inhibitors.  Drugs that act on other 
molecular targets besides topoisomerases are briefly described in following chapter. 
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Chapter Five 
Non-topoisomerase Interacting Agents 
 
5.1 Introduction. 
 Although some drugs interfere with DNA metabolism, they may do so without 
associating with a topoisomerase and should not be confused with the topoisomerase 
interacting agents described above. Thus, the primary mechanism by which these types of 
drugs exert their cytotoxic effect is independent of topo content or activity. For example, 
DNA alkylating agents such as Carmustine, a lipophilic nitosourea, undergoes hydrolysis 
in vivo to form reactive metabolites that produce lethal O6-chloroethylguanine DNA 
interstrand crosslinks (Egyhazi et al., 1991). The non-topoisomerase interacting agents 
can be used in laboratory studies to help distinguish mechanisms of cellular drug 
resistance that are a result of alterations in the quality or content of topo from other non-
topo related cellular events, such as alterations in drug transport. In some instances, 
exposure to one type of drug can result in cross-resistance to many other drugs that are 
structurally unrelated, a phenomenon known as multidrug resistance.  We assessed 
human myeloma cell lines for cross-resistance to taxol, ara-c, cisplatinum, and 
carmustine. These cytotoxic agents were selected because of their differences in chemical 
structure and mechanism of action (figure 13; table 4).  To improve drug sensitivity, the 
non-topoisomerase drugs are often given in combination with topo targeting cytotoxic 
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agents. For example, a combination of topotecan, ara-c, and cisplatin have reached phase 
II clinical studies for relapsed or primary refractory lymphomas (Coutinho et al., 2004). 
Unfortunately, multidrug resistance to combination chemotherapy is a limitation that 
needs to be overcome. Cisplatin, paclitaxel, ara-c, and carmustine are four examples of 
non-topoisomerase targeting agents described herein. 
 
5.2  Cisplatinum. 
Cisplatin (cis-diamminedichloroplatinum; CDDP) and its synthetic analogues are 
DNA crosslinking agents and platinum containing compounds that exert their cytotoxic 
effects by inducing the formation of various types of DNA lesions (Crul et al., 2002; 
Iikima et al., 2004).  Cisplatin is a DNA crosslinking agent with potent antitumor activity 
against various kinds of cancers including, non-small cell lung cancer (Wang et al., 
2004).  However, acquired drug resistance to CDDP is a common observation in these 
patients.  The mechanisms of drug resistance to cisplatin are unknown, but enhanced 
DNA repair, altered drug transport, and drug inactivation by metallothionine have all 
been associated with decreased drug sensitivity to CDDP (Wang et al., 2004).  
Furthermore, sensitivity to DNA-crosslinking reagents are inversely proportional to topo 
levels and activity, and thus elevated levels of topo II correlate with resistance to cisplatin 
(Tan et al., 1987).  This has been explained by the involvement of topo IIα in processing 
DNA damage induced by DNA crosslinking agents (Tan et al., 1987).  A deficiency in 
topo IIα activity correlates with increased drug sensitivity as a result of an increase in 
drug-induced sister chromatid exchanges.  These results suggest that the efficacy of 
CDDP in cancer chemotherapy can be improved through inhibition of topo IIα.   
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5.3  Paclitaxel. 
Microtubules are intracellular organelles, formed from the protein tubulin, 
involved in chromosome segregation, transport, motility, and cell structure (Jordan and  
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Figure 13. Paclitaxel (Taxol), Cytarabine (Ara-c), Cisplatinum (CDDP) and 
Carmustine (BCNU). Structures of the non-topoisomerase associated agents used 
in the soft agar cytotoxicity experiments (see “materials and methods”) . 
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Topoisomerase Associated Non-topoisomerase Associated  
Topotecan 
(TPT) 
Etoposide 
(VP-16) 
Mitoxantrone Paclitaxel 
(Taxol) 
Cytarabine  
(Ara-C) 
Carmustine 
(BCNU) 
Cis-platinum 
(CDDP) 
Class Alkaloid Epipodophyllotoxins Anthracenediones Mitotic inhibitor Anti-metabolite Nitrosourea (Alkylating) Alkylating 
MW* 457.9 588.6 517 853.9 243.2 214.06 300 
Mechanism of 
Action 
Topo I  
inhibitor Topo II inhibitor Topo II inhibitor 
Inhibits microtubule 
formation DNA polymerase DNA crosslinking 
DNA  
crosslinking 
 Cell-cycle   
 dependent? yes, S-phase 
yes, late S  
and G2 yes yes yes, S-phase some, G1 and G2/M no 
Examples of    
In vitro 
Mechanisms of 
Drug Resistance 
Altered cellular 
content or activity 
of topo I; altered 
drug transport 
Altered cellular 
content. location , or 
activity of topo IIα; 
altered drug 
transport 
Altered cellular 
content , location, or 
activity of topo IIα; 
altered drug 
transport 
Altered drug 
transport; gene 
mutations in β 
tubulin 
Altered drug 
transport  
Enhanced DNA 
repair 
Drug inactivation; 
enhanced DNA repair; 
altered drug transport 
Therapeutic Uses 
Ovarian cancer, 
SCLC, gliomas, 
AML, CML, MM, 
MDS, 
neuroblastoma,  
ALL, AML, Brain 
tumors, Ewing’s 
sarcoma, 
Histiocytosis X 
CML, AML, ALL, 
breast cancer, NHL, 
ovarian cancer 
breast cancer, 
ovarian cancer, head 
and neck cancer, 
lung cancer 
AML, ALL CML, 
NHL 
brain tumors, 
Hodgkin’s 
lymphoma, Non-
Hodgkin's 
lymphoma 
bladder cancer, 
adrenocortical cancer, 
lung cancer, ovarian 
cancer, testicular 
References Rasheed and Rubin, 2003 
Meresse et al., 2004; 
Hande, 2003 
Thomas and 
Archimbaud, 1997; 
Center, 1993 
Jordan and Wilson, 
2004 
Wills et al., 2000;  
Abdel et al., 2000 
Linfoot et al., 1988 
Ueda-Kawamitsu, et 
al., 2002; 
Henderson et al., 
1987 
Brabec and Kasparkova, 
2005; Arbuck, 1994 
Table 4.  Comparison of DNA Topoisomerase Inhibitors with Non-Topoisomerase Targeting Anticancer Agents 
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Wilson, 2004).  Taxol is a tubulin-binding antimitotic agent with antitumor activity in a 
variety of cancers including breast cancer (Yvon et al., 1999; Fountzillas et al., 2004).  
Cells acquire drug resistance to taxol by decreasing intracellular concentration through 
protein transport pumps and by gene mutations in the beta tubulin gene that alter drug 
binding properties (Zhou et al., 2004; Hadfield, et al., 2003; Dumontet and Sikie, 1999).   
 
5.4 Cytarabine (Ara-C). 
Cytarabine (ara-C) is an antimetabolite and nucleoside analog of deoxycytidine 
(Frei et al., 1973; Kufe and Spriggs, 1985).  Ara-c differs from deoxycytidine by the 
addition of a hydroxyl group on the 2' position of the sugar moiety.  Once inside the cell, 
ara-C is converted into an active form, cytarabine-5’-triphosphate (ara-CTP) (Frei et al., 
1973).  The rate limiting step of ara-C activation is catalyzed by deoxycytidine kinase 
(Coleman et al., 1975).  Ara-CTP competes with deoxycytidine triphosphate for 
incorporation into DNA, and thus is a competitive inhibitor of DNA polymerase (Kufe 
and Spriggs, 1985; Furth and Cohen, 1968).  Incorporation of ara-CTP into DNA 
eventually results in inhibition of DNA synthesis and cell death (Mikita and Beardsley, 
1988; Kufe et al., 1984).  Incorporation of Ara-c into DNA is also associated with local 
conformational changes in DNA, inhibition of DNA polymerase, and a decreased ability 
of transcription factor binding to DNA binding elements (Zhang et al., 2004b; Mikita and 
Beardsley, 1988).  Ara-C is often used in combination therapy for different types of 
leukemia (Szafraniec et al., 2004). Complete response rates in acute myelocytic leukemia 
(AML) reach 65-80%; however, patients usually relapse within 2-years and are resistant 
to subsequent chemotherapy (Cros et al., 2004).  Resistance to ara-C has been attributed 
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to overexpression of the P-glycoprotein drug efflux pump, but some patients who are 
resistant to ara-C do not express P-glycoprotein (Galmarini et al., 2002a). Drug resistance 
in these patients has been partially attributed to deficiency in the human equilibrative 
nucleoside transporter 1 (hENT1), a transmembrane drug influx pump (Boleti et al., 
1997). A lack of hENT1 presumably results in less intracellular concentrations of ara-C 
because of decreased intracellular drug import (Galamarini et al., 2002a; Lang et al., 
2001). 
 
5.5 Carmustine (BCNU). 
Carmustine (BCNU) is a nitosourea compound with DNA alkylating activity. 
BCNU forms a chloroethyl adduct on the O6 position of guanine, which spontaneously 
converts to N1-O6 ethanol-guanine (D’Incalci et al., 1988).  The adjacent cytosine 
covalently binds to the N1-O6 ethanol-guanine to form an intrastrand cross-link that 
interferes with DNA replication and transcription (Erickson et al., 1980).  Carmustine has 
antitumor activity against leukemias and gliomas, and is currently being evaluated in 
phase II clinical trials for recurrent glioblastoma (Brandes et al., 2004).  A major 
limitation to BCNU effectiveness is that acquired drug resistance usually occurs after the 
first administration of the drug (Brandes et al., 2002).  Acquired chemoresistance to 
BCNU has been attributed to the expression of the DNA repair enzyme, O (6)-
alkylguanine-DNA- alkyltransferase (AGT), because this enzyme removes alkyl groups 
from DNA (Brandes et al., 2002). 
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5.6 Conclusions. 
 Topoisomerases are not the molecular targets of DNA crosslinking agents (i.e., 
cisplatin), anti-metabolites (i.e., ara-C), DNA alkylating agents (i.e., carmustine), or anti-
microtubules (i.e., paclitaxel).  Non-topoisomerase targeting agents are sometimes used 
in combination with topoisomerase targeting agents in cancer chemotherapy.  Cancer 
cells have several molecular adaptations to evade drug induced cytotoxicity.  
Mechanisms of drug resistance to topoisomerase targeting agents are the focus of this 
investigation and are discussed in chapter five.   
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Chapter Six 
In vitro Mechanisms of Topoisomerase Associated Drug Resistance 
 
6.1 Introduction. 
 In the preceding sections, the family of DNA topoisomerases and commonly used 
chemotherapeutic drugs has been reviewed.  The focus has been on the topoisomerase I 
and II as the molecular targets of topoisomerase targeting cytotoxic agents. In this 
chapter, the mechanisms of tumor cell resistance to topo targeting agents and especially 
topo II mediated cellular drug resistance are explained (reviewed in Engel et al., 2003).   
 Although the development of new drugs and new drug combinations has resulted 
in more effective treatment of cancer, a major factor limiting their usefulness is the 
presence of drug-resistant cancer cells that can exist prior to (intrinsic or de novo drug 
resistance) or arise during cancer therapy (acquired drug resistance) (Bellamy et al., 
1990).  Whether drug resistance is intrinsic or acquired, mechanisms conferring altered 
drug sensitivity may be categorized as involving a pre-target event, a drug-target 
interaction, or a post-target event (Larsen and Skladanowski, 1998).  Mechanisms of drug 
resistance that result in a modification to the drug itself are called pre-target events 
because the cellular insult occurs before the drug reaches its intended molecular target.  
Drug metabolism is one example of a pre-target event because the drug becomes.  
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modified before reaching its intended molecular target.  Modifications to the drug's 
intended target, however, can also occur and results in altered drug-target interactions. 
For example, sequestration of the drug's intended target into a cellular compartment 
different from the drug results in an inability of the drug to interact with its target.  In 
other instances, neither the drug nor the drug's target is modified.  Post-target events 
occur after the drug-target interaction occurs, and thus do not directly involve the drug or 
the drug's target.  For example, altered cell-cycle progression can be a post target event, if 
the drug's target is not a cell-cycle regulatory protein.  Pre-target events, drug-target 
interactions, and post-target events are discussed herein as they pertain to mechanisms of 
drug resistance to topoisomerase targeting agents.  Figure 14 and figure 15 summarize the 
pre-target events, drug-target interactions, and post-target events that can lead to altered 
drug sensitivity to topo targeting agents.  Each type of mechanism of drug resistance that 
is illustrated in these two figures is explained separately in the following sections.  
However, mechanisms of drug resistance are not mutually exclusive events and thus, 
there is a fair amount of overlap between the types of drug resistance mechanisms.  
 
6.2 Pre-target Events: Altered Drug Transport. 
 Alterations in drug transport can either be a result of decreased drug import or 
increased drug efflux.  Some hydrophilic drugs need to be transported across the plasma 
membrane and into cells by specific drug transporters (Cass et al., 1998).  For example, 
cytarabine 
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Figure 14.  Alterations in Pre-target Events Associated with Drug Resistance.  Mechanisms of cellular drug resistance to 
topoisomerase inhibitors can be categorized as pre-target events, drug-target interactions, and post-target events (see reference Larsen 
and Skladanowski, 1998). Multiple cellular factors can be involved in conferring altered drug sensitivity. Altered drug transport is 
shown in (1) as the expression of drug transport protein pumps located on the plasma membrane that can result in either decreased 
drug import or increased drug efflux from the cell.  Once inside a cell, a drug can be sequestered into intracellular vesicles resulting in 
altered drug distribution as shown in (2). Some drugs undergo metabolic modifications, illustrated in (3), that alter their mechanism of 
action or result in an inactive form. Other drugs such as irinotecan are a prodrug that must be converted to an active metabolite.  
Cytotoxic agents that target topoisomerase must be move into the nucleus (4) where drug-target interactions occur.  Mechanisms of 
drug resistance by alterted drug-target and post-target events are illustrated in figure 15.  
Drug 
Effluxed drug 
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Figure 15.  Alterted Drug-target Interactions and Post-target Events Associated with Drug Resistance.  Altered drug-target interactions include (1) altered 
subcellular localization of nuclear enzyme that results in decreased amount of topo present in the nucleus (2) decreased amount of active enzyme in the 
nucleus is associated with resistance to topo poisons (3) increased amount of active topo enzyme is usually atttirbuted to decreased drug sensitivity to 
catalytic inhibitors of topo and (4) altered chromatin structure can result in altered topo-DNA binding activity.  Post-target events associated with drug 
resistance to topo targeting agents include (5) decreased amount of replicating cells, (6) DNA-repair of cleavable complexes, and (7) decreased ability to 
initiate apoptosis.  Topo is shown as yellow circles, the drug is shown as blue/grey circles, and DNA is shown as a red double helix except in (4) where 
DNA is shown in a relaxed conformation.  In diagrams (5-7) the area of the cytoplasm is omitted because these events occur in the nucleus. For a review of 
this topic see reference (Larsen and Skladanowski, 1998). 
2 4 3 7 
6 5 
1 
Post-target Events Drug-target Interactions
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(ara-C) is a hydrophilic nucleoside analogue that is transported into cells by the human 
equilibrative nucleoside transport protein 1 (hENT1), a drug influx pump that is 
expressed in the plasma membrane of some human cells (Boleti et al., 1997).  In vitro 
cellular drug resistance to ara-C has been associated with lack of hENT1 mRNA 
expression in human T-lymphoblast CCRF-CEM cell lines selected for resistance to ara-
C (Lang et al., 2001).  Furthermore, shorter disease-free survival correlates with the 
absence hENT1 gene transcription in patients with acute myeloid leukemia (Galmarini et 
al., 2002b).   
 Topoisomerase targeting agents must also be taken up by cells and transported to 
the nucleus to be effective as cytotoxic agents.  Therefore, reduced drug accumulation is 
a chief mechanism conferring drug resistance topoisomerase targeting agents in several 
drug-resistant cell lines (Matsumoto et al., 2005; Kamath et al., 1992; Hendricks et al., 
1992).  In general, topoisomerase targeting agents are presumed to enter cells by passive 
diffusion and are rarely found to be substrates of drug influx pumps.  However, both 
active and passive transport of camptothecin has been found to occur in human intestinal 
cells (Gupta et al., 200).  Influx of topotecan and SN-38 has also been suggested to occur 
by active transport in ovarian cells (Ma et al., 1998).  Drug resistance in these cells was 
attributed to decreased drug accumulation independent of P-gp and MRP expression.  
Nevertheless, topo targeting agents are more commonly shown to be substrates for 
several drug efflux pumps.  Therefore, tumor cells that express drug transport proteins 
involved in the extrusion of topo interacting agents are found to be drug resistant.   Table 
5 summarizes the chemotherapy related substrates for drug transport proteins.   
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Table 5. Drug Transporters and Chemotherapy Substrates 
rug Name Drug Transporters* Member of ABC-Transporter Superfamily? Drug Influx or Efflux? References 
Etoposide  
(VP-16) 
P-gp/MDR1, MRP1, MRP2, 
MRP3, Yes Efflux 
Lorico et al., 1995 
Neuhaus et al., 1995 
Teniposide P-gp/MDR1, MRP3 Yes Efflux Kool et al., 1999 
Mitoxantrone MRP2, BCRP Yes Efflux Neith and Lage, 2005 
Topotecan 
 (TPT) BCRP Yes Efflux Yang et al., 2000 
MRP2, MRP3 Yes MRP2 and MRP3: drug efflux  Cis-platinum (CDDP) 
CTR1 No, CTR1 is a plasma membrane carrier for nucleoside analogs. CTR1: drug influx 
Kool et al., 1997 
Kawabe et al., 1999 
Ishida et al., 2002 
Sn-38 
(active metabolite of 
CPT-11/ irinotecan) 
BCRP Yes Efflux Nakatomi et al., 2001 
Paclitaxel (Taxol) P-gp/MDR1, MDR2, BSEP Yes Efflux 
Gerloff et al., 1998 
Childs et al., 1998 
Reinecke et al., 2000 
Cytarabine  
(Ara-C) hENT1 
No, hENT1is an integral membrane 
proton belonging to the equilibrative 
nucleoside transport protein family 
Influx 
Boleti et al., 1997 
Cass et al., 1998 
Lang et al., 2001 
Galmarini et al., 2002b 
Carmustine 
(BCNU) 
Not a substrate for known drug 
transporters - 
BCNU enters the cell by 
diffusion 
Carter et al., 1972 
Balcerczyk et al., 2003 
Abbreviations used in this table: ABC-Transporter, ATP-binding cassette transporter; P-gp, P-glycoprotein; MDR, multidrug resistance; MRP, multidrug 
resistance-related protein; BCRP, breast cancer resistance protein; CTR1, copper transporter 1; BSEP, bile salt export pump; hENT1, human equilibrative 
nucleoside transporter1.  
*Reviewed in reference, Ambudkar et al., 2003 
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Under normal conditions, ATP-binding cassette (ABC) transport proteins pump cytotoxic 
agents and xenobiotics out of the cells (van der Does and Tampe, 2004).  Expression of 
ABC transporters in cancer cells results in decreased intracellular levels of the 
administered chemotherapeutic agent that is associated with the multi-drug resistance 
(MDR) phenotype (Ling, 1997). Multi-drug resistance describes the phenomenon that 
occurs when cells initially exposed to one class of cytotoxic agents become resistant to 
other unrelated drugs with various structural and chemical properties (Larsen and 
Skladanowski, 1998)  The ABC transport proteins identified in humans include, multi-
drug resistance protein-1/P-glycoprotein (MDR-1/P-gp) (Hoffmann and Kroemer, et al., 
2004), multi-drug resistance-associated protein (MRP) (Hoffmann and Kroemer, et al., 
2004), and breast cancer resistance protein (BCRP) (Doyle and Ross, 2003; Allen et al., 
1999).  The expression drug efflux pumps in cancer cells can reduce the intracellular 
accumulation of chemotherapeutic agents.   
 P-gp is a 170 kDa transmembrane glycoprotein that is able to expel a structurally 
heterogenous group of chemotherapeutic agents, including anthracyclines, vinca alkaloids 
and epipodophyllotoxins (Shustik et al., 1995).  P-gp can extrude chemotherapeutic 
agents out of cells against a concentrations gradient (Lankelma et al., 1990).  
Overexpression of P-gp is estimated to occur in approximately 50% of all human tumors, 
and thus P-gp activity likely has a role in treatment related failure of some chemotherapy 
(Gottesman, 1993; Sikic, B.I. 1993).  Overexpression of P-gp has been observed in many 
intrinsically drug resistant tumors derived from kidney, liver, adrenals, colon, and rectum 
(Goldstein et al., 1989).  However, many drug resistant cells do not express P-gp, 
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suggesting a role for other drug efflux pumps in cellular drug resistance (Mirski et al., 
1987, Zijlstra et al., 1987).   
 Some drug resistant cell lines express the multidrug resistance-associated protein 
(MRP) (Cole et al., 1992).  MRP has seven family members conferring different substrate 
specificities.  For example, methotrexate is a substrate for MRP1, but not MRP2 (Konno 
et al., 2003).  Both P-gp and MRP are able to transport glutathione-S-conjugated 
chemotherapeutic agents (Müller et al., 1994).  MRP expression is found in a wide range 
of tissues, but varies by family member.  For instance, MRP1 expression is found in most 
tissues, whereas MRP6 expression is limited to the liver and kidney.  The breast cancer 
resistance protein is another type of drug efflux pump that is found to be overexpressed in 
some drug resistant cell lines (Doyle and Ross, 2003).  BCRP is expressed in breast 
tissue, placenta, intestine, and liver. Overexpression of BCRP results in cross-resistance 
to mitoxantrone and topotecan, but not to microtubular inhibitors, such as paclitaxel 
(Litman et al., 2000).  The lung resistance related protein (LRP) is a major vault protein 
localized on lysosomes and in the nuclear pore complexes (Scheffer et al., 1995).  LRP 
was initially described in drug resistant non-small cell lung cancer cell lines that were 
deficient in P-gp expression (Scheper et al., 1993).  LRP modulates the transport of drugs 
between the nucleus and the cytoplasm.  Expression of LRP is associated with the 
multidrug resistance and intrinsic drug resistance to doxorubicin, vincristine, and 
cisplatin (Mossink et al., 2003; Scheffer et al., 2000; Izquierdo et al., 1996).  Drug uptake 
of [3H-VP-16] is one method that is used in the laboratory to determine the cellular 
uptake of etoposide (or other cytotoxic agents) and drug transport protein activity. 
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6.3 Pre-target Events: Altered Drug Distribution.  
 After cellular drug uptake, cells may sequester drugs into intracellular vesicles 
and thus, withhold the drug from reaching its molecular target.  Drug sequestration into 
cytoplasmic vesicles has been described in vitro in several drug resistant cell lines by 
following fluorescently labeled compounds, such as mitoxantrone (Schuurhuis et al., 
1991; Gervasoni et al., 1991).  Altered intracellular distribution of doxorubicin has also 
been described in leukemic cells obtained from patients with acute myeloid leukemia 
(Schuurhuis et al., 1995).  Altered drug distribution is usually described as a shift in the 
amount of fluorescence from the nucleus to the cytoplasm.  The pattern of fluorescence in 
the cytoplasm is consistent with vesicle formation.  The apparent shift in fluorescently 
labeled compounds from the nucleus to the cytoplasm may be a result of LRP, the major 
vault protein found on the nuclear membrane that modulates nuclear-cytoplasmic drug 
transport.  However, vesicle formation is not well understood (Slapak et al., 1992).  One 
mechanism has been proposed for the sequestration of DNA topoisomerase targeting 
agents inside acidic vesicles (Larsen and Skladanowski, 1998).  Accordingly, the 
cytoplasm of most cells is mildly alkaline, a requirement for the proper functioning of the 
trans-Golgi network and endocytotic secretory pathways (Tarakoff et al., 1983).  Since 
some topo targeting agents such as anthracyclines, anthracenediones and amascarine act 
as weak bases, they can be protonated and retained inside acidic vesicles that are present 
in the cytoplasm (Larsen and Skladanowski, 1998).  Drugs retained inside the lysosomes 
are then extruded from the cell via exocytosis (Tartakoff et al, 1983).  Protonation and 
retention of topo targeting agents inside cytoplasmic lysosomes would theoretically 
inhibit drug transport into the nucleus.  This hypothesis is supported by adriamycin-
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resistant MCF-7 cells that sequester protonated compounds within vesicles, and secrete 
the drugs by endocytotic secretory pathways (Schindler et al., 1996).  Hence, drug 
resistant tumor cells are able to maintain a pH gradient between the acidic environment of 
lysosomes and the alkaline environment of the cytoplasm, which ensures the entrapment 
of toxic substances inside acidic vesicles and subsequent extrusion of drugs out of the cell 
via the trans-Golgi network.  Conversely, drug sensitive cells fail to establish a pH 
gradient, which disrupts proper formation of acidic vesicles and functioning of the trans-
Golgi-network (Schindler et al., 1996).  In summary, sequestration of chemotherapeutic 
agents inside vesicular compartments may have a role in altered drug sensitivity by 
reducing the amount of drug available to interact with its molecular target.  
 
6.4 Pre-target Event: Drug Metabolism. 
 Once inside a cell, some topo I and II targeting agents can be modified by 
metabolic enzymes.  Modifications to chemotherapeutic drugs may be necessary for 
activation of a prodrug or can result in a less effective cytotoxic agent.  For example, 
CPT-11 is an inert drug that must be converted to the active compound SN-38 by 
carboxylesterases.  Thus, tumor cells expressing low levels of carboxylesterases are 
resistant to CPT-11 (Danks et al., 1998).  Furthermore, SN-38 can be detoxified when 
modified by one of several enzymes belonging to the family of UDP-
glucuronosyltransferases (UGT) (Ciotti et al., 1999).  The UGT enzymes can convert SN-
38 into SN-38 glucuronide.  Glucuronidation of SN-38 is associated with increased drug 
efflux from colon cancer cells and decreased drug sensitivity in colon, breast, and lung 
cancer cells (Cummings et al., 2002).  Modification of DNA alkylating agents has also 
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been attributed to altered drug sensitivity.  DNA alkylating agents can be detoxified when 
modified by the enzyme glutathione S-transferase (GST).  GST belongs to a family of 
enzymes that catalyzes the conjugation of glutathione (GSH) to cancer drugs (Hayes and 
Pulford, 1995).  Chemotherapeutic agents that are conjugated to glutathione are usually 
less active than their unconjugated counterparts.  Glutathione conjugated drugs can also 
become substrates for the drug efflux pump, multidrug resistance protein 1 (MRP), and 
thereby pumped out of the cell (Paumi et al., 2001).  Cellular drug resistance to 
anthracyclines is also associated with the intracellular amount of glutathione present 
because glutathione neutralizes free radicals.  Some topo targeting agents, including the 
anthracyclines, exert their cytotoxic effect at least in part by producing free radicals.  
Glutathione is implicated in modulation of free radical formation by decreasing OH 
production.  This is significant, because some human tumor cells have significantly 
higher levels of GSH.  In summary, acquired drug resistance to DNA alkylating agents is 
attributed to deactivation by GST and extrusion from the cell by MRP, whereas drug 
resistance to anthracyclines is attributed to neutralization of free radicals by GSH.  
Additional mechanisms of cellular drug resistance to topo I inhibitors has also been 
associated with induction of hepatic cytochrome P-450, activation of nuclear factor kappa 
B (NF-κB), and activation of DNA-tyrosine phosphodiesterase (DTP1) (Frei et al., 2002; 
Yang et al., 1996; Harris and Hochhauser, 1992).  DTP1 is an enzyme able to cleave the 
phosphodiester linkage between DNA and the active site tyrosine of topo I (Debethune et 
al., 2002).  Yeast cells expressing DTP1 gene mutations are hypersensitive to CPT and 
thus, DTP1 may modulate CPT activity and affect cell sensitivity to topo I inhibitors 
(Cheng et al., 2002).  
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6.5 . Drug-target Events: Altered Quantity of Topoisomerase I or II Protein. 
 Generally, topo targeting agents turn topo into a lethal DNA damaging agent, so 
that the more target enzyme that is available to induce DNA damage, the more effective 
the agent.  Thus, the amount of cleavable complex formation should increase as a 
function of increasing enzyme levels (Larsen and Skladanowski, 1998).  This is 
supported by findings that the cytotoxicity of topo II poisons frequently correlates with 
topo II levels and the proliferative status of the cells in vitro (Sullivan et al., 1987a, 
1987b; Chow and Ross, 1987).  Since cancer cells often have a higher level of topo IIα 
protein and activity at all stages of the cell cycle, topo II is a frequent target of 
antineoplastic agents. Tumor cells that are undergoing high rates of DNA replication are 
more sensitive to topo inhibitors because topo IIα is preferentially transcribed in S-phase 
cells and cells that are in S and G2/M have higher levels of topo IIα enzyme than non-
proliferating cells.  This has been demonstrated in breast cancer cell lines that are drug 
resistant to etoposide because of lower amounts of topo IIα protein relative to the parental 
cell line (Potmesil et al., 1988).  Colorectal tumors show a 5-35 fold increase in topo I 
protein levels compared to normal colorectal cells.  Topo I levels are also increased 2-10 
fold in prostate tumors compared to benign prostate tissues.  Alterations in the expression 
of topo protein may be due to loss or gain of gene copies or due to altered gene 
transcription.  For example, methylation of the topo I gene may account for 
downregulation of topo I protein content in resistant cells (Fujimori et al., 1996). 
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6.6 Drug Target Interactions: Altered Quality of Topoisomerase I or II Protein.  
 The phosphorylation status may contribute to alterations in cellular drug 
sensitivity.  Hyper and hypophosphorylation of topo II has been associated with reduced 
cleavable complex formation and decreased drug sensitivity to topo II targeting agents 
(Ritke et al., 1994).  Changes in topo II phosphorylation are also associated with both 
increased and decreased enzyme activity and a decrease in the cellular content of topo II 
protein (Kroll, 1997).  For example, hyperphosphorylation of topo IIα by casein kinase II 
is associated with decreased protein levels and decreased drug sensitivity to etoposide in 
breast cancer cells (Matsumoto et al., 1997).  However, topo II phosphorylation does not 
always result in attenuation of topo II content.  HL60 cells selected for resistance to 
doxorubicin were found to be cross-resistant to etoposide because of a reduction in the 
formation of VP-16 stabilized cleavable complexes, when compared to the parent cell 
line that were sensitive to both doxorubicin and etoposide (Ganapathi et al., 1996).  
However, the attenuation of cleavable complex formation was not a result of either a 
reduction in the amount or activity of topo II protein in these cells.  The reduction in VP-
16 stabilized cleavable complex formation was attributed to a 3-fold decrease in the 
phosphorylation status of topo IIα.  Further investigations determined that, unlike topo 
IIα, there is a concomitant hyperphosphorylation of topo IIβ in the HL60 cells selected 
for doxorubicin resistance (Grabowski et al., 1999).  Furthermore the changes in the 
phosphorylation status of both topo IIα and IIβ correlated with an increase in drug 
sensitivity to m-AMSA, a DNA intercalating agent that inhibits topo II.  The increased 
drug sensitivity to m-AMSA was attributed to a 2-fold increase in topo IIβ stabilized 
cleavable complex formation as compared to VP-16 -topo IIβ cleavable complex 
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formation.  These results suggest that the phosphorylation status of the different topo II 
isoforms may have a role in drug sensitivity that depends on the specific mechanisms of 
drug action.   
 Although topo I has been shown to be differentially phosphorylated during 
mitosis (D'Arpa and Liu, 1995), whether the changes in topo I phosphorylation have a 
role in conferring differences in drug sensitivity to topo I targeting agents has not been 
established.  Human purified topo I enzyme activity is inactivated by phosphatases and 
can be reactivated by casein kinase II or protein kinase C, suggesting that 
phosphorylation regulates topo I enzyme activity (Kaiserman et al., 1988; Pommier et al., 
1990).  However, differently phosphorylated forms of topo I have been shown to cleave 
chromosomal DNA and relax supercoiled DNA with about equal topo I activity (D'Arpa 
and Liu, 1995).  Alternatively, sumoylation followed by redistribution of topo I from the 
nucleoli to the nucleoplasm in response to topotecan or camptothecin exposure has been 
reported (Mo et al., 2002; Rallabhandi et al., 2002).  It is not clear whether the 
translocation of topo I from the nucleoli to the nucleoplasm results in altered drug 
sensitivity to topotecan or camptothecin.  Another cellular mechanism that could confer 
cellular resistance to topo I poisons appears to be the degradation of DNA-linked topo I, 
which is mediated by ubiquitination and small ubiquitin related modifiers (SUMO) 
(Desai et al., 1997). Proteins modified with ubiquitin molecules are frequently destroyed 
by the proteasome, whereas sumoylation has been shown to modulate gene transcription, 
protein-protein interactions, subcellular localization, and protein stability.  When Chinese 
hamster ovary cells are treated with camptothecin, topo I-DNA cleavable complexes are 
multi ubiquitinated and destroyed by the 26S proteasome mediated pathway.  However, 
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only 5-10% of the total amount of cellular topo I that was trapped in the cleavable 
complex after CPT treatment becomes conjugated to ubiquitin.  Thus, it appears that a 
fraction of topo I cleavable complexes are marked for ubiquitin mediated proteolysis.  
Additional investigations are needed to address whether ubiquitin modified topo I 
cleavable complexes can result in altered drug sensitivity to camptothecin and whether 
proteasome mediated degradation of topo I cleavable complexes is specific to CPT and 
topo I.  Camptothecin also induces sumoylation of topo I on Lys-117, located in the 
amino terminal region of topo I (Rallabhandi et al., 2002).  Sumoylation of Lys-117 is 
associated with the clearing of topo I from the nucleoli to the nucleoplasm in response to 
CPT treatment.   
 There are numerous examples found in the National Library of Medicine that 
describe posttranslational modifications of topo I and II occurring in cell lines that have 
been selected for resistance to topo targeting drugs (Yu et al., 2004; Matsumoto et al., 
2001, 1999; Yanase et al., 2000; Yu et al., 1997; Kasahara et al., 1992).  However, it is 
beyond the scope of this investigation to review the results of all of these in vitro studies.  
A reasonable conclusion that can be inferred from the collective results of all of these 
investigations is that post-translational modification of topo I or II likely has a role in 
conferring alterations in drug sensitivity by altering the amount or activity or the enzyme,  
cleavable complex formation, or the stability of cleavable complexes.  In vivo drug 
resistance is likely to be manifested by any one or more of these methods that is 
dependent on the drug class, enzyme targeted, and cell type.  
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6.7  Drug Target Interactions: Topoisomerase Gene Mutations.  
 In some cell lines, cellular drug resistance to topo I and II targeting agents has 
been attributed to both point mutations and deletions.  Mutations in the topo I gene 
usually confers in vitro cellular drug resistance to one class of topo I targeting agents 
(Chang et al., 2002; Yanase et al., 2000).  This is in contrast to topo II gene mutations 
that usually result in cells being cross-resistant to all classes of topo II targeting agents 
(Larsen and Skladanowski, 1998).  However, some point mutations in the topo I gene, 
including tyrosine 723 to phenylalanine (T723F) and tyrosine 727 to phenylalanine 
(T727F), result in cells that are resistant to CPT and the indolocarbazole derivates of the 
antibiotic rebeccamycin (Woo et al., 2002).  Topo I gene mutations conferring resistance 
to the camptothecins have been found in drug resistant human cell lines, yeast cells, and 
in tumor tissue from patients treated with irinotecan (Tsurutani et al., 2002).  Mutations 
in the topo I gene appear to cluster either around the active site tyrosine residue (Tyr723) 
or around amino acids 361 through 364 (Larsen and Skladanowski, 1998).  Gene 
mutations that involve amino acids 361, 362, 363, and 364, confer drug resistance to CPT 
and are believed to alter the DNA-enzyme binding properties of CPT (Rasheed and 
Rubin, 2003; Larsen and Skladanowski, 1998).  Point mutations that occur in the core 
domain of topo I have been attributed to cellular drug resistance to camptothecin because 
of a reduction in topo I-DNA interactions (Kingma et al., 1999).  Camptothecin resistant 
P388 murine leukemia cells contain both gene rearrangements and hypermethylation in 
one allele of the topo I gene, resulting in a reduction of topo I enzyme activity and 
mRNA transcripts (Tan et al., 1989).  
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 Mutations in the topo IIα gene that confer altered cellular drug sensitivity to topo 
targeting agents have been studies in both yeast and mammalian cell lines (Larsen and 
Skladanowski, 1998).  Point mutations in yeast cells have been shown to confer drug 
resistance to etoposide (Kingma et al., 1999). A point mutation in yeast topo II that 
results in histidine 1012 changed to a tyrosine (H1012Y) residue corresponds with a 3-4 
fold increase in drug resistance to etoposide as compared to yeast cells expressing non-
mutated topo II enzyme (Kingma et al., 1999).  The observed drug resistance in these 
cells was explained by a decreased affinity of etoposide-enzyme binding as compared to 
non-mutated enzyme (Kingma et al., 1999).  In human cell lines, selection for drug 
resistance to etoposide or teniposide has been shown to result in point mutations in the 
topo IIα gene (Patel et al., 1993; Bugg et al., 1991).  Mutations found in human topo IIα 
in drug resistant cell lines tend to cluster either around ATP binding domain or the active 
site tyrosine residue (Nitiss and Beck, 1996).  Furthermore, since topo II forms dimers, it 
is possible that heterodimers exist that consist of one drug-sensitive and one drug 
resistant subunit.  Many cell lines that have been selected for resistance to topo II poisons 
in vitro have been shown to carry mutations in the gene for topo IIα, but mutations are 
rarely reported in patient samples (Wessel et al., 2002). Alterations in topo gene copy 
number can also occur in human cancers.  For example, the topo IIα gene is coamplifed 
with the HER-2/neu oncogene in breast, ovarian, and bladder cancer cells because the 
two genes are in close proximity to each other (Simon et al., 2003; Hengstler et al., 
1999).  This is significant because an increase in topo IIα gene copy number is associated 
with cancers that have increased sensitivity to topo II poisons such as doxorubicin, while 
a deletion of one copy of the topo IIα gene is associated with resistance to doxorubicin. 
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The only mutation in topo IIβ that has been reported to date is derived from drug-resistant 
cell lines which contain topo IIβ gene mutations that completely abate the activity of the 
enzyme (Dereuddre et al., 1995). No study has been reported that assesses mutations in 
topo IIβ from clinical specimens.   
 
6.8 Drug Target Interactions: Altered Chromatin Structure. 
 The topological structure of DNA modulates the level of topoisomerase binding 
(Zechiedrich and Osheroff, 1990; Howard et al., 1991).  In general, eukaryotic 
topoisomerase I and II type enzymes prefer positive and negatively supercoiled DNA 
over relaxed DNA substrates (Osheroff, 1986).  Modifications such as glycosylation and 
methylation have been shown to influence DNA conformation; however, the molecular 
mechanism leading from DNA modification to cellular drug resistance is not well 
documented (Stopper and Boos, 2001; Lopez-Baena et al., 1998).  In mammalian cells, 
DNA methylation of cytosine in CpG islands is an important regulatory mechanism of 
gene expression.  DNA methylation has also been shown to influence local 
conformational changes in the structure of DNA (Zacharias et al., 1988; Diekmann, 
1987)  DNA methylation is associated with remodeling of euchromatin to 
heterochromatin, suggesting that methylated DNA somehow alters the accessibility of 
DNA to transcription factors and regulatory proteins (Hori, 1983).  Conformational 
changes that occur in methylated DNA have been also been suggested to alter the binding 
and DNA cleavage properties of topo I and II (Boos and Stopper, 2001; Leteurtre et al., 
1994).  For example, topo I and II cleavage patterns are modified in vitro by CpG 
methylation in c-myc gene DNA fragments (Leteurtre et al., 1994).  Topo I and II 
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cleavage activity is shown to be dependent on the location of the methylated cytosine on 
the DNA in relation to the scissile bond.  Methylated cytosine has both suppressive and 
stimulatory activity on topo I, whereas topo II cleavage activity is mostly suppressed by 
methylated cytosine.  DNA methylation of CpG islands been proposed to have a role in 
tissue selectivity and efficiency of DNA topo targeting agents (Leteurtre et al., 1994).  
DNA methylation has also been shown to alter topo II decatenation activity in vitro, 
which may result in genomic instability, but whether this contributes to cellular drug 
resistance is not known (Zwelling et al., 1989). 
 
6.9 Post-target Events: DNA Repair. 
Both topo I and topo II have roles in DNA damage recognition and repair 
processes, but how cells repair drug-stabilized DNA cleavable complexes is poorly 
understood.  Sensitivity to DNA-crosslinking reagents is inversely proportional to topo 
levels and thus, elevated levels of topo II correlate with resistance to DNA cross-linking 
agents such as melphalan and Cisplatin (Dvorakova et al., 2002; Hirota et al., 2002).  
This has been explained by the involvement of topo IIα in processing DNA damage 
induced by melphalan (Hirota et al., 2002).  A deficiency in topo IIα activity correlates 
with increased drug sensitivity because of an increase in melphalan-induced sister 
chromatid exchanges (Karpinich et al., 2002).  These results suggest that the efficacy of 
melphalan in cancer chemotherapy can be improved through inhibition of topo IIα.  
Similar observations have been reported in H69 small-cell lung cancer cells resistant to 
radiation and cisplatin, in part because of an increase in topo IIα expression (Hennes et 
al., 2002).  The results suggest that increased topo IIα expression may confer radiation 
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and drug resistance because of increased DNA repair, and that radiation followed by a 
topo IIα targeting agent may be a potential strategy for overcoming resistance in small 
cell lung cancer.  DNA repair pathways have also been implicated in conferring 
sensitivity to etoposide and camptothecin in human colorectal cancer cells (Jacob et al., 
2001; Aebi et al., 1997). DNA mismatch repair (MMR) is normally involved in 
correcting base/base mismatches during DNA replication but it is also implicated in 
double strand DNA break repair and for modulating the induction of apoptosis as a result 
of various types of drug induced DNA damage. Cell lines defective in DNA mismatch 
repair pathways show increased sensitivity to both CPT and etoposide as compared to 
MMR proficient colorectal cell lines and sensitivity to these drugs does not correlate with 
endogenous levels of topo I or topo II (Jacob et al., 2001).  In summary, differences in the 
processing and repair of DNA lesions are likely to have a role in drug sensitivity to topo 
targeting agents.  It is plausible that the way cells remove and repair drug-stabilized 
cleavable complexes could influence cellular sensitivity to DNA damaging agents.   
 
6.10  Post-target Events: Alterations in Cell Cycle Progression. 
 The cellular content of topo IIα protein is highest during G2/M and lowest during 
early G1 of the cell cycle (Meyer et al., 1997; Nakajima et al., 1996).  Topo IIα protein is 
also markedly decreased in growth-arrested cells as compared to proliferating cells 
(Holden et al, 1990, Turley, et al, 1997).  In contrast, topo I and topo IIβ have a relatively 
uniformed expression throughout the cell cycle as compared to topo IIα (Drake et al., 
1989).  The cell-cycle and proliferation dependent fluctuations of topo IIα gene 
expression may also explain why some slow growing cancers may be intrinsically 
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resistant to topo inhibitors.  Therefore, the application of drugs specifically directed 
against topo IIβ could be useful for tumors that express a mutant form of topo IIα or have 
a large fraction of cells in Go/G1.  In these cases, topo IIβ could be a preferred molecular 
target because unlike topo IIα, topo IIβ expression is not dependent on the cell cycle or 
proliferative stage of the cell.  XK469 is a new anticancer agent that is reported to 
specifically target topo IIβ, although it may also have an anti-proliferative role involving 
cell-cycle related proteins (Snapka et al., 2001; Gao et al., 1999).  XK469 exerts its 
cytotoxic effect by arresting cells in prophase as a result of an irreversible accumulation 
of cyclin B1 in the G2/M phase of the cell cycle (Ding et al., 2001).  XK469 has been 
shown to have activity against a broad spectrum of murine solid tumors, including tumors 
that express the multi-drug resistance gene (LoRusso et al., 1998-99). 
 
6.11 Post-target Events: Altered Cell Death Pathways. 
   Certain cellular conditions such as glucose starvation, hypoxia, and DNA 
damage, are associated with drug resistance to topo II inhibitors, such as etoposide and 
adriamycin, because of a decrease in topo IIα gene expression.  A decrease in 
transcription of topo IIα gene correlates with increased levels of Sp-3, YB1, and p53 
status.  Several studies have investigated the role of p53 in response to topo mediated 
DNA damage (reviewed in Valkov and Sullivan, 2003).  The p53 protein has been shown 
to interact with topo II in vitro and stimulates the decatenation activity of topo II (Cowell 
et al., 2000).  The p53 protein can arrest cell cycle progression and can commit cells to 
programmed cell death (Bladosklonny, 2002).  Since p53 is mutated in a large percentage 
of cancers, this could suggest that a failure to induce apoptosis results in resistance to 
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DNA-damaging agents (Bunz et al., 1999).  Since topo-targeting agents kill cells by 
inducing DNA damage, p53 deficient cells could be resistance to topo poisons.  Other 
alterations in the apoptotic pathway may also confer cellular drug resistance to topo 
inhibitors.  For example, an elevated level of the anti-apoptotic protein bcl-2 is associated 
with decreased drug sensitivity in cancer cells (Real et al., 2004).  
 
6.12 Conclusions. 
 In summary, cancer cells have multiple different ways to evade the cytotoxic 
effects of topo targeting drugs.  Tumor cells with de novo resistance fail to respond to 
initial drug treatment..  In contrast, tumor cells with acquired drug resistance are initially 
sensitive to drug exposure, but then become resistant with future drug exposures.  The 
most commonly observed mechanisms of in vitro drug resistance to topo targeting agents  
usually describes alterations in drug transport or alterations in the amount or activity of 
topo IIα protein that may or may not be accompanied by topo IIα gene mutations. 
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Chapter Seven 
In vivo Mechanisms of Topoisomerase Associated Drug Resistance 
 
7.1 Introduction. 
 The mechanisms of drug resistance described for topo I and topo II inhibitors in 
model human cell lines have been well established, but the actual in vivo situation in 
patients with solid tumors and hematologic malignancies is still uncertain.  Mechanisms 
of in vivo drug resistance to topoisomerase targeting agents are usually related with 
alterations in drug transport and the quantity of topo protein or mRNA in clinical 
preparations.  However, in vivo drug resistance to topo inhibitors is likely to be a 
phenomenon influenced by a network of physiological factors, such as drug dosage, 
presence of the molecular target, the tumor microenvironment, and presence or absence 
of specific genetic aberrations (reviewed in Lehnert, 1996).  The clinical activity of 
chemotherapy is also dependent on hepatic drug metabolism, extracellular drug 
concentration, intracellular drug transport, and ability of the drug to access the cancer 
cells.  Furthermore, antitumor agents differ in their ability to diffuse through different 
tissues.  For example, scar tissue from surgery or radiotherapy reduces response rates 
with chemotherapy, especially in head and neck cancers (Rooney et al., 1985).  
Furthermore, some tumors can be poorly vascularized and some drugs are unable to cross 
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the blood brain barrier.  Therefore, various in vivo factors can influence how much active 
drug reaches the molecular target withincancer cells.  Cellular drug resistance in humans 
is complex and appears to be both multifactorial and variable amongst individual 
patients.   
 The work presented herein definitively describes an in vitro mechanism of drug 
resistance observed to topo II targeting agents in a human leukemia and myeloma cell 
lines.  Although clinical applications are speculated from the in vitro data presented in 
this work (refer to pages 201-203 herein), a complete description of in vivo mechanisms 
of cellular drug resistance in the clinical environment was outside the limits of this 
investigation (reviewed in Engel et al., 2003).  The focus here is to briefly describe our 
current understanding of clinical drug resistance to topoisomerase targeting 
chemotherapeutic agents.  This chapter focuses on gene mutations, cellular content of 
topo I and II, and the tumor microenvironment as mechanisms of clinical drug resistance 
to topo targeting chemotherapeutic agents.   
 
7.2. Gene Mutations.  
 There has been a constant search for point mutations, deletions, truncations, and 
atypical isoforms of topo in a wide variety of clinical samples and diverse tumor types.  
Several genetic aberrations, such as allelic inactivation, deletions, and point mutations, 
have been reported to occur in the gene for topo I and II in human cell lines.  However, 
topo I and II gene mutations are rarely detected in patient samples.  Thus far, the 
bronchial aspirate of one patient with small cell lung cancer treated with either etoposide-
containing chemotherapy is the only reported case to have identified two point mutations 
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in the topo IIα gene (Kubo et al., 1996).  DNA sequence analysis of this tumor show two 
transversions at codons 486 (G to A) and 494 (A to G), resulting in two missense 
mutations (arginine to lysine and glutamate to glycine, respectively).  More frequently, 
chemotherapy with topo II inhibitors leads to gross genomic rearrangements, including 
gene amplifications and deletions of the topo IIα gene (Järvinen and Liu, 2003).  For 
example, a recent clinical trial has detected topo IIα gene amplification by fluorescence 
in situ hybridization (FISH) in clinical samples from primary breast cancer tumor 
samples, which correlates with response to topo II inhibitors (Järvinen et al., 1999).   
Breast cancer seems to be one disease where amplification or deletion of the topo IIα 
gene frequently occurs (Järvinen and Liu, 2003).  Furthermore, topo IIα has been shown 
to be a marker of tumor aggressiveness and invasive potential in breast cancer, but the 
complexity of the response of breast tumors to chemotherapy is usually determined by 
evaluation of several markers (Cardoso et al., 2001; Nakopoulou et al., 2000).   
 There have been a limited number of clinical studies reporting topo I gene 
mutations (Ohashi et al., 1996).  One patient with large cell lung carcinoma who did not 
respond to cisplatin or irinotecan was found to have a missense mutation at codon 737 in 
the topo I gene (Tsurutani et al., 2002).  However, it was not determined if the missense 
mutation altered CPT induced topo I cytotoxicity.  Colorectal carcinomas have a high 
expression of topo I protein that is due to an increased topo I gene copy number, reaching 
up to eight copies (Boonsong et al., 2002, 2000).  For this reason, irinotecan, a topo I 
inhibitor, is being evaluated in clinical trials for the effective treatment of colorectal 
carcinoma.  Additional clinical studies are needed to determine if gene mutations found 
in drug resistant cell lines are clinically relevant.  
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7.3 Topoisomerase I and II Gene and Protein Expression.   
 The amount of topo protein has been investigated as a predictive factor for 
clinical response to topo I and topo II targeting chemotherapeutic agents.  All studies 
point to a substantial interpatient variability in the amount of topo content and often fail 
to correlate the amount of topo enzymes with either the prognosis or with the clinical 
response to topo I and topo II inhibitors used in different combinations (McKenna et al., 
1994).  For example, in acute lymphoblastic leukemia (ALL), Western blot analysis, 
polymerase chain reaction (PCR), Northern blot analysis and immunohistochemistry 
demonstrate that topo I and topo II gene and protein expression are variable (Stammler et 
al., 1994; McKenna et al., 1994).  In these studies, a total of 60% of the blasts are shown 
to be positive for topo II while the levels of topo I are in the range of 25-85% of the 
control cell line.  However, no correlation is found between the level of topo and clinical 
response.   
 
7.4 Tumor Microenvironment.  
 Additional physiological conditions exist in vivo that contribute to decreased drug 
sensitivity.  For example, under physiological conditions in the bone marrow, tumor cells 
aggregate to form tumor cell masses that confer drug resistance.  This is supported by in 
vitro studies demonstrating that when cancer cells are cultured in monolayers they are 
more susceptible to cytotoxic agents than when cultured as 3D aggregates, a phenomenon 
referred to as multicellular drug resistance (Jianmin et al., 2002; Desoize and Jardillier, 
2000)).  Cell adhesion mediated drug resistance (CAM-DR) is another phenomenon 
whereby tumor cells bind stromal cells or extracellular matrix proteins (Dalton, 2003).  
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CAM-DR represents an intrinsic mechanism of drug resistance used by malignant cells 
(Dalton, 2003).  Collectively, these findings suggest that the resistance to anticancer 
drugs that are often observed in the clinic is likely to be a result of many physiological 
conditions that act simultaneously (Mattern and Volm, 1993).  This hypothesis is 
supported by in vitro findings that cells selected for drug resistance have multiple 
mechanisms conferring decreased drug sensitivity (Hazlehurst et al., 1999; Harker et al., 
1995).  An example of an in vitro cell model that supports this theory comes from the 
mitoxantrone resistant 8226/MR4 8226/M20 myeloma cells (Hazlehurst et al., 1999).  
When compared to the drug-sensitive parental cell line, the 8226/MR4 cells were 10-fold 
resistant to mitoxantrone and 4-fold resistant to etoposide, whereas the 8226/M20 cells 
were 37-fold resistant to mitoxantrone and 15-fold resistant to etoposide.  Drug resistance 
in both cell lines was associated with decreased drug accumulation in a P-gp and MRP 
independent mechanism.  Decreased drug accumulation in these cells was attributed to an 
ATP dependent ouabain-insensitive drug transport mechanism.  Drug resistance could be 
reversed by the chemosensitizer, fumitrenogin C.  However, drug resistance in the 
8226/M20 cells was also attributed to a 70-88% reduction in topo IIα and topo IIβ protein 
content and reduced topo II enzyme activity, which was not observed in the 8226/MR4 
cells (Hazlehurst et al., 1999).  Thus, cancer cells have numerous mechanisms for 
overcoming the drug cytotoxicity.    
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7.5 Conclusions. 
 Resistance to chemotherapy is a common problem in patiens with cancer and a 
major obstacle that must be overcome for cancer therapy to be effective.  In vivo drug 
resistance is likely to be a multifactorial problem.  Tumor cells can manipulate their 
tumor microenvironment to gain growth and proliferative advantages and some tumor 
cells may have gene mutatins that contribute to altered drug sensitivity.  Therefore, 
clinicians must consider numerous biological variables that may differ between patients 
to optimize the effectiveness of cancer chemotherapy.   
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Chapter Eight 
Nuclear-cytoplasmic Trafficking of Proteins 
 
8.1  Introduction.  
 The separation of the nucleus from the cytoplasm plays a central role in regulating 
the subcellular localization of proteins, but is also a variable in drug delivery and 
cytotoxicity.  Generally, topo poisons convert the enzyme into a lethal DNA damaging 
agent, such that the more active enzyme that is present in the nucleus, the more effective 
the poison (reviewed in Engel et al., 2003).  Without the co-existence of the ternary drug-
DNA-topo complex, topo inhibitors are less effective as cytotoxic agents.  Thus, 
investigating the selective movement of macromolecules across the nuclear envelope 
represents a recent area of drug development (Dean et al., 2003).  The potential of the 
DNA topoisomerases to shuttle between the nucleus and cytoplasm has been one area of 
recent investigations (Engel et al.2004; Valkov et al., 2000).   
 
8.2 The Nuclear Pore Complex. 
 Recent investigations have elucidated several molecular pathways for the nuclear 
import and export of proteins across transport passageways or nuclear pore complexes 
(NPCs) (Weiss, 2003).  The NPCs are located in the nuclear envelope where the inner 
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and outer membranes are fused, providing a link between the cytoplasm and the interior 
of the nucleus (Davis, 1995; Doye and Hurt, 1997; Görlich and Mattaj, 1996).  The NPC 
is a large (125 MDa) (Reichelt et al., 1990) multimeric protein structure that perforates 
the nuclear envelope and channels proteins greater than 40 kDa into or out of the nucleus 
(Pante and Kann, 2002; Hinshaw et al., 1992).  The NPC consists of a central ring-spoke 
structure flanked by filaments emanating from its nuclear and cytoplasmic surfaces 
(Hinshaw and Milligan, 2003; Akey and Radermacher, 1993).  The pores are 25 nm in 
diameter and form 9 nm long channels (Peters, 1986).  The number of NPCs per nucleus 
varies with the organism, cell type, and growth conditions (Maui, 1977).  It is common 
for cells to have between 102 and 5 X 107 NPCs present per nucleus, depending on the 
metabolic or differentiation state of the cell.  Mammalian cells typically have 3,000-5,000 
NPCs, whereas yeast cells have approximately 120 NPC per nucleus (Winey et al., 1997).  
 
8.3 Nucleoporins. 
The NPCs are composed of approximately eight copies of 30 different proteins, 
the nucleoporins (Nups) (Rabut et al., 2004).  A number of membrane and nonmembrane 
anchored Nups have been described in yeast and mammalian cells by mass spectroscopy 
(Cronshaw et al., 2002).  Nup210 and glycoprotein 121 (gp121) are believed to play 
critical roles in anchoring the NPC to the nuclear envelope (Wozniak et al., 1989).  The 
Nups are phosphorylated in a cell-cycle dependent manner and are hyperphosphorylated 
during M-phase (Favreau et al., 1996).  During mitosis, the nuclear membrane 
breaksdown and the NPC is disassembled.  Phosphorylation of nucleoporins is associated 
with the disassembly of the NPC as well as reformation of the NPC when cell division is 
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complete.  Nucleoporins contain characteristic domains featuring multiple repeats of 
short peptide sequences ending in the amino acids phenylalanine and glycine (FG 
repeats) (Bayliss et al., 2000).  The FG repeats provide docking sites for protein- receptor 
cargo complexes (Radu et al., 1995).  Binding of transport receptors to the FG domains 
on the nucleoporins triggers the pore to dilate (Shahin et al., 2005; Shulga and Goldfarb, 
2003). One model suggests that multiple FG rich repeats in the NPC channel form a 
meshwork through weak hydrophobic interactions, which can function as a sieve 
(Ribbeck and Görlich, 2001).  Hydrophobic receptor-cargo complexes can transiently 
interact with the hydrophobic repeats, and thus dissolve the meshwork and translocate 
thorough the NPC.  In contrast, hydrophilic proteins remain excluded, explaining the high 
selectivity of the NPC.  Transport through the NPC machinery appears to be regulated by 
mitogenic signals, phosphorylation, and Ca2+ concentrations within the endoplasmic 
reticulum and nuclear lumen (Harreman et al., 2004; Greber and Gerace, 1995).  For 
example, Ca++ stores in the nuclear envelope of Xenopus laevis oocytes, is suggested to 
regulate NPC gating (Perez-Terzie et al., 1996).  In these cells, conformational changes in 
the NPC require calcium, such that when the Ca++ stores are depleted, a central plug 
occludes passage of nuclear transport processes.  Similar results have been observed in 
HeLa cells grown in the presence of the calcium pump inhibitor, thapsigargin, which 
blocks signal-mediated protein import (Greber and Gerace., 1995). These results suggest 
that calcium stores present in the lumen of the endoplasmic reticulum, which is 
contiguous with the nuclear envelope, may have a role in regulating nuclear–cytoplasmic 
trafficking.   
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8.4  Nuclear and Cytoplasmic Targeting Sequences. 
Since 1999, when Günter Blobel received the Noble Prize in Physiology and 
Medicine for discovering that proteins have intrinsic signals that govern transport and 
localization in cells,  there have been significant advancements in understanding  the  
mechanisms of nuclear-cytoplasmic transport of proteins (Raju, 2000; Shields, 2001).  
Investigative reports now describe many different types of nuclear-cytoplasmic targeting 
sequences, including nuclear localization sequences (NLS), nuclear export sequences 
(NES), nuclear retention sequences (NRS), cytoplasmic retention sequences (CRS), and 
bi-directional shuttling sequences (Jans et al., 1998).  Proteins targeted for receptor-
mediated transport across the NPC must either contain an NLS or NES. However, some 
proteins that do not contain a nuclear-targeting sequence still traverse the NPC by piggy-
backing with another protein containing a NLS or NES.   
  
8.5 Nuclear Localization Signals. 
 The first NLS, PKKKRK was identified in the Simian Virus 40 (SV 40) large T 
antigen (Kalderon et al., 1984).  The NLS found in the SV40 large T antigen was later 
referred to as a monopartite sequence to distinguish it from the bipartite sequence, 
KRPAATKKAGQAKKKKLD, found in Xenopus nucleoplasmin (Robbins et al., 1991). 
The monopartite sequence is often referred to as the “classical” NLS and consists of a 
short cluster of basic amino acids, often preceded by an acidic amino acid or proline 
residue.  Human DNA topo I has a classical monopartite NLS between amino acids 150-
156 (Stewart and Champoux, 1996).  The amino acid sequence of the monopartite NLS in 
topo I is KKIKTED.  Recently, a second non-classical monopartite signal was identified 
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in topo I between amino acids 117-146 (Mo et al., 2000).  In contrast to the basic amino 
acid residues found in a classical NLS, this NLS is unique because it  is characterized by 
two clusters of acidic amino acids at amino acids 117-146 and 151-156.  The first cluster 
of acidic amino acids is KDEPEDDG followed by a spacer region of 16 amino acids, and 
then the second cluster of acid amino acids is DEDDAD.  Thus, topo I has two 
independent NLS with opposite charged amino acids.  The precise amino acid sequence 
that targets topo IIβ to the nucleus has not been determined, but the last 116 amino acids 
found in the C-terminal domain in necessary and sufficient for nuclear localization of 
topo IIβ in mammalian cells (Cowell et al., 1998).  The C-terminal domain is presumed 
to have a bipartite NLS, which has been implied by the presence of several bipartite NLS 
type motifs found in the C-terminal domain of topo IIβ.  
Bipartite NLS, a second type of NLS, consists of two clusters of basic amino 
acids separated by a spacer region of approximately ten amino acids, often flanked by a 
neutral or acidic amino acid (Robbins, et al., 1991).  Topo IIα contains a bipartite NLS 
located in the carboxy-terminus between amino acids 1454-1497 that consists of a spacer 
region of 21 amino acids (Mirski et al., 1997).  The amino acid sequence for the NLS in 
topo IIα is KPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDD 
(Mirski et al., 1997).  The two clusters of basic amino acids are shown in bold text. 
Computer software programs are available that can scan amino acid sequences for 
potential bipartite NLS (Shelagh et al., 1999).  Additionally, previously described NLS 
are annotated in SWISS-Prot and PIR and can be retrieved at the NLS database located at 
the Predict NLS server (Nair et al., 2003).  
 
 87
8.6 Nuclear Export Signals. 
Classic protein NES are hydrophobic rich sequences that have a characteristic 
spacing of leucine, isoleucine, valine, and/or phenylalanine amino acid residues (Elfgang 
et al., 1999). The Center for Biological Sequence Analysis at the Technical University of 
Denmark has prepared an NES predictor, called the NetNes 1.1 server, accessible to the 
public and found on the worldwide web (la Cour et al., 2004).  The NetNes 1.1 server 
uses a prediction algorithm based on previously described NES, but also uses a “hidden 
Mark model” to identify non-hydrophobic residue that are not included in the consensus 
sequences for classical NES. To date, approximately 80 experimentally validated protein-
NES have been identified and compiled on the NESbase version 1.0 database, which is 
also accessible on the worldwide web (la Cour et al., 2003). NES have been identified 
based on the fact that mutation or deletion of the NES renders it inactive in mediating 
nuclear export of the protein carrying it, or that the NES is active in effecting export from 
the nucleus of a carrier protein such as beta-galactosidase (Jans et al., 1998).  
 
8.7  Retention Signals. 
Some proteins contain nuclear retention or cytoplasmic retention signals, which 
do not specifically target a protein to the nuclear or cytoplasmic compartments, but 
assures their retention once there (Jans et al., 1998).  The nuclear retention signals usually 
consist of an arginine rich motif and may include an arginine rich α-helical structure.  
One example of a NRS has been described in an SR protein.  The SR proteins are RNA 
splicing factors that contain RNA recognition motifs and a C-terminal domain rich in 
alternating serine (S) and arginine (R) amino acids, known as the RS domain. The RS 
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domain can become phosphorylated and direct the subcellular localization and 
nucleocytoplasmic shuttling of individual SR proteins (Cazalla et al., 2002).  The human 
SC35 SR protein, however, contains a dominant nuclear retention signal located in the 
RS domain, and thus is not shuttled between the nucleus and cytoplasm.  The nuclear 
retention signal for the SC35 SR protein is, PPPVSKRESKSRSRSKSPPKSPEEEGAVSS 
(Cazalla et al., 2002). The adenovirus E4orf6 protein also contains an amphipathic 
arginine rich α-helical region with the amino acid sequence ARRTRRLMLRAVRIIAE, 
which has been associated with E4orf6 nuclear retention.  The cytoplasmic retention 
signals are less well characterized (Satoshi et al., 2003).  For example, cyclin B1 contains 
a cytoplasmic retention signal that consists of a stretch of 45 amino acids located in the 
amino terminus (Pines and Hunter, 1994).  The CRS is situated within a CRM1 
dependent NES of cyclin B1 (Yang et al., 1998).  During interphase, cyclin B1 is 
exported to the cytoplasm via the NES and is retained in the cytoplasm through its 
cytoplasmic retention signal.  Cyclin B1 is then imported back into the nucleus by  NLS 
phosphorylation (Hagting et al., 1999; Li et al., 1997).  Cytoplasmic retention signals 
have been identified in human and Xenopus cyclin B1 and Xenopus cyclin B2 
(Yoshitome et al., 2003; Pines and Hunter, 1994). The amino acid sequence alignments 
for CRS and NES for human and Xenopus cyclin B are shown in Figure 16.  
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  Human cyclin B1      142  PVKEEKLSPEPI LVDTASPSPMETSGCAPAEEDLCQAFSDVILAVN                    154 
  Xenopus cyclin B1      91                         EP              SSPSPMETSGCLPDE     LCQAFSDVLIHVKDVDADD   126 
  Xenopus cyclin B2      89                                                PSPVPMDVSLKEEE  LCQAFSDALTSVEDIDADD     121 
 
 
Figure 16. Cytoplasmic Retention Signals and Nuclear Export Sequences for Cyclin B. The CRS in human 
cyclin B1 consists of a stretch of 45 amino acids (residues 142-154) and a NES between amino acids 142-
151. The CRS for Xenopus cyclin B1 and B2 contains amino acid residues 91-126 and 89-121, 
respectively. All of the NES (shown in bold text) that have been found in either cyclin B1 or B2 are nested 
within the CRS. (Yoshitome et al., 2003; Pines and Hunter, 1994). 
 
8.8 Bi-directional Shuttling Signals. 
Another type of shuttling signal is characterized by the M9 sequence of 
heterogeneous nuclear ribonucleoprotein A1, which consists of a 38-amino acid stretch 
that is enriched in aromatic residues and glycine (Pollard et al., 1996).  The M9 sequence 
functions in both nuclear import and nuclear export and is now referred to as a “shuttling 
sequence” to distinguish it from the unidirectional targeting sequences (NLS and NES). 
 
8.9 Signal-mediated Nuclear Transport. 
 Active transport between the nucleus and cytoplasm involves primarily three 
classes of macromolecules: substrates, adaptors, and receptors.  In general, protein import 
occurs when the transport receptors, importin-α and importin-β, form a complex with the 
protein-NLS and escort the protein cargo across the NPC into the nucleus (Figure 17) 
(Nigg, 1997; Görlich and Mattaj, 1996; Moroianu et al., 1996).  The protein cargo is 
released into the nucleus when the guanine nucleotide exchange factor, RCC1/RanGEF, 
replaces Ran bound GDP with GTP.  In the presence of GTP. importin-α binds the export 
receptor, cellular apoptosis susceptibility protein (CAS), and is transported back into the 
cytoplasm.  Importin-β remains bound to GTP and is recycled back to the cytoplasm.  
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Once in the cytoplasm, RanBP1 and RanGAP1 hydrolyze the bound GTP to GDP 
(Gasiorowski and Dean, 2003).   
 Protein export occurs when Ran-GTP and the nuclear export receptor, 
chromosome region maintenance-1 (Crm-1 or exportin-1), bind to a protein bearing an 
NES and transports the protein cargo into the cytosol (Figure 18) (Fukuda et al., 1997).  
The protein cargo is released into the cytoplasm when Ran-GTP is hydrolyzed by 
RanBP1 and RanGAP1, small GTPase activating proteins (Yamada et al., 2004; Görlich 
et al., 2003).  In this manner, continued nuclear-cytoplasmic shuttling occurs by 
maintaining a gradient of Ran-GTP in the nucleus and Ran-GDP in the cytoplasm 
(Görlich et al., 1996).  
 Several notable exceptions to this general mechanism have been reported 
(Miyamoto, 2002). For example, HIV-1 Rev proteins are recognized by importin-β rather 
than the importin-α/importin-β heterodimer (Tiganis et al., 1996).  Moreover, the 
accessory protein Tat of HIV-1 Rev is not recognized by either importin α or β 
(Efthymiadis et al., 1998), but rather, by other receptors related to importin β.  At least 21 
different importin β family members have been identified in humans.  Furthermore, Crm-
1 belongs to the growing Kapβ family of proteins (table 6) (Moroianu, 1998).  Crm-1 was 
identified as a general receptor for proteins bearing hydrophobic rich NES, but table 6 
establishes that receptor mediated nuclear export may be more specific (Jans et al., 2000).  
Many more import and export receptors are believed to exist, so it is possible that nuclear 
import and export pathways show sufficient specificity to be considered targets for 
therapeutic intervention. The precise nuclear transport pathways for topo enzymes has not 
been elucidated (Engel and Turner et al., 2004; Mirski et al., 2003).  
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Figure 17. Nuclear Import Pathway.  Protein cargo containing a nuclear localization signal binds to the nuclear import receptor, importin α.  Importin 
β-bound to Ran-GDP forms a complex with the importin-α protein cargo and escorts the entire complex across the nuclear pore complex.  Once inside 
the nucleus, the nucleotide exchange factor, RCC1, replaces Ran-GDP with Ran-GTP.  Importin-β-Ran-GTP  is transported back to the 
cytoplasm.where GTPases recycle Ran-GTP back to Ran-GDP.  Importin-α is exported from the nucleus by the export receptor, cellular apoptosis susceptibility protein 
(CAS). 
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Figure 18. Nuclear Export Pathway. The presence of guanine nucleotide exchange factors in the nucleus maintains a 
high concentration of Ran-GTP in the nucleus and Ran-GDP in the cytoplasm.  In the nucleu, Ran-GTP binds the export 
receptor, Crm-1 and a NES-containing protein cargo.  Crm-1 escorts the complex across the nuclear por complex. In the 
cytoplasm, Ran-GTPases hydrolyze GTP to GDP.  Crm-1 and Ran-GDP are recycled.  
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Table 6 .  Nuclear Export Receptors. 
Mammalian Kapβ Family Export Receptors 
Protein Receptor Export Cargo 
CRM-1 (exportin-1) general export receptor for leucine rich export sequences 
CAS importin-α 
Importin-13 eukaryotic translation factor-5A 
Exportin-4 hypusine-modified eukaryote translation factor-5A* 
Exportin-5 dsRNA binding proteins 
Exportin-6 actin export 
Exportin-7 p50RhoGAP 
Non-Kapβ Family Nuclear Export Receptors 
Mex67p (yeast) mRNA 
TAP/NXF (metazoans) mRNA 
*hypusine, [N(epsilon)-(4 amino-2-hydroxybutyl)lysine], is a rare amino acid. Hypusine 
is formed when a lysine residue is post-translationally modified by the transfer of a 
butylamine from spermidine followed by hydroxylation reaction (Mehta et al., 1994; 
Shiba et al., 1971). 
 
 
8.10 Regulating Nuclear-cytoplasmic Transport. 
Signal mediated transport has been shown to be regulated by several cellular 
processes that are summarized in Figure 19.  Phosphorylation (Engel et al., 1998), 
ubiquitination (Lohrum et al., 2001), and sumoylation (Salinas et al., 2004) are the most 
widely reported mechanisms of transport regulation.  Like ubiquitination, sumoylation is 
a three-step process involving an EI-activating enzyme heterodimer Aos/Uba2, the E2-
conjugating enzyme Ubc9 and substrate-specific E3 ligases (Gill, 2004).  The 
nucleoporin Nup358 (or RanBP2) is an example of an E3 ligase involved in modifying 
nucleo-cytoplasmic shuttling proteins with small ubiquitin-like modifiers (SUMO) 
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(Azumo and Daso, 2002).  This finding illustrates the intimate association of SUMO 
modification in regulating nuclear-cytoplasmic protein transport.   
Several drugs and molecular agents have been used to decipher transport 
processes in the laboratory (Table 15 appearing on page 213).  LMB is an unsaturated 
branched-chain fatty acid isolated from Streptomyces pombe (Hamamoto et al, 1983a).  
LMB is an antifungal antibacterial agent with anti-tumor activity (Hamamoto et al., 
1983b) and was  also shown to be an inhibitor of the nuclear export receptor, 
chromosome region maintenance protein-1 (Crm-1) (Kudo et al., 1998).  LMB attacks the 
sulfydryl groups on cysteine-529 of Crm-1 in a Michael-type reaction (Kudo et al., 1999). 
In this way, LMB blocks all Crm-1-mediated nuclear export.  The ratjadones represent a 
new class of natural compounds which inhibit proliferation in eukaryotes by blocking 
nuclear export (Meissner et al., 2004). Like LMB, the ratjadones covalently bind to Crm-
1. Additional compounds are being screened for their ability to block nuclear-export of 
proteins at different points in the export pathway.  
 
8.11  Conclusions. 
 The nuclear-cytoplasmic trafficking proteins have potential applications in drug 
delivery and drug-target interactions. The nuclear pore complexes are the gateway 
between the nuclear anc cytoplasmic compartments.  Protein transport across the NPC 
requires the presence of nuclear localization or nuclear export signals.  Crm-1 has been 
identified as the major export receptor that transports NES containing proteins out of the 
nucleus.  Leptomycin B specifically inhibits Crm-1 mediated nuclear export of proteins 
and is being investigated for its therapeutic potential in the treatment of cancer. 
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Chapter Nine 
Experimental Objectives and Rationale 
 
 In vitro experiments demonstrate that cancer cells may exhibit multiple different 
mechanisms to evade drug cytotoxicity.  We were interested in identifying mechanisms 
of cellular drug resistance to DNA topoisomerase targeting agents.  Altered drug 
transport and alterations in the quantity or quality of topo protein, which may or may not 
be a result of topo gene mutations, have already been described in cell lines selected for 
drug resistance.  In culture, most cell lines also display a differential sensitivity to topo II 
inhibitors, which depends on cell density (Sullivan et al., 1986, 1987; Chow and Ross, 
1987; Markovits, 1987). It is well established that when cell lines become confluent and 
maintain extensive cell-cell interactions they become intrinsically drug resistant (Croix 
and Kerbel, 1997).  How cell adhesion controls cell growth, apoptotic signal, cell cycle 
progression and drug resistance remains to be elucidated.  One mechanism of in vitro 
drug resistance to topo II inhibitors has been described to occur when cells transition 
from log to plateau cell density.  For example, in non-transformed cell lines, the 
transition from log to plateau density may lead to an attenuation of cellular topo IIα 
amount and activity, with concomitant drug resistance (Sullivan et al., 1987).  However, 
tumor cell lines do not necessarily downregulate topo protein content at plateau cell 
density, yet the cells are resistant (Sullivan et al., 1986, 1987).  Therefore, tumor cell 
lines must have other ways besides the degradation of topo II protein for evading drug 
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cytotoxicity.  Thus, we investigated the differences in drug sensitivity of several leukemia 
and myeloma cell lines at three levels of increased cell densities, called log, plateau, and 
accelerated-plateau, and then explained any observed drug resistance experimentally.  
Therefore, we investigated possible alterations in the cell cycle, drug transport, topo II 
enzyme activity, cleavable complex formation, and subcellular distribution of topo I, topo 
IIα, and topo IIβ. 
 Much of our current understanding of drug resistance is derived from cell lines 
that have been selected for drug resistance by applying a continuous drug pressure, and 
then correlating the total cellular content of topo or expression of drug efflux pumps with 
drug resistance (Davis et al., 1998).  Our data establish  a novel mechanism of drug 
resistance in human myeloma cell lines that is detectable prior to any drug exposure and 
independent of protein expression or P-gp mediated drug resistance. We demonstrate that 
topo IIα translocates to the cytoplasm in a cell-density dependent manner and that the 
nuclear export of topo IIα has a role in decreased drug sensitivity to VP-16 and other topo 
targeting agents, but less so with non-topoisomerase inhibitors. The cytoplasmic 
localization of topoisomerase IIα has thus far been attributed only to C-terminally 
truncated proteins that have lost a critical nuclear localization signal (Wessel et al., 1997).  
Our data are the first to describe a nuclear export signal of topo IIα by cells expressing 
full-length topo IIα-GFP.  We also demonstrate that a cytoplasmic transport of 
endogenous topo IIα in human myeloma cells can be abrogated in the presence of the 
nuclear export inhibitor, leptomycin B. The clinical significance of these findings is the 
treatment of multiple myeloma is suggested.
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Chapter Ten 
Materials and Methods 
 
10.1 Materials. 
Etoposide (VP-16), phenylmethylsulphonyl fluoride (PMSF), cis-platinum, 
paclitaxel (taxol), carmustine (BCNU), ara-C (cytosine 1-β-D-arabinofuranosyl 
hydrochloride), dimethyl sulphoxide (DMSO), 2-mercaptoethanol, and leptomycin B, 
NonidetP-40 (NP-40), phenylmethylsulphonyl (PMSF), adenosine triphosphate (ATP), 
dithiothreitol (DTT), ethylenediaminetetroactetic acid (EDTA),  MTT, and vincristine, 
were all obtained from Sigma Chemical (St. Louis, MO).  Mitoxantrone was generously 
provided by Immunex Corp (Seattle, WA).  Topotecan was generously provided by 
SmithKline Glaxo (Philadelphia, PA). 
  
10.2 Cell Culture. 
All cells were obtained from the American Type Culture Collection (Manassas, 
VA).  The RPMI-8226 cell line is from the peripheral blood of a 61 year old male with 
multiple myeloma and the NCI-H929 cell line is from the malignant effusion of a 62 year 
old Caucasian female with myeloma.  The HL-60 cell line was obtained from a 36-year 
old Caucasian female with acute promyelocytic leukemia.  This cell line is positive for 
the myc oncogene.  The KG-1a human acute myelogenous leukemia cells are a subline 
variant of the KG-1 cell line.  The parental KG-1 cells were obtained from a 59-year old 
Caucasian male with erythroleukemia that evolved into acute myelogenous leukemia. 
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After 10 passages, the KG-1 cells were split and cultured by two different 
laboratories in the same department and under identical conditions.  After 35 passages, 
one of the cultures exhibited different morphological characteristics (reviewed in ATCC) 
and were called KG-1a cells.  The CCRF cell line was obtained from the peripheral blood 
buffy coat of a 4-year old Caucasian female with lymphoblastic leukemia.  The L1210 
cells were derived from a female mouse with lymphocytic leukemia.  HeLa cells are 
epithelial adenocarcinoma cells that were obtained from the cervix of a 31 year old black 
female.  
HeLa cells were grown in Alpha Minimal Essential Media (Gibco) containing 0.1 
mM nonessential amino acids, 1.0 mM sodium pyruvate, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 10% fetal bovine serum (FBS) (Hyclone).  The HL60, KG1a, RPMI-
8226, and CCRF cells were grown in RPMI medium containing100 U/ml penicillin and 
100 µg/ml streptomycin from Gibco BRL (Gaithersburg, MD) and 10% FBS (Hyclone).  
The NCI-H929 cells were grown in RPMI medium containing 100 U/ml penicillin, 50 
µM β-mercaptoethanol (Sigma) and 100 µg/ml streptomycin from Gibco BRL 
(Gaithersburg, MD).  The L1210 cells were grown in RPMI medium containing 100 
U/ml penicillin, 100 µg/ml streptomycin from Gibco BRL (Gaithersburg, MD) and 20% 
FBS.   The Chinese Hamster Ovary (CHO) cells were grown in Alpha Minimal Essential 
Media (Gibco) containing 100 U/ml penicillin, 100 µg/ml streptomycin, and 5% fetal calf 
serum (FCS).  Flow fibroblast 2000 cells were grown in Alpha Minimal Essential Media 
(Gibco) containing 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% fetal calf 
serum.   
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10.3 Log, Plateau, and Accelerated-plateau Cell Model.  
Cell density and viability were determined by staining cells in a 1:1 dilution with 
trypan blue and counting them with a hemacytometer. Growth curves were performed on 
all cell-lines described above (HL60, KG1a, RPMI, 8226, CCRF, L1210, CHO) to 
determine log and plateau phase cell density.  Log-phase was defined as 3.0 X 105 to 4.0 
X 105 cells/ml with ≥ 85% viability.  The log cell densities for the CHO and Flow 
fibroblasts were 2.0 X 104 cells/ml for 10 ml of media in a 25-cm2 flask, whereas plateau 
phase was reached at 8.0 X105 cells/ml for CHO cells and 2.0 X 105 cells/ml for the Flow 
fibroblast cells.  
When the log growing cells reached confluence, they were referred to as “natural-
plateau”.  Natural-plateau is defined as cell viability ≥ 85% (by trypan blue dye 
exclusion) and no net gain in cell number.  The plateau density was different for each cell 
line: 9.0  X 105 cells/ml for RPMI 8226, 1.0 X 106 cells/ml for H929, 1.6 X 106 cells/ml 
for HL-60, 2.0 X 106 cells/ml for CEM-CCRF and L1210, and 8.0 X106 cells/ml for KG-
1a cells.   
 For convenience, the “accelerated-plateau” model was established by 
concentrating log-phase H929, 8226, HeLa, CCRF, or HL-60 cells to a super-confluent 
cell density for 16 h or 24 h before experimentation (Valkov et al., 2000; Engel et al., 
2004). Log-phase cells were centrifuged at 100 x g for 5 min at room temperature and 
resuspended in fresh media to obtain a superconfluent cell density and grown with 5% 
CO2 at 37οC.  The super-confluent cell density was between 2.0 x 106 and 2.5 x 106 
cells/ml for RPMI-8226, H929, and HeLa cells.  The super-confluent cell density for HL-
60 and CEM-CCRF was set between 3.0 X 106 cells/ml and 4.0 X 106 cells/ml.  KG-1a, 
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Chinese hamster ovary, and Flow Fibroblast cells were not used in the accelerated-
plateau cell model.   
 
10.4 Bone Marrow Samples. 
Bone marrow samples were obtained after informed consent from patients with 
multiple myeloma on a high-dose chemotherapy study, approved by the Institutional 
Review Board.  Approximately 5 ml of bone marrow aspirate was collected in EDTA 
tubes and diluted to 30 ml with PBS.  This was then layered over 15 ml of Ficoll-Paque 
Plus (Pharmacia Biotech) and centrifuged at 400 x g in a swinging bucket rotor at 4°C  
for 30-min.  The mononuclear cell interface was collected and washed twice with cold 
PBS.  The cell number was determined and 105 cells were cytospun onto double 
cytoslides.  The cells were fixed with 4% formaldehyde and stored at -85°C. Aliquots of 
cells were preserved in freezing media consisting of 40% RPMI-1640, 50% FCS, and 
10% DMSO in liquid nitrogen.  Where noted, samples were also obtained in a similar 
manner but from two untreated myeloma patients.  Mononuclear fractions of these 
samples were obtained by centrifuging the bone marrow aspirates at 700 x g over a 
Ficoll-Hypaque density gradient (Valkov et al., 2000).  
 
10.5 Clonogenic Cytotoxicity Assays. 
Cytotoxicity assays were performed by treating 1.0 X 105 cells from either log, 
plateau, or accelerated plateau cell suspensions (Valkov et al., 2000; Engel, 2004).  Drug 
treatment was for 1 hour with various concentrations of etoposide, mitoxantrone, 
topotecan, and cis-platinum (diluents were DMSO, water, MeOH, and DMSO, 
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respectively).  Cells were treated with paclitaxel for 24 hours and the drug was diluted in 
DMSO.  Cells were treated with carmustine for 4 hours and the drug was diluted in 
ethanol.  Cells were treated with ara-C (cytosine 1-β-D-arabinofuranosyl hydrochloride) 
for 20 hours and the drug was diluted in water.  Cells were exposed to γ-irradiation (Cs-
137 gamma irradiator) (0-800 rads).  Controls had the same concentration of dilutent.  A 
total of 2500 drug-treated cells were plated in triplicate in 0.3% select agar (Gibco BRL) 
in RPMI-1640 containing 15% FBS for 14-17 days at 37οC in the presence of 5% CO2.  
Colonies > 50 cells were counted manually. 
 
10.6 Flow-cytometric Cell Cycle Analysis. 
The cell cycle was analyzed by measuring BrdU incorporation and total amount 
of DNA by propidium iodide staining (Engel et al., 2004).  To measure BrdU 
incorporation, one million log and accelerated-plateau cells each were treated with 30 
µg/ml BrdU (Becton Dickinson, San Jose, CA) in serum free media for 30 min.  Cells 
were washed twice in PBS and resuspended in 4 ml of ice cold PBS.  While vortexing, 6 
ml of ice cold 100% ethyl alcohol was slowly added and the cells fixed overnight at -
20ºC. At least 1 X 106 cells were centrifuged at 100 x g for 5 min and resuspended in 
pepsin solution (0.04% pepsin in 0.1% HCl) for 1 h at 37º C with gentle shaking.  Whole 
cells were pelleted at 100 x g for 5 min, resuspended in 3 ml of 2 N HCl, and then 
incubated for 30 min at 37ºC. To this solution, 6 ml of 0.1M sodium borate was added, 
vortexed for 20 seconds and then recentrifuged.  Cells were washed once with a wash 
buffer containing 0.5% BSA and 0.5% Tween-20 in PBS and brought to a final volume 
of 200 µl FITC-conjugated anti-BrdU antibody (Becton Dickinson, San Jose, CA) was 
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added in a 1:20 dilution and allowed to incubate in the dark for 60 min at room 
temperature.  These same cells were washed once with wash buffer and resuspended in 
10 µg/ml PI in wash buffer to achieve 1 X 106 cells/ml. Cells were treated with 250 µg of 
RNase (Sigma) from a 10 mg/ml solution in PBS for 30 min at 37ºC.  The sample was 
passed through an 18 G needle and transferred to a Falcon 2054 vial and read by FACS-
Scan (Becton Dickinson, San Jose, CA).  The experiment was repeated three times and 
the mean values were plotted using Prism 2.01 (GraphPad Software, San Diego, CA).  
In addition to the above, DNA content was also determined by measuring 
propidium iodide staining alone in three separate flow cytometry experiments.  To 
measure DNA content by propidium iodide staining, one million log and accelerated-
plateau cells each were centrifuged at 1000 r.p.m. for 5 min at 4ºC and  resuspended in 
100 µl of ice cold PBS.  The cells were fixed with 70% ice cold ethanol by slowly 
trickling the ethanol into the cell suspension with constant vortexing.  The cells were 
fixed overnight at -20ºC, centrifuged at 1,400 r.p.m. for 5 min at room temperature, 
resuspended in 200 µl of PBS, and transferred to a 10 X 75 mm tube (Fisher Scientific, 
Pittsburgh, PA). An RNase (Sigma) stock, equivalent to 100 K units/mg solid, was 
diluted to 10 mg/ml in PBS and added to the cell suspension in a 1:4 dilution. A 1 mg/ml 
propidium iodide stock solution was prepared in ethanol and added to the cells in a 1:10 
dilution immediately before reading and DNA histograms were determined by FACS-
Scan (Becton Dickinson, San Jose, CA).  The experiment was repeated 3 times.  
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10.7 Gel Electrophoresis and Immunodetection.  
Log-phase H929 and 8226 cells were seeded at 2.0 X 106 cells/ml, returned to the 
incubator and then lysed either 4h, 16h, or 24 h later (Engel et al., 2004).  Whole cell 
lysates were prepared from log and accelerated-plateau cells by centrifuging 2.0 X 106 
cells at 100 x g. for 5 min at 4°C.  The pellet was washed once with ice cold PBS and 
then resuspended in 250 µl of H2O (pH 9.0; adjusted with 0.1 M borate buffer).  Cells 
were sonicated on ice with 15 pulses from a Branson sonifier (output 4.0, duty cycle 
30%), and then boiled for 3 min in 1X sample buffer (2% SDS, 0.1M DTT, 10% 
glycerol, and 0.025% bromphenol blue). Protein concentration was determined by using 
the BCA protein assay kit (Pierce, Rockford, IL).  A total of 50-100 µg of protein were 
loaded onto a 7.5% SDS-page gel, electrophoresed under 7 watts and transferred at 65 
volts overnight onto a polyvinylidene difluoride (PVDF) membrane (Bio-Rad 
Laboratories, Hercules, CA).  Membranes were blocked in 0.05% dry milk in TBST 
buffer containing 0.05% Tween-20 , 0.5M NaCl, 20 mM Tris, pH 7.5.  Primary 
antibodies used were polyclonal antibody 454 against topo IIα diluted 1:5000 
(Hochhauser et al., 1999), polyclonal antibody JB1 against topo IIβ diluted 1:5000 
(Valkov et al., 2000; Austin et al., 1995), or C-21 murine monoclonal IgM antibody 
directed against the C-terminus of topo I  (a generous gift from Dr. Y.-C. Cheng, Yale 
University Medical School, New Haven, CT) diluted 1:2500, or polyclonal anti-LDH 
(Research Diagnostics, Flanders, NJ) diluted 1:500 in blocking buffer.  Membranes were 
blocked for 1 h, and treated with either the polyclonal antibody 454 against topo IIα or 
JB1 against topo IIβ for 1 h or blocked overnight at 4°C and treated with the monoclonal 
antibody C21 for 2 h.  Membranes were washed in TBST every 15 min for 1 h and then 
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treated with secondary antibody for 1 h at room temperature. Secondary antibodies used 
were either donkey anti-rabbit (topo IIα and topo IIβ), sheep anti-mouse (topo I) 
(Amersham, Arlington Heights, IL) or mouse anti-goat (LDH) (Santa Cruz 
Biotechnology, Santa Cruz, CA) conjugated to horseradish peroxidase.  The topo IIα and 
IIβ secondary antibodies were diluted 1:3000 and the LDH secondary antibody was 
diluted 1:500 in blocking buffer.  The signal was detected with ECL (Amersham) and 
exposed to film.  The bands were quantified with Adobe PhotoShop 5.0 imaging 
software.  The experiment was done one time for topo IIβ and repeated 3 times for topo 
IIα and topo I in NCI-H929 and RPMI-8226 cell lines (Engel et al., 2004). 
 
10.8  Nuclear-cytoplasmic Separation. 
Subcellular fractions was prepared from 1.0 X 107 cells as previously described 
(Oloumi et al., 2000) with the following modifications (Engel et al., 2004; Valkov et al., 
2000).  Cells were washed in PBS and resuspended into cold Buffer A (10 mM HEPES 
(pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 300 mM sucrose, 1 mM EDTA (pH 8.0), 1 mM 
DTT, 0.2% NP-40, 1 mM phenylmethylsulphonyl fluoride, 10 µg/ml protease inhibitors 
mixture (Sigma), and 0.1 mM Na3VO4).  The cells were incubated in Buffer A on ice for 
15 min., sheared with a pipette 20 times, and then centrifuged for 10 min at 830 x g at 
4°C.  The supernatant was reserved and the nuclear pellet was prepared for protein 
determination and gel electrophoresis as described above (refer to "Gel Electrophoresis 
and Immunodetection") except that the DNA was sheared with 10 pulses from a Branson 
sonifier after being resuspended in Buffer B (250 mM Tris-HCl (pH 7.9), 5 mM MgSO4, 
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250 mM sucrose, 2 mM NaTT, 1% thiodiglycol, 1% NP-40, 1mM PMSF, 10µg/ml PI, 
and 0.1 mM Na3VO4).  
 
10.9 Immunofluorescence Microscopy.  
Slide preparations from log and accelerated-plateau cells were immunostained as 
previously described (Engel et al., 2004; Valkov et al., 2000). Log and accelerated 
plateau cell suspensions were diluted to 5.0 X 104 cells/ml with PBS and cytocentrifuged 
for 3 min at 500 r.p.m. onto double cytoslides (Shandon, Pittsburgh, PA).  The cells were 
fixed in 4% paraformaldehyde for 4 min at room temperature and permeablized with 
0.5% Triton X-100 and 1% glycine in PBS overnight at 4°C.  After permeablization, the 
slides were washed in fresh PBS every 15 min for 1 h.  The slides were treated with the 
following combinations of primary antibody: either rabbit polyclonal antibody 454 
against topo IIα (Hochhauser et al., 1999) was used simultaneously with a mouse 
monoclonal antibody against histone (Roche Molecular Biochemicals) or a C-2 murine 
monoclonal IgM antibody against topo I (a generous gift from Dr. Y.-C. Cheng, Yale 
University Medical School, New Haven, CT) was used simultaneously with the 
polyclonal antibody JB1 against topo IIβ (Austin et al., 1995). The primary antibodies 
were diluted 1:100 with staining solution containing 0.1% NP-40 and 1% BSA in PBS 
and the incubation period was for 1 h at room temperature.  Slides were washed in PBS 
every 10 min for 1 h and then incubated with goat anti-rabbit IgG-TRITC labeled 
antibody (Sigma) diluted 1:80 and goat anti-mouse IgG FITC-labeled antibody (Sigma) 
diluted 1:64 in staining solution as above for 35 min in the dark at room temperature.  
The slides were washed in PBS every 15 min for 2 h, air dried and covered with 
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antifade/DAPI (Vector, Burlingame, CA).  Immunofluorescence was observed with a 
Leitz Orthoplan 2 microscope and images were captured using a CCD camera with Smart 
Capture program (Vysis, Downers Grove, IL).  
 
10.10 Quantitative Measurement of the Immunofluorescence of Topo IIα. 
Slide preparations from log and accelerated-plateau cells were immunostained as 
previously described (Valkov et al., 2000; Engel et al., 2004).  Topo IIα 
immunofluorescence was analyzed as previously described (Valkov et al., 2000; Engel et 
al., 2004) using Adobe PhotoShop 5.0 (Adobe Systems, San Jose, CA) and Prism 2.01 
(GraphPad Software, San Diego, CA).  The nuclear/cytoplasmic ratios were calculated 
for each cell by dividing [the number of pixels X (mean intensity - background)] of the 
nuclear compartment by [the number of pixels X (mean intensity – background) of the 
cytoplasmic compartment. At least 50 cells per experiment were analyzed and the 
experiment was repeated 3 times. 
 
10.11 Equilibrium concentrations of [3H]-VP-16. 
[3H]-VP-16 was obtained from Moravek Biochemical (Brea, CA). Equilibrium 
concentrations of [3H]-VP-16 were measured as previously described (Sullivan et al., 
1986, 1987).  Briefly, equal numbers of log and accelerated-plateau cells were incubated 
in the presence of 5 to 50 µM of [3H]-VP-16 diluted with cold etoposide for 1 h at 37ºC.  
Whole cells were centrifuged at 100 x g for 10 min and washed with cold PBS.  Drug 
uptake for log and accelerated-plateau cells was determined as cpm/mg of cells. 
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10.12 Band Depletion Assay.  
Cleavable complex formation was measured in log and accelerated-plateau H929 
cells as previously described (Engel et al., 2004) with few modifications (Kaufmann et 
al., 1997).  Briefly, 2.0 X 107 cells were centrifuged at 1,000 r.p.m. for 5 min in a 
swinging bucket rotor.  The pellet was resuspended in 10 ml of buffer A (10 mM HEPES, 
pH 7.4 in serum free media).  2.0 X 106 cells were transferred to a 1.5 ml microcentrifuge 
tube and treated with VP-16 in DMSO for 45 min in a 37ºC water bath and mixed by 
inverting the tubes every 15 min. After the incubation period, the cells were centrifuged 
at 3200 X g for 1 min.  Proceeding one tube at a time, the supernatant was aspirated and 1 
ml of lysis buffer (6M guanidine HCl, 0.25 M Tris, pH 8.5 with HCl, 10 mM EDTA, 1% 
2-BME, and 1X protease inhibitors containing (20 mM PMSF, and 20 µg/ml each of 
antipain, aprotinin, chymostatin, leupeptin, soybean trypsin inhibitor, benzamidine, and 
pepstatin A) was added with brisk vortexing. The cells were incubated in lysis buffer 
overnight at 20ºC.  Genomic DNA was sheared with 20 pulses from a Branson sonifier 
(output 4.0, duty cycle 35%).  To each sample, 100 µl of 150 mM iodoacetamide in lysis 
buffer without 2-BME was added and allowed to incubate in the dark for 1 h at room 
temperature.  After incubation, 10 µl of 2-BME was added to each sample.  The samples 
were dialyzed at 4ºC in the dark as follows: 3 X 90 min in 1 L of 4M Urea, 2 X 90 min in 
0.1% SDS, and 1 X overnight in 0.1% SDS. Samples were lyophilized and stored at -
20ºC.  Immediately before gel electrophoresis, protein was solublized by heating the 
samples in sample buffer (4M Urea, 2% SDS, 62.5 mM Tris-HCl, pH 6.8, 1 mM EDTA, 
0.03% bromphenol blue and 1% 2-BME) for 20 min at 65-70ºC.  Proteins were separated 
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by gel electrophoresis on a 10% bis-acrylamide gel for western analysis.  The experiment 
was repeated two times. 
 
10.13 Comet Assay. 
DNA damage was analyzed by the comet assay as previously described with some 
modifications (Engel et al., 2004; Kent et al., 1995).  Briefly, 2.5 X 105 cells/ml were 
treated with VP-16 for 1 h at 37ºC.  After treatment, 5,000 cells were removed and 
washed in cold PBS.  The supernatant was aspirated and 1.5 ml of 1% agar (Nusieve 
GTG) was added to 500 µl of PBS, mixed with the pellet, and spread onto a frosted glass 
microscope slide.  The slides were solidified at room temperature for 2 min and then 4 
min at 4ºC. Cells were lysed for 1 h at 4ºC in batches (6-8 slides) in 200-250 ml lysis 
buffer containing 0.5% SDS (w/v), 30 mM EDTA, pH 8.0, and Proteinase K was added 
(375 units/100 ml) immediately before use.  After 1 h, the slides were incubated in the 
same lysis buffer overnight at 37ºC for 12-16 h.  The lysis buffer was washed off with 
200 ml of 1X TBE (pH 8) for 2 h, changing buffer every 15 min. The cells were 
electrophoresed in 1X TBE under 25 volts for 20 min.  The DNA was stained with a 
1:10,000 dilution of Syber Green (Molecular Probes) in 1X TBE for 25 min in the dark at 
room temperature. Slides were washed two times with 1X TBE for 5 min each, stored in 
a dark humidified box at 4ºC, and viewed within 24 h with a Leitz Orthoplan 2 
microscope.  Images were captured using a CCD camera with Smart Capture program 
(Vysis, Downers Grove, IL). Fifty single cells with no overlapping tails were captured 
per drug dosage per condition and the experiment was repeated three times.  The comet 
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moments were captured and analyzed with Optimas and calculated by using the formula:  
∑0→n (Intensity X Distance)/Total Intensity. 
 
10.14  Putative NES Peptides.  
 The complete amino acid sequence for human topo IIα (accession number NP 
001058) was downloaded from the National Center for Biotechnology Information 
database and searched for matches to the NES consensus sequence from table 12 (Engel 
and Turner et al., 2004). Six amino acid sequences in topo IIα matched the NES 
consensus sequence (refer 
to Table 11, page 163), and 
were synthesized as native 
(nt) or mutated (∆) 
peptides.  The mutated 
peptides contained alanine 
in place of those hydrophobic residues suspected of being critical for nuclear export 
(leucine, isoleucine, or valine).  To facilitate conjugation with preactivated 
sulfosuccinimidyl 4-[N-maleimidomethyl] cyclohexane-1-carboxylate (SMCC-BSA) 
(Pierce) (Figure 20), the NES-peptides were designed with a cysteine residue at the 
amino terminus.  The peptides obtained from the Biopeptide Company (San Diego, 
California) were as follows: (ntNES80-91), C80GLYKIFDEILVN91; (∆NES80-91), 
C∆80GAYKAFDEAAAN91; (ntNES230-241), C230SLDKDIVALMVR241; (∆NES230-241), 
C∆230SADKDAAAAMAR241; (ntNES467-476), C467TLAVSGLGVVG477; (∆NES467-477), 
C∆467TAAASGAGAAG477, (ntNES1017-1028), C1017DILRDFFELRLK1028; (∆NES1017-1028), 
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Figure 20.  Sulfosuccinimidyl 4-[N-maleimidomethyl] 
cyclohexane-1-carboxylate (Sulfo-SMCC). Sulfo-SMCC is a 
water soluble non-cleavable crosslinking agent. 
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C∆1017CDIARDAFEARAK1028. Peptides (ntNES569-580), C569FLEEFITPIVKV580; 
(∆NES569-580), C∆569AAEEAATPAAKA580; (ntNES1054-1066), C1054FILEKIDGKIIIE1066; 
and (∆NES1054-1066) C∆1054FIAEKADGKAIAE1066 were obtained from the University of 
Florida Protein Chemistry Core Facility (Gainesville, FL). All peptides were HPLC 
purified to ≥ 95% and analyzed by mass spectroscopy. In addition, peptide sequences and 
purity were confirmed by Rick Feldhoff, Ph.D at the University of Louisville, School of 
Medicine (Louisville, KY). 
 
10.15 Generation of BSA-Peptide-FITC Conjugates.   
 Peptides were crosslinked to BSA and FITC.  Figure 21 illustrates the plausible 
binding of peptides and FITC to BSA.  First, a total of 2 mg Imject® Maleimide activated 
sulfosuccinmidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate bovine serum 
albumin (Sulfo-SMCC BSA) (Pierce, Rockford, IL) was reconstituted in 200 µl distilled 
water for a final concentration of (0.1 M sodium phosphate buffer, 0.15 M NaCl, 0.1 M 
EDTA, pH 7.2).  Then, a molar excess (1-2 mg) of native or mutated topo IIα NES 
peptide in 400 µl of conjugation buffer (83 mM sodium phosphate buffer, 0.1 M EDTA, 
0.9 M NaCl, 0.002% sodium azide, pH 7.2) was mixed with the Sulfo-SMCC BSA and 
reacted for 30 min at room temperature.   
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The reaction was quenched by adding 40 mM cysteine solution in deionized water to the 
peptide-SMCC-BSA solution to obtain a molar excess of cysteine to peptide sample 
(approximately 7 nmoles cysteine/nmole of SMCC-BSA-peptide).  The conjugates were 
purified by size exclusion chromatography at room temperature using the Pharmacia P- 
 
Figure 21. An Illustration of BSA-FITC-Peptide Complexes. Multiple peptides 
covalently bind BSA-SMCC ( )via disulfide bonds (red) formed by the placement 
of a cysteine residue (blue) at the carboxyl terminus of the peptide. Here the peptide 
is illustrated as the backbone of any amino acid residue (shown in black brackets [  ]  
FITC is shown in green. FITC covalently binds to any primary amine, whether 
located on the BSA or peptide molecules. Theoretically, multiple FITC and peptides 
will be crosslinked per mole of BSA .  
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500 FPLC system with LKB control Unit UV-1.  The high resolution column (10 mm 
inner diameter and 30 cm length) (Amersham Pharmacia, Piscataway, NJ) was packed at 
2.0 ml/min with Superdex 200 prep grade (Amersham Pharmacia) in filtered and 
degassed PBS, pH 7.4.  The peptide conjugates were loaded onto the column using a 500 
µl Superloop and were run at 0.5 ml/min in degassed dH2O.  The 500 µl fractions were 
collected with a Fraction-100 collector (Pharmacia Biotech) and stored at 4°C overnight. 
Total protein was estimated in peak samples by measuring absorbance at 562 nm using 
the Fisherbrand Protein Assay.  Approximately 25 µg of protein from eluted fractions 
were loaded onto a 10% SDS-page gel and electrophoresed with 7 watts for 2-3 h. 
Peptide conjugation was confirmed by silver stain analysis.  Similar fractions of 
crosslinked BSA-peptide were pooled and concentrated on a microsep 30k filter (Pall 
Corporation) by centrifuging at 5,000 x g in an SS-34 rotor until dry.  The samples were 
eluted with 400 µl of PBS, pH 7.4 to obtain approximately 2 mg/ml peptide-conjugate 
solution. FITC was solubilized in DMSO to 1 mg/ml and added to the peptide sample in 
four 5 µl aliquots until a total of 20 µl of FITC (Sigma) was added.  FITC was reacted 
with the peptides for 6 h at 4°C, and then 23 µl of 1 M NH4Cl in PBS, pH 7.4 was added 
to the sample and incubated for 2 h at 4°C.  FITC-BSA-peptide conjugates were 
separated from unincorporated label by FPLC.  The ratio of fluorescein to protein was 
determined by measuring the absorbance at 495 nm and 280 nm.  The nuclear control, 
tetramethylrhodamine-bovine serum albumin (TRITC-BSA), was obtained from Sigma.  
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Figure 22.  Eppendorf FemptoJet and 
Micromanipulator on a Nikon TE 2000 
Inverted Microscope. 
10.16 Microinjection.   
 To promote cell adherence, Fisherbrand glass coverslips were pretreated with 1N 
HCl for a minimum of 4 hours at 50°C and then rinsed extensively with deionized water. 
Coverslips were washed in 100% ethanol and dried between pieces of Whatman paper. 
Subconfluent HeLa cells growing in Alpha Minimal Essential Medium (Gibco) 
containing 0.1 mM nonessential amino acids, 1.0 mM sodium pyruvate, 100 U/ml 
penicillin, 100 µg/ml streptomycin and 10% FBS (Hyclone) were plated onto the center 
of glass coverslips in NUNC brand petri dishes and incubated at 37°C for 24-48 h 
preceding microinjection.  Prior to microinjection, cells were gently rinsed with sterile 
PBS warmed to 37°C and replaced with Leibovitz’s L-15 Medium containing no phenol 
red.  
 FITC labeled BSA-NES peptide conjugates were centrifuged at 13,000 x g for 30 
min at 4°C, and the supernatant then loaded into Eppendorf Femptotips (diameter of 0.5 
µm ± 0.2 µm). All cells were injected 
using the semi-automated Eppendorf 
Injectman NI2 and Femtojet 
microinjector on a Nikon TE 2000 
inverted microscope (Figure 22) under 
exactly the same conditions (injection 
pressure (Pi), 100 hPa; compensation 
pressure (Pc), 30 hPa; injection time (It) 
0.2 sec, atomospheric conditions).  Following  injection, the cells were incubated at 37°C 
for up to 90 min, washed with Leibovitz’s L-15 Medium, and then fixed with 4% 
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paraformaldehyde for 3 minutes at room temperature, rinsed in PBS and mounted onto 
Shandon microscope slides with mounting medium containing DAPI.  Fluorescence was 
observed with a Leitz Orthoplan 2 microscope and images were captured using a CCD 
camera with Smart Capture program (Vysis, Downers Grove, IL).  
 
10.17 Topoisomerase IIα Cloning and Site Directed Mutagenesis.  
 Topo IIα primers were designed which contained the eight amino acid FLAG 
peptide preceded by a start codon and a Kozak motif (5’-ATG GAC TAC AAA GAC 
GAT GAC GAC AAG GAA GTG TCA CCA TTG CAG CCT GTA AAT GAA AAT 
ATG-3’ forward primer, 5’-ATG CGG CCG CTT AAA ACA GAT CAT CTT CAT 
CTG ACT CTT C-3’ reverse primer).  Amplification was performed with an enzyme 
mixture of Taq and Pyrococcus species GB-D thermostable DNA polymerases 
(Elongase, Invitrogen), in 60 mM Tris-SO4 (pH 9.1), 18 mM (NH4)2SO4, 2 mM MgSO4, 
200 µM dNTP mixture and 200 nM each primer.  Forty cycles were performed (94°C for 
30s, 60°C for 30s, and 5.5 min at 68°C), and the PCR products were agarose gel-purified 
and ligated to a pcDNA3.1 vector using a TOPO-TA cloning system (Clontech).  The 5’ 
end of the new FLAG-topo IIα fusion protein vector was sequenced to ensure that the 
DNA was in-frame.  Site-directed mutagenesis was performed using a Quickchange XL 
site-directed mutagenesis kit (Stratagene).  Briefly, 100 ng of template dsDNA were 
mixed with 125 ng of each oligonucleotide primer, 2.5 units of PfuTurbo DNA 
polymerase, in a reaction mixture containing 2 mM dNTPs.  Eighteen cycles were 
performed (95°C for 50 s, 60°C for 50s, and 68°C for 20 min), after which the parental 
plasmid was digested with methylation specific enzyme Dpn-I.  Ultra-competent cells 
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were transformed with mutated plasmid and clones were sequenced to determine the 
presence of desired mutations.  DNA sequencing was performed at the H. Lee Moffitt 
Cancer Center Molecular Biology Core Facility.   
 
10.18 Transfection Protocol.   
 Human myeloma H929 and human leukemia HL-60 cells (ATCC) were plated at 
log phase density (2x105 cells/ml) two days prior to transfection.  Transfection was 
performed as previously described (Van den Hoff et al., 1992).  Briefly, 40 µg of wild-
type or mutated topo IIα plasmid in 300 µl tris-EDTA (TE) buffer was precipitated by the 
addition of 30 µl of 5 M NaCl and two volumes of 95% ethanol on ice for ten minutes.  
Plasmid was pelleted by centrifugation for fifteen minutes at 20,000 x g at 4°C, washed 
with 75% ethanol and re-centrifuged.  All remaining ethanol was removed by pipette and 
the DNA immediately resuspended in 50 µl of cytomix buffer containing 120 mM KCl, 
0.15 mM CaCl2, 10 mM K2HPO4/KH2PO4, 25 mM Hepes, 2 mM EGTA, 5 mM MgCl2, 2 
mM ATP, and 5 mM glutathione, pH adjusted to 7.6 by the addition of KOH.  ATP and 
glutathione were made fresh and added prior to each transfection (26).  Two days prior to 
transfection, human myeloma H929 cells and leukemia HL-60 cells were placed in fresh 
growth media (RPMI/10% FBS/pen-strep) at a concentration of 2 x105 cells/milliliter.  
Cells were collected and 1.6x107 cells pelleted by centrifugation at 1500 x g for 5 
minutes.  Cell pellets were washed twice in 10 ml of sterile PBS, resuspended in 350 µl 
of cytomix buffer (4°C), mixed with prepared DNA, and placed in a 4 mm 
electroporation cuvettes.  Electroporation was at 250V/750 capacitance, after which cells 
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were split into even groups and plated at log and plateau growth conditions for twenty 
hours in 5 % CO2 incubator at 37°C with RPMI medium containing a 5% FBS.  
 
10.19 Immunofluorescence of FLAG-Topo IIα.   
 Twenty hours post-transfection, live cells were isolated by centrifugation for 20 
minutes at 20°C on a ficoll gradient, and then washed with PBS.  Transfected cells were 
plated on a glass microscope slide using cytospin funnels and fixed with 4% 
paraformaldehyde at 20oC for ten minutes.  The fixation was stopped by washing in PBS 
and cells were permeabilized for twenty-four hours in a solution containing 1% glycine 
and 0.25% Triton X-100 in PBS.  Slides were stained with anti-FLAG M2 monoclonal 
antibody-FITC conjugate (Sigma) diluted 1:100 with 0.1% NP-40 and 1% BSA in PBS, 
and incubated one hour at room temperature.  Slides were washed in PBS, dried briefly 
and counterstained with Vectashield mounting media antifade/DAPI (1:1) (Vector 
Laboratories Inc., Burlingame, CA).  Immunofluorescence was observed with a Leitz 
Orthoplan 2 fluorescent microscope and images were captured by a CCD-camera with 
Smart Capture program (Vysis, Downers Grove, IL).  Quantitation of FITC fluorescence 
was performed using the Adobe Photoshop 7.0 program. 
 
10.20 Western Blot of FLAG-Topo IIα.   
 Hela cells grown in RPMI media containing 5% FBS were transfected directly on 
100 cm2 tissue culture plates.  Plasmid DNA (10 µg) was mixed with 60 µl of Superfect 
transfection reagent (Qiagen) in 300 µl of serum-free media for 10 minutes, followed by 
600 µl of serum containing media, and the entire mixture was then added directly to cell 
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culture plates.  Transfection was allowed to proceed for three hours at 37°C in a 5 % CO2 
incubator, and terminated by the removal of transfection solution and the addition of 15 
ml of 5% FBS containing RPMI media.  After incubation for twenty-four hours, the cells 
were harvested by the addition of 0.53 mM EDTA, washed with cold PBS, and lysed in 
SDS buffer (2% SDS, 10% glycerol, 0.06 M Tris, pH 6.8).  Protein from 2x105 cells per 
lane was separated on an 8% SDS-PAGE gels and electrobloted (Biorad) onto 
nitrocellulose membranes (Amersham).  The blots were blocked for one hour at ambient 
temperature in a blocking buffer containing 0.1M Tris-HCl buffered saline, 0.5% Tween-
20, and 5% non-fat milk.  Blots were stained by the direct addition of anti-FLAG M2 
(Sigma) antibody and incubated overnight at 4ºC.  Membranes were washed three times 
for ten min with  0.1M Tris-HCl buffered saline and incubated with anti-mouse IgG 
antibody (Sigma) in blocking buffer containing 0.1M Tris-HCl buffered saline, 0.5% 
Tween-20, and 5% non-fat milk for sixty minutes at room temperature.  Antibody 
binding was visualized by ECL (Amersham) on autoradiography film (Kodak). 
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Chapter Eleven 
Experimental Results  
Part I:  Cell density-dependent VP-16 Sensitivity of Leukemic Cells is Accompanied by 
the Translocation of Topo IIα from the Nucleus to the Cytoplasm. 
 
 
11.1  Preliminary Results. 
 The results of the data described immediately below were obtained prior to my 
entering the laboratory, but are important because they established a foundation for my 
doctoral work on mechanism of drug resistance to topoisomerase targeting agents.  A 
complete description of the data is given in Valkov et al., 2000.  I became a contributing 
author of Valkov et al., 2000 for my immunostaining and microscopy work on log and 
plateau 8226 and CCRF cell lines, which included the development of an in vitro cell 
model for investigating the nuclear-cytoplasmic distribution of topo IIα.   
 
11.2 Drug Resistance Phenotype of Plateau-phase Tumor Cell Lines.  
Most cell lines display a differential sensitivity to topo II targeting agents such 
that when cells reach confluence they become drug resistant to topo II poisons (Sullivan 
et al., 1987, 1986; Chow and Ross, 1987; Markovits, 1987).  Drug resistance to topo II 
poisons in non-transformed plateau cell lines have been attributed to attenuations in the 
amount and activity of topo IIα protein.  However, the transition from log to plateau cell 
density does not necessarily lead to a decreased cellular content of topo IIα protein in 
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transformed cell lines (Sullivan et al., 1987).  Thus, we were interested in explaining the 
observed drug resistance in transformed cell lines at plateau density, which is 
independent of the cellular content of topo IIα.   
First, the differences in drug sensitivity between log and plateau cell densities of 
several transformed and non-transformed cell lines were investigated.  To do this, the 
cytotoxic effects of two topoisomerase II poisons (i.e., VP-16 and MTX), one topo I 
poison (TPT), and two non-topoisomerase targeting agents (i.e., cisplatin and vincristine) 
in several log and plateau cell lines was determined.  A comparison of the drug sensitivity 
of four leukemic cell lines (CCRF, HL-60, KG-1a, L1210), one myeloma cell line 
(RPMI-8226) and non-transformed human Flow 2000 fibroblasts and Chinese hamster 
ovary (CHO) cells shows that, at plateau cell density, all cell lines become resistant to 
VP-16 (Table 9).  The magnitude of cross-resistance to another topo II inhibitor, 
mitoxantrone, was uniformly less in all cell lines, but followed a similar pattern of 
resistance as that observed with VP-16.  The mouse leukemia L1210 and Chinese 
hamster ovary (CHO) cell lines showed significant plateau phase drug resistance to the 
topo I inhibitor topotecan. Resistance to drugs that act by mechanisms other than the 
inhibition of topo was low, except for the resistance of human leukemia KG-1a cells to 
vincristine. These data suggest that the log to plateau phase transition involves specific 
changes in topo in these leukemic and non-transformed cell lines.  Altered drug 
sensitivity to VP-16 has been shown to result from a cell-cycle dependent degradation of 
topo IIα protein.  It is well established that the cellular content of topo IIα is maximal in 
G2/M of the cell cycle, and thus alterations in the cell cycle can result in altered drug 
sensitivity to topo II poisons.  The specific contributions of topo IIβ in conferring drug 
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resistance to topo II poisons are less well understood.  Attenuation in the cellular content 
of topo I protein, however, has also been attributed to decreased drug sensitivity to topo I 
targeting agents.  Furthermore, topotecan is reported to be S-phase specific cytotoxic 
agent.  Thus, we examined the cell cycle distribution by flow cytometric analysis and the 
cellular content of topo I, topo IIα, and topo IIβ by Western blot analysis in log and 
plateau cells.   
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VP-16 
IC50 * 
(µmol/l) Rf** 
MTX 
IC50 
(µmol/l) Rf 
TPT 
IC50 (µmol/l) Rf 
CDDP 
IC50 
(µmol/l) Rf 
Vincristine 
IC50  
(µmol/l) Rf 
Fibroblasts 11.5±6.6a. 5.2±0.2a 17, 17.1b 2.6  2.4±0.6 3.3±0.1 ND ND ND ND 
CHO 4.0** 15.0d 25.0†† 8.0 0.18±0.15 274±168 3.0c 1.0 ND ND 
CRRF 0.63±0.61 39.0±11.5e 1.37±0.66 7.7±3.9g 0.37±0.28 16.8±12.6 0.71±0.29 1.9±0.05 1.25±0.91 1.3±0.4 
HL-60 0.55±0.04 7.6±0.3 18.0c 2.2 0.06±0.02 1.0±0 ND ND ND ND 
8226 0.57±0.26 10.4±2.1 8.5±0.5 2.6±0.2 0.95±0.55 2.0±1.0 1.15±0.35 1.1±0.1 1.8 1.3 
L1210 1.33±0.29 17.7±6.6f 7.5±0.5 4.9±0.5 0.30±0.29 282±156 0.55±0.55 1.3±0 3.55±0.05 1.3±0.1 
KG-1a 5.67±1.7 3.5±1.4 22.3±12.2 1.1±0.1 1.25±0.75 2.5±0 3.1±0.1 1.1±0.1 1.0, 1.1b 27.5, 25.3b 
Table 7. Drug Resistance of Natural Plateau Phase Non-transformed and Tumor Cell Lines 
*IC50, drug concentration that inhibits growth by 50% as determined by the colony forming assay; values reported are for log phase cells 
**Rf, the resistance factor or ratio of IC50 values of plateau and log phase cells 
aMean ± SEM 
bn = 2, the experiment was done two times and both values are shown 
cn = 1, the experiment was done one time and the individual value is shown 
dFrom Sullivan et al., 1986 
eSimilar results found with MTT assay (n = 3), where Rf = 26.0 ± 4.9. 
fSimilar results found with MTT assay (n = 3), where Rf = 10.5 ± 0.5 
gSimilar results found with MTT assay (n = 3), where Rf = 6.0 ± 4.3 
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11.3 Cell Cycle Distribution and [3H]-thymidine Incorporation.  
 The drug resistance to topotecan observed in the L1210 and CHO cell lines may 
be explained in part by the decrease in the number of S-phase cells at plateau density 
(Table 10), as topotecan is thought to be an S-phase specific agent.  However, the 
magnitude of the decrease in S-phase cells at confluence did not parallel the degree of 
resistance. The fibroblast cells were only minimally resistant to topotecan, and yet had 
the second greatest decrease in number of S-phase cells at confluence.  Although the HL-
60 cells showed no decrease in the number of S-phase cells at confluence, they had 6.5 
fold less [3H]-thymidine incorporation, suggesting a significant decrease in the number of 
cycling cells.  The sensitivity of HL-60 cells to topotecan, however, paralleled the flow 
cytometry results (no apparent change in S-phase).  Factors other than a simple change in 
percentage of S-phase are probably involved in the sensitivity to topotecan in this log and 
plateau cell model. 
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Table 8. Analysis of S-phase and [3H]-thymidine Incorporation in Log and Natural Plateau Phase Cell Lines* 
 
BrdU Incorporation 
Log S (%) 
BrdU Incorporation 
Plateau S (%) 
Log [3H] thymidine  
(cpm/106 cells) 
Plateau [3H] thymidine 
(cpm/106 cells) 
Flow fibroblasts 29.6 ± 6.9a 10.1 ± 10.3 NDb ND 
CHO 37.4 ± 5.1 14.9 ± 9.2 ND ND 
CCRF-CEM 34.7 ± 8.9 25.9 ± 8.2 20760 ± 371 (P < 0.0001)c 2089 ± 256 
HL-60 30.0 ± 8.9 30.5 ± 4.9 2289 ± 401 (P = 0.003) 352 ± 33 
RPMI-8226 25.4 ± 7.8 15.5 ± 2.3 6819 ± 351 (P = 0.41) 6504 ± 39 
L1210 37.3 ± 9.5 27.9 ± 8.1 10570 ± 750 (P = 0.0004) 2306 ± 188 
KG-1a 21.6 ± 7.1 11.7 ± 7.9 2860 ± 120 (P <0.0001) 695 ± 50 
*Cell cycle distribution was determined by flow cytometry of log and plateau phase cells in three to five independent experiments,     
  while incorporation of [3H] thymidine was measured in appropriate cells in three or four separate experiments. 
aMean ± SEM 
bNot determined 
cP-values relative to uptake in plateau phase 
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11.4 Cellular Content of Topo in Log and Plateau-phase Cell Lines. 
 The overall quantity of topo was determined by Western blot analysis of whole 
cell lysates of log and plateau phase leukemic, myeloma and non-transformed cell lines.  
A notable difference between malignant and non-transformed cell lines was the near 
disappearance of topo IIα from CHO and fibroblasts cells at a time when they reach 
confluency and lose their proliferative potential (Figure 23 ).  In contrast, all tumor cell 
lines preserved their total cellular topo IIα content, independent of cell density. Topo IIβ 
did not show any substantial changes in the cell lines studied and was not downregulated 
in either normal or neoplastic cells.  The content of topo I was not found to be 
significantly changed by the log to plateau phase transition in fibroblasts, 8226, HL-60, 
KG-1a, CCRF, or L1210 cells.  Furthermore, a reduction in the total cellular amount of 
topo IIα could not account for the decreased sensitivity to VP-16 and mitoxantrone in 
transformed cell lines. The relatively high level of resistance of plateau phase L1210 cells 
to topotecan also does not appear to result from a downregulation of cellular topo I 
content.   
  Thus far, we have been able to attribute the drug resistance to topo VP-16 and 
MTX observed in non-transformed cell lines to attenuation of topo IIα protein.  However, 
we have not been able to fully describe the mechanism(s) of drug resistance to VP-16 or 
mitoxantrone in the transformed cell lines at plateau cell density.  Although alterations in 
the cell cycle may have a role in the decrease drug sensitivity of L1210 cells to topotecan, 
the data obtained from analysis of the cell cycle was not always consistent with the drug 
sensitivity.  Furthermore, there were discrepancies between the percent of S-phase cells 
as determined by flow cytometric analysis and the number of cycling cells determined by 
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[3H] thymidine incorporation.  For example, plateau HL-60 cells have minimal resistance 
to topotecan, which is consistent with the analysis of S-phase by flow cytometry. 
However, HL-60 cells demonstrated relatively large decrease in the amount of [3H] 
thymidine incorporation.  Thus, we speculated that other cellular events must be 
occurring that have a role in drug sensitivity to topoisomerase targeting agents.  We 
questioned whether transformed cell lines may alter their subcellular distribution of topo 
IIα protein to evade drug-target interactions with VP-16 or mitoxantrone.  To address this 
possibility, we compared the subcellular distribution of topo IIα in 8226 and CCRF cells 
at log and plateau density by immunofluorescence microscopy.   
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Figure 23. Western Blot Analysis of Topo I, Topo IIα, and Topo IIβ from 
Whole-cell Lysates of Cell Lines at Log and Plateau Densities. One million 
cells were loaded in all lanes, and the ECL signal was quantified by 
densitometry. These results are representative of experiments performed a 
minimum of three times for each cell line.  Lane A, log-phase cells; lane B, 
plateau-phase cells.  
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11.5 Subcellular Distribution of Topo in Log and Plateau-phase Cell Lines. 
 At log density,  topo IIα was strictly nuclear, while at plateau cell density, the 
tumor cell lines demonstrated an increase in topo IIα present in the cytoplasm (Figure 
24).  In order to evaluate the amount of topo IIα at the single cell level statistically, the 
pixel intensity of nuclear and cytoplasmic topo IIα in 200 individual cells (50 
cells/experiment four times) at log, midlog and plateau densities was determined 
(complete data not shown here, refer to Valkov et al., 2000).  CHO cells had a 
proportional decrease in the nuclear/cytoplasmic ratio, such that at plateau phase the ratio 
was less than one (<1).  This suggested that for the remaining undegraded topo IIα there 
was relatively more in the cytoplasm than in the nucleus.  From early log phase to plateau 
phase, there was a significant decrease in the topo IIα nuclear/cytoplasmic ratio for all 
cell lines except KG-1a. Thus, at confluent densities, all cell lines (except KG-1a) had 
significantly more topo IIα in the cytoplasmic compartment. The immunolabelling of 
three cells lines (CCRF, L1210, and HL-60) for topo I and topo IIβ demonstrated no 
significant trafficking of these topoisomerases to the cytoplasm during the transition from 
log to plateau phase (data not shown).   
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Figure 24.  Immunofluorescent Staining and Confocal Microscopy. 
Immunofluorescent staining for topo IIα (A, D, G, J, histones (B,E, H, and K), and 
merged images (C, F, I,and L) in log and plateau phase CCRF and 8226 cells. Log 
phase 8226 cells (A-C) were at a density of 2.0 X 105 cells/ml; plateau-phase 8226 
cells (D-F) at 9.0 X 105 cells/ml; log phase CCRF cells (G-I) at 2.0 X 105 cells/ml; 
and plateau phase CCRF cells (J-L) at 1.6 X 106 cells/ml. Cell viability in all 
experiments was ≥ 95% and the immunofluorescence was observed with a Leitz 
Orthoplan 2 microscope and captured digitally using the Smart Capture program. 
Topo IIα Histones Merged 
8226 
Log  Phase 
8226 
Natural Plateau 
CCRF 
Log Phase 
CCRF 
Natural Plateau 
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11.6 Conclusions. 
 The resistance of several leukemia and myeloma cell lines (CCRF, L1210, HL-60, 
KG1a, and RPMI-8226) to VP-16 was found to increase with cell density and to be 
maximal (3.5 to 39-fold) in plateau phase cell cultures, as measured by clonogenic and 
MTT assays. Non-transformed confluent Flow 2000 human fibroblasts and Chinese 
hamster ovary (CHO) cells were also five and 15-fold resistant to VP-16, respectively.  
The transition from log to plateau phase was accompanied by a drastic decrease in 
topoisomerase IIα content in CHO cells and human fibroblasts, while the leukemic cells 
maintained constant cellular levels of topo IIα and topo IIβ.  The nuclear-cytoplasmic 
ratio of topo IIα may be critical in determining the sensitivity of leukemia cells to topo II 
inhibitors.   
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Chapte Twelve 
 
Experimental Results  
 
Part II: The Cytoplasmic Trafficking of DNA Topoisomerase IIα Correlates with 
  Etoposide Resistance in Human Myeloma Cells 
 
12.1  Introduction. 
 The data described in Part I, suggests that the nuclear-cytoplasmic ratio of topo 
IIα may be critical in determining the sensitivity of myeloma and leukemia cells to topo 
II inhibitors.  However, many questions remain.  Does a nuclear-cytoplasmic trafficking 
of topo IIα contribute to drug resistance in vitro?  Are plateau leukemia and myeloma 
cells cross-resistant to other classes of antitumor agents besides topo targeting agents?  
How does a cytoplasmic topo IIα contribute to altered drug sensitivity?  Is the 
cytoplasmic distribution of topo IIα a result of deceased nuclear import or increased 
nuclear export?  Can we manipulate the nuclear-cytoplasmic trafficking of topo IIα by 
either inducing its cytoplasmic location or by blocking the cytoplasmic relocation of topo 
IIα in plateau cells? These question, and others established the purpose of my doctoral 
work.  
 
12.2 Accelerated-plateau Human Myeloma Cell Line Model. 
To more precisely define the role that the nuclear-cytoplasmic shuttling of topo 
IIα has in modulating drug sensitivity to topo inhibitors and other classes of anti-cancer 
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agents, we developed a human multiple myeloma cell line model.  The data presented 
inthe log and plateau cell models suggest that the nuclear-cytoplasmic trafficking of topo 
IIα could be cell-density dependent, and thus influenced by cell-cell contact.  To exploit 
cell-cell contact, log-phase (defined as 3.0 x 105 cells/ml) human myeloma cell lines 
(NCI-H929 and RPMI-8226) and the human leukemia HL-60 cell line were concentrated 
to a superconfluent cell density (2.0 x 106 cells/ml) and grown at this density for up to 24 
h before experimentation.  After growing at the superconfluent density for as long as 24 
h, the accelerated-plateau cells were still > 85% viable by trypan blue exclusion.   
The superconfluent cell density was initially determined by obtaining growth curves for 
NCI-H929 (Figure 25) and RPMI-8226 (data not shown) cells to establish the cell-density 
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Figure 25. Growth Curves. Growth curves for human myeloma H929 and 8226 
(data not shown) cells were plotted to determine log and plateau cell densities. 
H929 cells enter logarithmic growth approximately 2 days after being seeded to an 
initial cell density of 2.0 x 105 cells/ml in fresh media. After growing continuously 
for 2 days, H929 cells reach “natural-plateau” near 1.2 x 106 cells/ml The graph 
illustrates the relatively long plateau phase (~4-5 days) characteristic of these cell 
lines. Cell density  as cell count x 105 cells/ml (o); Percent viability, (▲). 
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of “naturally-plateaued” H929 and 8226 cells. For example, after being seeded at 2.0 X 
105 cells/ml, H929 cells require approximately 48 hours to reach log-phase, and then  The 
remain in log-phase for an additional 36-48 hours before reaching plateau phase.  H929 
cells remained in plateau phase for approximately 2 days.  The H929 cells reach 
confluence when their cell density nears 1.2 X 106 cells/ml (natural plateau).  Thus, the 
superconfluent or accelerated-plateau was set to approximately double the natural-plateau 
cell density (2.0 x 106 -2.5 x 106 cells/ml).growth curve also illustrates the relatively long 
natural plateau-phase (approximately 4-5 days) characteristic of H929 human myeloma 
cells. Other cell densities were also analyzed (1.0 X 106 cells/ml, 5.0 x 106 cells/ml, and 
1.0 x 107 cells/ml) however, 2.0 x 106 cells/ml was determined to be an optimal cell-
density that preserved cellular viability and demonstrated topo IIα export in a measurable 
period of time.   
  
12.3   Drug Sensitivity of Human Myeloma Cell Lines in Accelerated-plateau. 
To determine if topo IIα protein trafficking correlates with cellular drug resistance 
to other topo targeting agents as well as other classes of antineoplastic agents, the toxic 
effects of several classes of antineoplastic agents were examined in log and accelerated-
plateau H929 and 8226 cells.  We expanded the drug sensitivity data that was described 
for log and plateau cells (in Valkov et al., 2000) to include an antimetabolite (ara-C), a 
nitosourea DNA crosslinking agent (BCNU), a platinum containing DNA crosslinking 
agent (cisplatin), an antimicrotubule (Paclitaxel), and γ-irradiation.  A comparison of 
drug sensitivity of log-phase and accelerated-plateau phase H929 and 8226 (data not 
shown) cells shows that the log-phase cells are more sensitive to topo inhibitors, such as 
 134
VP-16 and mitoxantrone, compared to cells seeded at the plateau-phase density for 16 h 
or 24 h, as determined by colony forming assays (similar results were obtained with 8226 
cells) (Table 11). The accelerated-plateau cells were most resistant to VP-16, 10-fold at16 
h and 24-fold at 24 h). The accelerated-plateau H929 cells demonstrated less resistance to 
the non-topo inhibitors such as ara-C, taxol, BCNU, and γ-irradiation, but were found to 
be 3-fold resistant to topotecan. Thus, the observed drug resistance appears to be more 
specific for topo inhibitors than other classes of chemotherapeutic agents.  These data 
suggest that the principal mechanism of drug resistance involves quantitative or 
qualitative changes in topoisomerase. However, other cellular events, such as alterations 
in either drug transport or cell-cycle can also contribute to a decrease in drug sensitivity 
to topo poisons. To explain the mechanism(s) of observed drug resistance to topo poisons 
in accelerated-plateau cells, changes in total amount of topo protein, drug uptake, cell 
cycle distribution, and subcellular localization were examined.  
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Resistance Factord  (RF) Antitumor Drugb Log-phase IC50c 16 h 24 h 
VP-16 (DMSO, 1 h) 0.360 ± 0.08e 9.6 ± 3.3 23.5 ± 5.1 
Mitoxantrone (water, 1 h) 0.0009 ± 0.0001f 5.3 ± 0.2 5.1 ± 0.2 
Topotecan (methanol, 1 h) 3.32 ± 1.0g 3.1 ± 0.4 3.5 ± 0.3 
Taxol (DMSO, 24 h) 1.40 ± 0.92 1.2 ± 0.3 2.8 ± 0.2 
γ-Irradiation 75 cGy ± 8.6 0.33 ± 0.2 1.3 ± 0.1 
Cis-platinum (DMSO, 1 h) 7.00h 0.43 0.5 
Ara-C (water, 20 h) 1.20h 1.3 5.0 
BCNU (ethanol, 4 h) 1.0h 1.5 1.0 
     aUnless otherwise noted, three to five independent experiments were performed for each drug in triplicate.   
     The mean values ± SEM are shown. 
     bSolvent for drug dissolution and hours of drug exposure are shown in parentheses. 
     cIC50 is the concentration of drug that inhibits growth by 50% and the values reported are for log- phase cells  
     in µM concentrations. 
     dFold resistance (RF) is the ratio of 50% inhibition concentration values (IC50’s) obtained from  
    colony-forming assays. 
     eSimilar results were found in 8226 cells at 24 h, IC50 = 0.460 ± 0.06 (n =3), where RF = 10.3 ± 1.6. 
     f Similar results were found in 8226 cells at 24 h, IC50 = 0.003 ± 0.001 (n =3), where RF = 5.0 ± 0.5. 
     g Similar results were found in 8226 cells at 24 h, IC50 = 1.1 ± 0.5 (n =3), where RF = 2.0 ± 1.1. 
     hThe colony-forming assay was performed one time in triplicate. 
Table 9.  Drug Sensitivity of Log and Accelerated-plateau H929 Cells to Cytotoxic 
A a
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12.4  Cell-cycle Analysis. 
 The cellular amount and activity of topo IIα is regulated in a cell-cycle and 
proliferation dependent manner, and alterations in the amount and activity of topo IIα 
correlate with cellular drug resistance to topo inhibitors.  Therefore, it was necessary to 
separate the contributions of the cell cycle to the observed drug resistance from other 
cellular events. The cell cycle was analyzed over a 24 h period for changes in the S-phase 
cell population from the time that the log-phase cells were concentrated to 2.0 X 106 
cells/ml (time zero) (Figure 26).  Analysis of BrdU incorporation in H929 cells indicates 
that 19.4% ± 5.0% of log-phase cells are in S-phase compared to 14.4% ± 1.3% of  
Figure 26.  Percent of Accelerated-plateau Cells in S-phase. BrdU incorporation 
was measured to determine the percent of NCI-H929 and RPMI 8226 cells in S-
phase. The experiment was repeated three times and the mean values with 
standard deviation are shown (o), 8226 cells; (•), H929 cells.  
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accelerated-plateau cells at 16 h. These data suggest that the changes in the cell cycle 
distribution that occur within 16 h of being plated at 2.0 x 106 cells/ml are not likely to be 
the main mechanism contributing to the drug resistance observed to topo inhibitors.  A 
greater reduction in the S-phase population of accelerated-plateau cells was observed at 
24 h and this difference could account for the increase in drug resistance observed with 
ara-c (1.3 fold to 5.0 fold) and taxol (1.2 fold to 2.8 fold).  To more specifically 
determine the contribution that topo IIα trafficking plays in drug sensitivity, subsequent 
experiments were performed within 16 h to minimize contributions of cell cycle changes 
to drug sensitivity in the accelerated-plateau cell model. 
 
12.5  Cellular Amount of Topoisomerase by Immunoblotting.  
An attenuation of topo enzymes can contribute to drug resistance by decreasing 
the amount of drug target.  To determine if there are any changes in the total cellular 
amount of topo protein in accelerated-plateau cells that could contribute to the observed 
drug resistance, the amount of topo protein in whole cells was determined by Western 
blot analysis.  No significant changes in the amount of topo II protein were observed in 
whole cells when compared to log-phase cells 4-24 h after seeding at the super-confluent 
cell density (Figure 27).  Thus a decrease in the total amount of topo II protein is unlikely 
to account for the observed drug resistance in accelerated-plateau H929 and 8226 cells to 
VP-16 and mitoxantrone, while a decrease in topo I (20-30%) may contribute to the 
resistance to topotecan. 
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The observed decrease in topo I may also contribute to the decrease in drug 
sensitivity to ara-C because recent data shows that topo I cleavable complexes can be 
trapped by ara-C incorporation into DNA (Pourquier et al., 2000).  Inhibition of topo I by 
ara-C is suggested to occur by structural modifications that occur in the DNA helix when 
ara-CTP is incorporated.  Ara-c incorporation into DNA results in structural 
modifications in the DNA helix and inhibition of DNA synthesis (Pourquier et al., 2000)  
Ara-c incorporation into DNA is believed to result in misalignment of the DNA 5'-
hydroxyl with the enzyme-DNA tyrosyl phosphodiester bond, which is necessary for 
nucleophilic attack and DNA religation (Pourquier et al., 1997, 1998, 2000).  Thus, it 
Figure 27. Western blot Analysis of DNA Topoisomerase I and II.  The total cellular 
amount of topo I, topo IIα, and topo IIβ protein in whole cell lysates from 1.0 x 106 log 
and accelerated-plateau H929 and 8226 cells was determined by Western blot analysis. 
There are no significant differences in the amount of topo IIα or IIβ protein up to 24 h 
by densitometry. A small decrease in topo I is seen in H929 cells ≥ 16h, while a 30% 
decrease in topo I is seen in 8226 cells at times ≥ 4 h. Hours refer to the time after 
concentrating log-phase cells to super-confluent densities. The expermiment was 
performed one time in duplicate for topo IIβ and repeated three times each for topo I 
Topo IIα 
 Log 4 hr 16 hr 24 hr
100%  105% 100% 101% 
100% 100% 87% 84% 
  100%  104%  104% 104%
Log  4 hr 16 hr 24 hr 
H929 8226
100% 67% 60% 66% 
100% 89% 90% 88% 
100% 103% 105% 101% 
Topo I 
Topo IIβ 
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appears that ara-C cytotoxicity is a result of both inhibition of DNA polymerization and 
topo I poisoning.  Inhibition of topo I by ara-C could explain the 5-fold resistance of 
plateau cells to ara-C at 24 hours because there is a concomitant decrease in the total 
cellular amount of topo I protein in plateau cells.  Thus, it is possible that cell death 
induced by ara-C in the log growing cells was due in part to the formation of topo I 
cleavable complexes in addition to cessation of DNA synthesis.   
 
12.6  Drug Transport in Tumor Cell Lines. 
Reduced drug accumulation is a major mechanism conferring drug resistance in 
several drug-resistant cell lines, and many important mammalian drug transport proteins 
are ATP-dependent proteins that belong to the ABC superfamily (reviewed in Leonard et 
al., 2002).  Under normal conditions, these pumps protect cells from accumulating toxic 
substances by actively pumping out cytotoxic substances.  Thus, topo I and II inhibitors 
may be effectively eliminated from cells by a variety of these drug transporters.  To 
determine if the differences in log and accelerated-plateau cells in drug sensitivity to topo 
inhibitors was a function of altered drug transport, cellular uptake of [3H]-VP-16 was 
measured as described in "Materials and Methods" (Sullivan et al., 1987).  Briefly, H929 
cells were incubated in the presence of [3H]-VP-16 for 1 h to achieve steady state, 
washed, and pelleted by centrifugation.  The pelleted cells were transferred to drying 
paper and dried overnight, and then weighed.  After weighing, the pellets were dissolved 
in a buffer, and then 3H content was determined by scintillation counting.  Drug uptake 
for log and accelerated-plateau cells was determined as cpm per milligram of cells.  No 
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considerable difference was observed in the uptake of [3H]-VP-16 between log (1.7 x 104 
counts/mg of dry weight) and accelerated-plateau cells (1.8 x 104 counts/mg of dry 
weight).  We have previously shown that there are no differences between several log and 
natural-plateau human myeloma and leukemia cell lines (Valkov et al., 2000; Sullivan et 
al., 1986, 1987).  Thus, an alteration in drug transport of VP-16 is not likely to be the 
main mechanism conferring drug resistance to topo inhibitors in the accelerated-plateau 
model.  
 
12.7  Subcellular Distribution of Topoisomerase IIα. 
 Although the total amount of topo protein does not appear to change in the whole 
cells, a change in the subcellular distribution of topo could alter the amount of topo 
protein located in the nucleus.  Therefore, we examined the subcellular distribution of 
topo IIα (28 ) and topo I and topo IIβ (29) was examined by immunofluorescence 
microscopy and confirmed by scanning confocal microscopy.   
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Topo IIα Histones Merged 
Plateau 
 (16 h) 
Plateau 
(24 h) 
 
Log 
Figure 28. The Subcellular Distribution of Topo IIα in Log and Accelerated-plateau H929 Cells at 16 h and 
24 h. Histones are non-shuttled proteins that define the area of the nucleus. Topo IIα is nuclear in log-phase 
cells and has a markedly increased cytoplasmic distribution in accelerated-plateau cells at 16 h and 24 h. 
Arrows point to cells with cytoplasmic topo IIα. 
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DNA Topo IIβ Topo I Merged 
Log 
Plateau 
 (24 h) 
 
Figure 29. The Subcellular Distribution of DNA, Topo I, and Topo IIβ in Log and 
Accelerated-plateau H929 Cells at 24 h. DNA was stained with DAPI which defines 
the area of the nucleus. Topo I appears nuclear in log and accelerated-plateau cells. 
Topo IIβ is found in the nucleus and cytoplasm of log and plateau cells. 
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A least 50 cells per experimental condition (i.e., log or plateau) were randomly picked by 
4'-6-diamidino-2-phenylindole (DAPI) staining of the nucleus.  Cells were numbered as 
1-50 and then, analyzed for the pixel intensity of either tetramethyl rhodamine 
isothiocyanate (TRITC) or fluorescein isothiocyanate (FITC) labeled antibody as 
described in Figure 30.  Topo IIα is predominately nuclear in log-phase cells, but there is 
a time-dependent translocation of topo IIα in the accelerated-plateau cells after 16 h.  
Similar results were observed in the natural plateau cells (data not shown).   
 
 
 
Figure 30. Method for Selecting Cells by Confocal Microscopy. Cells 
were selected randomly by positive DAPI staining and images captured 
using a CCD camera as described in“Materials and Methods”. The cells 
were numbered 1-50. Mitotic cells and cells touching the edge of the field 
of vision were not included in the data. Furthermore, any cell staining 
positive for DAPI but histone negative were presumed to be cell debris 
and also were not included in the data. 
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The subcellular distribution of topo protein was quantified in log and accelerated- 
plateau H929 and 8226 cells by calculating the nuclear/cytoplasmic ratio (N/C) from the 
pixel intensity of the individual compartments from 50 cells per time point.  The staining 
for nuclear topo I and II was internally controlled in each cell by DAPI staining of DNA 
and histone staining. Figure 31 illustrates the method, as described in "materials and 
methods", for analyzing the subcellular localization of topo by immunofluorescence.  A 
least 50 cells per experimental condition (i.e., log or plateau) were analyzed.  These 
experiments were performed in duplicate and repeated three times in both H929 and 8226 
cells.  The median N/C ratio of topo IIα is 29.9 ± 9.1 for log-phase H929 cells and 
decreases to 1.3 ± 1.3 for the accelerated-plateau cells after 16 h and to 0.90 ± 1.1 after 
24 h.  The median N/C ratio of topo I and IIβ did not change.  The median N/C ratio of 
Figure 31.  Determination of Nuclear-cytoplasmic Ratios (N/C).  Using 
AdobePhotoshop, we were able to zoom-in on each cell.  To obtain the value of the 
pixel intensity between the nuclear and cytoplasmic compartments for either TRITC or 
FITC labeled antibody, the nuclear and cytoplasmic compartments were outlined using 
the "lasso" feature.  In the cell shown here, the cytoplasm is outlined in blue, whereas 
the nucleus is outlined in yellow.   The N/C ratio was determined from the following 
equation: number of pixels in nucleus x (mean-background)/number of pixels in 
cytoplasm x (mean - background). 
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topo I was 27.0 ± 3.2 in log-phase H929 cells and 29.2 ± 4.1 at 16 h accelerated plateau.  
The median N/C ratio of topo IIβ was 10.1 ± 5.5 in log-phase and 8.9 ± 5.4 at 16 h 
accelerated plateau.  The subcellular distribution of histones was monitored as a nuclear 
control and also does not change in the accelerated-plateau cells.  Similar results were 
obtained in 8226 cells (data not shown).  For example, the median N/C ratio in 8226 cells 
of topo IIα in log-phase was 9.5 ± 6.3 versus 2.1 ± 1.6 at 16 h accelerated plateau.   
 The subcellular distribution of topo IIα in H929 cells was confirmed by 
biochemical separation of the nuclear and cytoplasmic compartments with subsequent 
western blot analysis (Figure 32).  The subcellular locations of topo I and LDH were used 
as nuclear and cytoplasmic controls, respectively. The amount of topo IIα found to be 
distributed to the cytoplasmic compartment in plateau-phase H929 cells varied between 
25% and 50% of the total cellular amount. This experiment was repeated seven times and 
the majority of the experiments demonstrated 40-50% cytoplasmic topo IIα in plateau-
phase cells. These results agree with the microscopy findings above, which demonstrated 
a N/C ratio of 1.3 ± 1.3 for 16 h plateau-phase H929 cells.  The partial degradation of 
topo IIα that occurred during the nuclear-cytoplasmic separation was not observed when 
cells were immediately immunoblotted, and was not prevented by the addition of several 
protease inhibitors (see “Materials and Methods”). Similar immunoblot results were 
obtained in HL-60 cells (data not shown) and 8226 cells. Thus, it appears that topo IIα, 
but not topo I or IIβ, is shuttled to the cytosol when H929 cells are grown at a super-
confluent cell density. 
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12.8 Topoisomerase II Enzyme Activity. 
Although the total amount of topo IIα protein does not change between log and 
accelerated-plateau cells, a redistribution of topo IIα from the nucleus to the cytoplasm 
would be expected to decrease the amount of drug target in the nucleus.  If the nuclear-
cytoplasmic trafficking of topo IIα results in attenuation of nuclear content, then there 
would be less drug-induced DNA damage and fewer cleavable complexes expected.  
Thus, we hypothesized that a cytoplasmic distribution of topo IIα would protect cells 
from drug induced DNA damage by attenuating the amount of lethal drug-enzyme-DNA 
Figure 32. Nuclear-cytoplasmic Separation and Western Blot Analysis of DNA 
Topoisomerase I and II and LDH.  Nuclear-cytoplasmic separation of log and 
plateau (16h) H929 cells followed by Western blot analysis for topo IIα, topo I, and 
LDH. Experiment A demonstrates that in plateau phase there is approximately one-
half of the cellular topo IIα (partially degraded) in each of the nuclear and 
cytoplasmic compartments. In experiment B, the amount of total cellular topo IIα is 
distributed as approximately 75% to the nucleus and 25% to the cytoplasm in 
plateau phase growth (determined by densitometry). The subcellular locations of 
topo I and LDH were used as nuclear and cytoplasmic controls, respectively. WC, 
whole cells; N, nucleus; C, cytoplasm. 
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complexes formed. To test this hypothesis, the amount of VP-16 induced DNA damage 
was compared in log and accelerated-plateau phase (16 h) H929 cells by the alkaline 
comet assay (Figure 33).  The mean of three experiments showed that the average comet 
moment was higher in log-phase cells than accelerated-plateau cells at each drug 
concentration. For example, the average comet moment for log-phase cells was 80 ± 7 
and 50 ± 5 for accelerated-plateau cells in the presence of 10 µM VP-16. The results 
indicate that there are less drug-induced double strand DNA breaks in cells seeded at the 
super-confluent cell density.  
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Figure 33 . Determination of VP-16 Induced Double-strand DNA Breaks.  
Measurement of VP-16 induced double-strand DNA breaks in log and 
accelerated-plateau H929 cells at 16 h using the comet assay.  Cells were 
treated with 0-50 µM VP-16 as described in “Materials and Methods”. The 
average comet moment of 50 cells at each drug concentration was 
calculated from three experiments and is shown in panel B. A 
representative comet is shown in A. (o), log-phase cells; (•), accelerated-
plateau cells.  
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 To determine if the decrease in DNA damage can be explained by a reduction in 
the number of drug-induced enzyme-DNA complexes formed, the amount of topo IIα 
drug-stabilized cleavable complex formation was compared in log and accelerated-
plateau (16 h) cells using a modification to the band depletion assay originally described 
for observing topo I cleavable complex formation in the presence of topotecan.  We 
adapted the same procedure to observe topo IIα cleavable complex formation in the 
presence of etoposide.  This assay is based on the observation that topo II covalently 
bound to DNA migrates more slowly than free topo II on sodium dodecyl sulfate (SDS)-
polyacrylamide gels (Figure 34).  Accordingly, as topo II forms increasing amounts of 
cleavable complexes in the presence etoposide, there is a corresponding decrease in the  
Figure 34 . Illustration of Band Depletion Assay.  The band depletion 
assay was preformed as described in "materials and methods". Briefly, 
cells treated with increasing concentrations of etoposide (VP-16) are 
lysed in a buffer containing guanidine hydrochloride, which acts as a 
strong protein denaturant that traps preexisting covalent topo II-DNA 
complexes. Cell preparations are then electrophoresed on an SDS-
polyacrylamide gel.  Topo IIα-DNA complexes run more slowly than 
free topo IIα, which is observed as a decrease in the intensity of the topo 
IIα by Western blot analysis. 
 
Free topo IIα 
Trapped topo IIα 
VP-16
Stacking gel 
Separating gel 
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molecular weight signal of topo IIα by Western blot analysis (Figure 35) (Kaufmann et 
al., 1997).  Results from the band depletion assays showed that a 7-fold higher 
concentration of etoposide was needed to deplete the topo IIα levels by 50% in 
accelerated-plateau H929 cells.  The drug concentration to achieve 50% band depletion is 
5 µM in log-phase cells and 35 µM in accelerated-plateau cells, suggesting that there are 
fewer enzyme-drug DNA complexes formed in accelerated-plateau cells relative to log-
phase cells.  These results were further confirmed by measuring the catalytic activity 
(kDNA decatenation) of topo II present in the nuclear extracts from log and accelerated-
plateau H929 and HL-60 cell lines (data not shown). Approximately 4-times more 
nuclear extract protein was needed to decatenate 1 µg of kDNA in either accelerated-
plateau H929 or HL-60 cells than in log-phase cells. 
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Figure 35.  Measurement of Cleavable Complexes.  Differences in the 
formation of VP-16-stablized enzyme-DNA complexes were examined in 
log and accelerated-plateau H929 cells using the band-depletion 
assay.These results show that a 7-fold increase in VP-16 was needed to 
achieve a 50% reduction in the topo IIα band in plateau-phase cells 
relative to log-phase cells. (o), log-phase cells; (•), accelerated-plateau 
cells.  Topo IIα cleavable complexes become trapped in the stacking gel 
 
 
 
 
 
 
 
Topo IIα 
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Collectively, these data suggest that there are significantly fewer topo catalyzed 
double-strand DNA breaks in VP-16 treated accelerated-plateau cells than log H929 cells 
because there are fewer drug-induced DNA-protein complexes formed. Thus, a decrease 
in drug-induced DNA-protein complexes could explain in part the observed drug 
resistance to topo inhibitors; attenuation in the total amount of cleavable complexes 
formed can best be explained by the cytoplasmic trafficking of topo IIα enzyme. Also, 
nuclear topo IIα present in plateau H929 cells appears to be less drug sensitive. 
 
12.9  Subcellular Distribution of Topo IIα in Malignant Plasma Cells. 
We next studied the distribution of topo I, topo IIα, and topo IIβ in clinical 
samples: bone marrow aspirates from myeloma patients.  Representative aspirates from 
two out of 10 patients examined are shown in Figure 20 and figure 21.  The aspirates 
(both with >90% plasma cells) were obtained before high-dose chemotherapy but after 
standard-dose chemotherapy.  Figure 37 shows the subcellular distribution of topo IIα in 
one untreated patient with multiple myeloma.  In all patients, there was a considerable 
proportion of topo IIα in the cytoplasmic compartment of the plasma cells.  The 
percentage of plasma cells that was brightly fluorescent and displayed a nuclear 
distribution of topo IIα was always in the range of 10-15% and reflected cells that were 
probably in the S-or G2/M-phase of the cell cycle.  Topo I was found to be strictly nuclear 
or nucleolar except for one patient (90% of cases).  In the one patient who had relapsed 
after high-dose chemotherapy, topo I was found to be exclusively cytoplasmic.  The topo 
IIβ subcellular distribution was mostly a mixed nuclear and cytoplasmic pattern, and in 
~50% of the patients showed nucleolar staining as well.  Generally, topo IIβ labeling 
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demonstrated a low expression by immunofluorescence and was nearly undetectable on 
Western blots.  When the nuclear/cytoplasmic ratios of topoisomerases were examined in 
the malignant plasma cells from 10 myeloma patients by confocal laser scanning 
microscopy, only topo IIα was present with ratios below 1 in the majority of cells.  
Collectively, the data in this study suggests that a correlation may exist between the 
cytoplasmic location of topo IIα and decreased sensitivity of these cells to topo inhibitors.  
 
12.10 Conclusions. 
 
 In this study, we have investigated the role of topoisomerase IIα trafficking in 
cellular drug resistance.  We developed a cell model (called accelerated-plateau) using 
human myeloma H929 and 8226 cells that reproducibly translocates topo IIα to the 
cytoplasm.  It was necessary to separate the influence of the cell cycle, drug uptake, topo 
protein levels, and enzyme trafficking of drug sensitivity in this cell model.  Compared to 
log-phase cells, the cytoplasmic redistribution of topo IIα in the accelerated-plateau cells 
correlated with a 10-fold resistance to VP-16 and a 40-60% reduction in the number of 
drug-induced double strand DNA breaks.  In addition, 7-fold more VP-16 was necessary 
to achieve 50% topo IIα band depletion, suggesting that there are fewer drug-induced 
topo-DNA complexes formed in the accelerated-plateau cells than the log-phase cells.  
The total cellular amount of topo IIα and topo IIβ protein in log- and accelerated-plateau 
was similar as determined by Western blot analysis.  There was a 25% reduction in S-
phase cell number in plateau cells (determined by bromodeoxyuridine (BrdU) 
incorporation).   
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 The data from this study support the hypothesis that the nuclear-cytoplasmic 
trafficking of topo IIα mediates, at least in part, cellular drug resistance to topo inhibitors 
by reducing the amount of topo IIα in the nucleus and the subsequent number of enzyme 
drug-induced DNA complexes formed.  Thus, we established a novel mechanism of de 
novo drug resistance that is independent of drug transport and cellular quantity of topo 
IIα.  Furthermore, Western blot analysis demonstrates that the cytoplasmic location of 
topo IIα is not likely to be a result of expression of a truncated enzyme that has lost the 
C-terminal NLS (Wessel et al., 1997).   
 These data may have clinical implications in the treatment of human myeloma, as 
immunohistochemistry (Figures 36 and 38 ) and Western Blot analysis (Figure 37) 
demonstrates that topo IIα has a cytoplasmic distribution in malignant plasma cells 
obtained from the bone marrow aspirates of myeloma patients before (Figure 36) and 
during treatment (Figures 37 and 38).  The data also suggests that topo IIβ and topo I may 
be more appropriate molecular targets in multiple myeloma because neither their amount 
nor their subcellular localization were found to be altered at plateau densities.    
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Figure 36. Subcellular Distribution of Topoisomerase IIα in Plasma Cells 
from One Untreated Multiple Myeloma Patient.  Immunofluroescent staining 
for Topo IIα and histone. Goat anti-rabbit IgG-TRITC labeled antibody was 
used for detecting topo IIα (appears red).  Goat anti-mouse IgG-FITC labeled 
secondary antibody was used to detect histone (appears green) as a nuclear 
control.  Cells were mounted on microscope slides containing Vectashield 
mounting media containing DAPI, which binds DNA (appears blue). 
Figure 37 . Western Blot Analyses of Topoisomerase I and  Topo IIα in 
Two Patients with Multiple Myeloma being Treated with Chemotherapy.  
The nuclear and cytoplasmic compartments were separated as described in 
"Materials and Methods" and the equivalent of 5.0 x 105 cells was loaded 
in each lane. The CCRF cells were loaded as a positive control for topo I 
and topo IIα immunoreactivity.  WC, whole-cell lysates; nu, nuclear 
fraction; cy, cytoplasmic fraction. 
Topo IIα Histone Merged 
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Figure 38. Subcellular Distribution of Topoisomerase in Two Multiple Myeloma Patients 
being Treated with Chemotherapy. Confocal microscopy was performed on plasma cells 
obtained from patient 1 (A-F) and Patient 2 (M-R). Cells were stained for topo IIα (A and 
M) with polyclonal antibody 454 and histones (B and N). The merged image (C and O) 
demonstrates that topo IIα is nuclear ~ 10% of the cells (proliferative fraction) and 
cytoplasmic or faintly nuclear in the remaining plasma cells. Histone staining was used to 
define the nucleus. Patient plasma cells were also stained for topo IIβ (D and P) with the 
polyclonal JB1 antibody, for topo I with the C-21 monoclonal antibody (E and Q) and the 
merged images (F and R). Topo IIβ was observed in the nucleus  (D), cytoplasm (F) and 
nucleoli (P), but its amount was relatively low compared with topo IIα. Topo I 
distribution was typically nuclear (E) or nucleolar (Q). 
Merged Histones Topo IIα 
Topo IIα Histones Merged 
Merged Topo I Topo IIβ 
Topo I Merged Topo IIβ 
Patient 1 
Patient 2 
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Chapter Thirteen 
Experimental Results  
Part III:  Human Topoisomerase IIα Contains Two  
Leptomycin B Sensitive Nuclear Export Signals 
 
13.1 Introduction.  
 Resistance to chemotherapeutic drugs is a major obstacle in the treatment of 
leukemia and myeloma.  We have previously found that myeloma and leukemic cells in 
transition from low-density log phase conditions to high-density plasteau phase 
conditions exhibit a cell density dependent translocation of topo IIα to the cytoplasm.  
The determination of the mechanism of topo IIα transport across the nuclear membrane 
could lead to a better understanding of how to regulate the levels of active enzyme in the 
nucleus, and thus sensitize cells to topo inhibitors.  We questioned whether the 
cytoplasmic distribution of topo IIα was a result of decreased import or increased export.  
Initially, we tried to block the import of topo IIα in log and plateau density cells by using 
the general nuclear import inhibitor, lectin.  Wheat germ agglutin (WGA) is a non-
specific inhibitor of general nuclear import (Duveger et al., 1995).  WGA is believed to 
inhibit nuclear import by binding nucleoporins and "clogging" the nuclear pore 
complexes.  We did not observe a difference in the nuclear-cytoplasmic distribution of 
topo IIα in log or accelerated plateau 8226 or H929 cells treated with lectin as determined
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by confocal microscopy (unpublished data).  One possible explanation of these results is 
that in log-phase cells, topo IIα was already present in the nucleus prior to drug treatment 
and does not shuttle continuously between the nucleus and cytoplasm of log-growing 
cells.  We also treated accelerated plateau 8226 and H929 cells with lectin to determine if 
a greater percentage of topo IIα protein would become trapped in the cytoplasmic 
compartment of lectin treated cells compared to untreated cells.  We observed no 
significant differences in the nuclear-cytoplasmic distribution of topo IIα in the presence 
of lectin.  These results suggest the possibility that topo IIα is exported from the nucleus 
to the cytoplasm, and thus is not inhibited by lectin.  Therefore, we investigated the 
ability of the nuclear export inhibitor, Leptomycin B, to block the nuclear export of topo 
IIα in the accelerated-plateau cells.   
 
13.2 LMB Modulation of Topoisomerase IIα Trafficking.  
   To determine the mechanism by which topo IIα accumulates in the cytoplasmic 
compartment, accelerated-plateau H929 cells were treated with the nuclear export 
inhibitor, LMB (Figure 39).  This Streptomyces metabolite has been shown to inhibit 
CRM1-mediated nuclear export of proteins with leucine-rich nuclear export signals 
(Engel et al., 1998; Wolff, B. et al., 1997; Nishi et al., 1994; Hamamoto et al., 1985). 
Immunofluorescent microscopy demonstrates that the median N/C ratio of topo IIα is 
increased 58-fold in plateau H929 cells treated with 0.5 ng/ml of LMB for 16 h when 
compared to untreated cells.  The median N/C ratio of untreated accelerated-plateau cells 
is 0.98 ± 2.0 and increases to 57.5± 170.2 in the presence of LMB. A total of 50 cells 
were examined per condition and the experiment was repeated three times. Similar results 
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were obtained in HL-60 cells (data not shown).  The large standard deviation observed in 
the LMB-treated cells can be accounted for by the presence of several cells with N/C 
ratios > 300.  Therefore, the median values have been reported as a more representative 
value of the true N/C ratio.  These data indicate that the cytoplasmic translocation of topo 
IIα can be blocked by LMB and suggests that topo IIα is exported from the nucleus as 
opposed to retained in the cytoplasm in untreated cells.  Furthermore, the average total 
pixel density of topo IIα in whole cells decreased from 113,929 ± 51,530 in control cells 
to 38, 053 ± 41, 040 in LMB-treated cells, a 67% reduction in pixel density of whole 
cells.  These data suggest that topo IIα may be downregulated in the presence of LMB 
because there is a greater reduction in total pixel density of treated cells relative to 
untreated plateau cells.  The pixel density of topo IIα immunofluorescence in the nuclear 
compartment is reduced from an average pixel density of 52,241 ± 21,716 to 868 ± 1226 
pixels.  One possible explanation is that LMB blocks the export of topo from the nucleus 
and topo becomes degraded by nuclear proteasomes. The degradation of topo has been 
shown to occur in the nucleus, but Western Blot analysis of topo IIα protein content in 
LMB treated plateau cells would be necessary to confirm these results.  These results 
suggest that topo IIα trafficking in the log-plateau cell model could be a result of 
increased nuclear export.   
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Figure 39. Confocal Microscopy and Nuclear-cytoplasmic Ratios of DNA Topoisomerased IIα Immunoflurescent Staining in the Presence or 
Absence of Leptomycin B.  Subcellular localization of topo IIα and pan-histone in 16 h accelerated-plateau H929 cells ± 0.5 ng/ml LMB (panel A, 0 
ng/ml LMB; panel B, 0.5 ng/ml LMB). The nuclear-cytoplasmic ratio per cell is shown for 50 plateau-phase cells (± LMB) in panels C and D. 
tetramethylrhodamine isothiocyanate (TRITC) staining (red) is for topo IIα and FITC staining (green) is for histones, in the immunofluorescence 
figures.  The experiment was repeated three times in H929 cells and once in HL-60 cells (data not shown). Cytoplasm ( ■ ), nucleus (□). 
Plateau (16 h), 0 ng/ml LMB A. Plateau (16 h), 0.5 ng/ml LMBB. 
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Table 10.  Determination of a Consensus Sequence from Established Nuclear Export Signals (NES) 
α-actin  
(Wada et al., 1998) 
A L* P H A I M R L D L A 
β-actin 
(Wada et al., 1998) 
A L P H A I L R L D L A 
TFIIIA 
(Fridell et al., 1996) 
 L  P V L E N L T L  
PKIα 
(Wen et al., 1995) 
E L A L K L A G L D I N 
MAPKK 
(Fukada et al., 1996) 
A L Q K K L E E L E L D 
RevHIV 
(Fischer et al., 1995) 
Q L  P P L E R L T L D 
Ran BP-1 
(Zolotukhin and Felber, 
1997) 
K V A R K L E A L S V R 
C-Abl 
(Taageoera et al., 1998) 
 L E D N L R E L Q I C 
hZyxin 
(Nix and Beckerle, 1997) 
L T M K E L E E L E L L 
MdM2 
(Roth et al., 1998) 
S L S G D L S  L A L C 
P53 
(Strommel et al., 1999) 
F R E L N E A L E L K D 
Consensus HX1-4HX2-3HXH(X = Leu, Ile, Val, or Phe) 
*Bold letters represent hydrophobic residues thought to be crucial for nuclear export 
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13.3 Determination of Consensus Sequence for Nuclear Export Signals. 
Since we observed a 58-fold increase in the nuclear-cytoplasmic ratio of topo IIα 
immunofluorescence in accelerated-plateau H929 cells treated with leptomycin B when 
compared to untreated cells, we hypothesized that topo IIα may contain a LMB sensitive 
nuclear export signal.  Thus, we aligned several proteins with established nuclear export 
signals to determine a consensus sequence (table 10).  We determined the consensus 
sequences as HX1-4HX2-3HXH (where H represents the hydrophobic amino acids, leucine, 
isoleucine, valine, or phenylalanine). The hydrophobic amino acids are separated by a  
characteristic spacer region containing any amino acids (represented as the letter "X").  
Using the consensus sequence we identified six matching nuclear export sequences in the 
amino acid sequence for human topo IIα (Table 11 ), which was downloaded from the 
National Center for Biotechnology Information database (accession number NP 001058). 
We initially expected to express exogenous topo IIα in human myeloma cells to 
investigate the nuclear cytoplasmic distribution between log and plateau cell-density.    
 
13.4  Transfection of Topo IIα and Alternative Experiments.   
 For one year, I attempted to transfect a number of human myeloma and leukemia 
cell lines with a full-length topoisomerase IIα green fluorescent (GFP-topo IIα) fusion 
protein expression vector.  The expression vector that I worked with was obtained from a 
laboratory that described a method for cloning the GFP-topo IIα gene that produced high 
levels of expression of the topo IIα-GFP chimera in the nucleus of human cells (Mo et al., 
1998).  During this time, I worked with the combined efforts of Dr. Terresita Muñoz and 
her laboratory personnel.  However, we found that in most cases we were unable to 
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obtain a positive clone.  The clones that were achieved often failed to grow exponentially, 
suggesting that the bacteria were resistant to the uptake of the large topo IIα gene.  Thus, 
many of my initial experiments resulted in a low yield of plasmid with the topo IIα gene 
making subsequent transfection procedures unsuccessful.  We used several different 
methods for transfecting human myeloma cell lines including cationic lipids and 
electroporation. We also attempted to express topo IIα-GFP under the regulation of an  
inducible promoter, but also had negative results.  The most successful experiments 
demonstrated transient expression of the topo IIα-GFP chimera, but at very low 
transfection efficiency.  For example, I tried to transfect human myeloma H929 cells, 
HL-60, and 8226 cells by electroporation.  However, electroporation also produced 
negative results that included a high rate of cell death and low transfection efficiency.  Of 
the cells that were transfected, I observed gross morphological changes in their 
appearance.  In addition, translocation of GFP-topo IIα to the cytoplasm in plateau 
density cells was extremely limited when compared to endogenous topo IIα (data not 
shown).  I found that expression of GFP-topo IIα recombinant protein was cytotoxic, 
inducing cell death in all cell lines tested (CCRF, H929, HeLa, HL-60, 8226, Flow 
fibroblast 2000) within 12-16 hours after transfection.  This was a significant problem 
that impeded our ability to monitor the nuclear cytoplasmic trafficking of the topo IIα-
GFP fusion protein because according to my accelerated-plateau cell model, the 
transfected cells would need to grow for 16-24 hours at a high-cell density.   
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Table 11. Putative Nuclear Export Signals in Human DNA Topoisomerase IIα                               
Topo IIα 
Amino Acids 
Consensus Sequence 
HX1-4HX2-3HXH(X = Leu, Ile, Val, or Phe) 
80-90  G L* Y K  I F D E I L V 
230-241  S L D K D I V A L M V R 
467-476  T L A   V S G L G V V 
569-580  F L E E F I T P I V K V 
1017-1028  I L R D  F F E L R L K 
1054-1065 F I L E K  I D G K I I I 
*Bold letters represent hydrophobic residues thought to be crucial for nuclear export 
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 The lack of success with expressing exogenous topo IIα into human cells led us to 
look for an alternative method for defining a nuclear export signal.  Different methods for 
defining a nuclear export signal have been described (Koster et al., 2005; Henderson and 
Eleftherion, 2000; Bogerd et al., 1996).  We decided to crosslink the putative nuclear 
export signals found in topo IIα to bovine serum albumin (BSA), a large carrier molecule 
that is unable to be transported across the nucleus, and then microinject the NES-peptide 
BSA conjugates into the nucleus of cells.  By labeling the NES-peptide BSA conjugates 
with a fluorescent molecule (ie FITC or TRIC) we were able to visualize the subcellular 
localization of the microinjected peptides.  Nuclear export was observed when the NES-
peptide was able to transport BSA from the nucleus to the cytoplasm.  BSA is a suitable 
molecule for investigating nuclear-cytoplasmic transport pathways because it does not 
contain a functional NES.  Therefore, putative nuclear export signals can be crosslinked 
to BSA to determine if they are sufficient to transport BSA across the nuclear membrane 
and into the cytoplasm.  Although the objective of transfecting human myeloma cells 
with topo IIα was not abandoned, my specific efforts were redirected towards the 
microinjection experiments.   
The six putative NES shown in table 11 were synthesized and their sequences 
confirmed as described in "materials and methods".  The peptides were synthesized as 
native (nt) or mutated (∆) sequences.  The mutated peptides contained alanine in place of 
those hydrophobic residues suspected of being critical for Crm-1 mediated nuclear 
export.  Crm-1 is a nuclear export receptor that recognized specific types of NES 
containing a characteristic spacing of hydrophobic amino acids.  Although other export 
receptors are likely to exist, crm-1 is the only export receptor for NES containing proteins 
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that has been described to date.  To facilitate conjugation with preactivated SMCC-BSA, 
the NES peptides were designed with a cysteine residue at the amino terminus.  In this 
manner, SMCC-BSA forms a disulfide bond with the cysteine residue in the peptide 
sequences.  We did an initial experiment to determine the optimal duration required to 
incubate the NES peptides with SMCC-BSA and the approximate quantity of total 
protein needed for gel electrophoresis.  Figure 40 shows that after five minutes of 
reaction time, detection of NES peptides crosslinked with SMCC-BSA are noticeable as a 
shift in the apparent molecular weight of SMCC-BSA (compare lanes 4 and 5).  We 
determined that 20-30 minutes are optimal for NES peptide crosslinking to SMCC-BSA.  
Proceeding one peptide at a time, the peptides were reacted with SMCC-BSA, and then 
the conjugated peptides were purified by size exclusion chromatography on a using a 
Pharmacia P500 FPLC system.  As peptides passed through the LKB control Unit UV-1, 
the absorbance spectra was recorded.  An example of the absorbance spectra obtained for 
peptide containing amino acids 80-90 is shown in figure 41.  Three main peaks are 
evident and correspond with the size of the eluted fractions.  The largest compounds elute 
first, whereas the smallest molecules become impeded within Superdex gel matrix beads 
and elute last.  FPLC fractions 4-7 (Figure 41) are likely to be large SMCC-BSA 
molecules crosslinked with each other, fractions 16-18 represent conjugated BSA 
peptides, and fractions 30-32 represent unreacted peptide molecules.  Peptide conjugation 
was confirmed by running FPLC eluted fractions on a 10% SDS-PAGE gel, and then 
visualizing the proteins by silver stain analysis (Figure 43 and 44).  Similar conjugated 
BSA peptide fractions were pooled and concentrated before reacting with fluorescein 
isothiocyanate (FITC).  FITC labeled BSA-peptides were again purified by gel filtration 
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chromatography (Figure 42) and a large single peak was noticeable on the absorbance 
spectra (data not shown).  The type of cell to be microinjected was an additional 
experimental parameter that we had to determine before beginning our experiment.  We 
initially wanted to microinject human myeloma or leukemia cell lines with the 
crosslinked peptide, but we ran into two problems.  First, the myeloma and leukemia cell 
lines are suspension cells.  To microinject suspension cells, they must be held in place by 
suction with one capillary while being pricked with a needle with the opposite hand.  The 
human myeloma and leukemia cell lines proved to be too small, and instead became 
trapped inside the capillary (Figure 45).  So, we tried using the adherent cell lines, HeLa 
and FlowFibroblasts2000.  We found that pre-treating glass coverslips with HCl 
optimized the adhesion of HeLa cells to the coverslips.  The HeLa cells spread out across 
the coverslips and gave us an easily identifiable nucleus to inject (Figure 45).  
Furthermore, microinjection of the HeLa cell directly onto the glass coverslips facilitated 
their visualization by fluorescence microscopy.   
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Figure 40. Coomassie Blue Stain of SDS PAGE gel with NES- peptide BSA Conjugates.  Lanes 
1 & 2 are molecular weight markers; lane 3, bovine serum albumin; lane 4, preactivated SMCC-
BSA; lane 5, NES peptides incubated with SMCC-BSA for 5 minutes; lanes 6 and 7 are NES 
peptides incubated with SMCC-BSA for 20 minutes; lames 8-10 are NES-peptides conjugated 
with SMCC-BSA for 30 minutes; lanes 11-13 are NES peptides conjugated with SMCC-BSA 
for 1 h.  Approximately 25µg of protein were loaded in lanes 4-8; 50 µg were loaded into lane 9, 
and 10 µg were loaded into lanes 10-13.  Lane 4 represents free SMCC-BSA (lower smear) and 
SMCC-BSA crosslinked with itself (upper smear). Lane 5 shows that after 5 min, some peptide 
already began to crosslink with SMCC-BSA (compare lanes 4 and 5, notice upward shift). 
Arrow indicates conjugated peptides. We determined that 20-30 minutes was optimal for 
peptide conjugation to SMCC-BSA.  
1       2       3       4       5       6       7      8       9      10     11    12      13 
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Figure 41.  Absorbance Spectra of a BSA NES-peptide Conjugate at 
562 nm.  Three main peaks are evident and represent elution of 
different sized molecules. SMCC-BSA cross linked with itself is 
likely to be the largest complex to elute first (fractions 4-7) followed 
by BSA-peptide conjugates (fractions 16-18) and then unreacted 
peptides (fractions 30-34).  An absorbance spectra was obtained for 
each BSA crosslinked peptide. 
Figure 42.  FITC-Labeled-BSA NES-
peptide on Size Exlusion Coulmn.  Arrows 
indicate the separation of FITC-conjugates 
from unreacted FITC. 
Unreacted FITC 
FITC-BSA-Peptides 
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Figure 43.  Silver-stain Analyses of SDS-Page BSA-NES-Peptide FPLC 
Fractions.  FPLC Peptide fractions were collected and electrophoresed as 
described in Materials and Methods. Gels were stained with Silver staining.  
Lanes 20-28 show a shift in the apparent molecular weight of free peptide 
(lane 2) and free SMCC-BSA (lane 3). Lane 3 also shows that some SMCC-
BSA crosslinks with itself. 
FPLC Fractions  
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1 2
5 6 
3 
Figure 44.  Silver Stain Analysis of each BSA Conjugated Peptide. SDS-PAGE gels were 
scanned into AdobePhoto Shop 6.0.  (1) native peptide 80-91 (2) mutated peptide 80-91 (3) 
native peptide 230-241. Please note that mutated peptide 230-241 data not available because gel 
was shattered during the drying process. Since the native peptide did not export, SDS-PAGE 
was not repeated for the mutated peptide. (5) native pepide 569-580 (6) mutated peptide 569-
580.  Arrows indicate FPLC fractions containing SMCC-BSA crosslinked to peptides Figure 44 
continued on next page. 
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7 8 
1211 
Figure 44 continued.  (7) native peptide 569-580 (8) mutated peptide 569-580 (9) native peptide 1018-1024 
(10) mutated peptide 1018-1024 (11) native peptide 1054-1065 (12) mutated peptide 1054-1065 Arrows 
indicate FPLC fractions containing SMCC-BSA crosslinked to peptides.  
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Figure 45.  Comparison of H929 Cells with HeLa Cells for Microinjection. (A) 
H929 cells (low magnification) (B) H929 cells (High magnification) (C) HeLa 
cell.  H929 cells are suspension cells, whereas the HeLa cells are adherent.  
The suction capillary is necessary to hold suspension cells in place while being 
microinjected. 
A B 
C 
Microinjection 
capillary 
Suction 
capillary Microinjection 
capillary 
Suction 
capillary 
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13.5 Peptides NES1054-1066 and NES1017-1028 Signal the Nuclear Export of BSA-FITC. 
 The data suggest that topo IIα may be translocated from the nucleus to the 
cytoplasm under specific conditions, and this may result in altered drug sensitivity.  Of 
the six putative NES identified in topo IIα, two peptides, NES1054-1066 and NES1017-1028, 
exported BSA into the cytoplasm when microinjected into the nuclei of HeLa cells 
(Figures 46).  BSA-NES1054-1066 showed strong cytoplasmic staining and were seen in the 
cytoplasm within 15 minutes of microinjection, as compared to TRITC-BSA alone, 
(Figure 47), or the mutated BSA-NES1054-1066 conjugate.  BSA-NES1017-1028 also appeared 
cytoplasmic within 15 min of being microinjected into the nucleus, but complete nuclear 
clearing (like the ntNES1054-1066) was not observed even after 90 min. The mutated 
BSA-NES1054-1066 was nuclear in all cells observed even 90 min after microinjection. 
BSA-NES80-90 (Figure 47) mutated BSA-NES80-90 (Figure 47), BSA-NES230-241, mutated 
BSA-NES230-241, and BSA-NES467-476, BSA-NES569-580, and mutated BSA-NES569-580 all 
remained in the nucleus even 4 h after microinjection (data not shown). 
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Native Peptide Mutated Peptide 
NES 1054-1066 
NES 1017-1028 
NES 80-90 
Figure 46. HeLa cells Microinjected with Peptide-BSA-FITC Conjugates.  HeLa cells 
microinjected with either wild-type (left column) peptide-BSA-FITC conjugates (green), 
and then counterstained with DAPI (blue). A total of 20-50 cells were successfully 
microinjected per peptide and similar results were seen in all cells.  
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13.6 LMB Blocks ntNES1054-1066 and ntNES1017-1028   Mediated Nuclear Export. 
 LMB is a specific inhibitor of Crm-1 mediated nuclear export of proteins.  To 
determine if the nuclear export of BSA conjugated to peptides NES1054-1066 and NES1017-
1028 was Crm-1 dependent, LMB pretreated HeLa cells were microinjected in the 
presence of 2 ng/ml LMB in ethanol.  Fluorescence microscopy demonstrated that LMB 
blocked the export of BSA conjugated to peptides NES1054-1066 and NES1017-1028 (Figure 
48). Peptide NES1054-1066 had a strong perinuclear staining, suggesting that the protein 
cargo is docking at the NPC.  Although the NES defined by microinjection are sufficient 
to transport a non-shuttling protein to the cytoplasm, these leucine rich sequences may or 
may not serve a role in exporting topo IIα.
TRITC-BSA DAPI Merged 
Figure 47. HeLa Cells Microinjected with TRITC-
BSA. HeLa Cells were microinjected with BSA-
TRITC in the nucleus and counterstained with 
DAPI.  
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Figure 48. HeLa Cells were microinjected with wild-type peptide-BSA-FITC 
conjugates in the presence of 2 ng/ml LMB (leptomycin B).   
LMB NES 1054-1066 LMB NES 1017-1028 
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13.7 Topoisomerase IIα Cloning, Site Directed Mutagenesis, and Gene Expression.  
 While obtaining results from the microinjection of the BSA-peptides, we began to 
obtain promising results with the transfection of a FLAG-epitope tagged topo IIα in HeLa 
cell lines.  Although my focus in the laboratory was concerned with the microinjection of 
conjugated BSA-peptides, I had a vested interest in the project and maintained a 
significant involvement with the transfection studies.  As such, I shared responsibility for 
certain experimental procedures such as, design of the experiments, selection of the 
mutated nucleotides (Table 12), and immunostaining of the FLAG-topo IIα chimeras.  In 
the earlier stages of the work, I transformed bacteria and performed a number of plasmid 
preparations.   
 FLAG peptide is an eight amino acid protein (NYKNNNNK) that does not occur 
in nature. FLAG does not contain any putative nuclear export signal and its small size 
limits any secondary protein structure problems.  Hela cells transfected with a FLAG-
topo IIα plasmid vector expressed a full-length (170 kDa) topo IIα recombinant protein 
(Figure 49 )  Using a specific transfection protocol previously described by VandenHoff 
et al., 1992, we were able to transfect H929 and HL-60 cells by electroporation with a 
high degree of efficiency for these cell lines (2-20%).  The success of the transfection 
experiments is attributed to the buffer described by Van den Hoff et al., 1992.  The buffer 
contains ATP and glutathione to promote the rapid repair of cellular membranes.   
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13.8  FLAG-topoisomerase IIα Immunofluorescence.  
 BSA-peptide microinjection data indicated that the putative nuclear export sites at 
1017-1028 and 1054-1066 may function to signal export of topo IIα. To confirm these 
data with a full- length topo IIα protein, H929 human myeloma cells were transfected 
with FLAG-topo IIα expression vectors possessing mutated hydrophobic residues in the 
nuclear export sites at 1017-1028 and 1054-1066 (Table 14). Twenty hours post-
transfection, live cells were isolated by centrifugation on a ficoll-paque gradient and 
plated on glass microscope slides using cytospin funnels.  After fixing and 
permeabilization, slides were stained with anti-FLAG M2 monoclonal antibody-FITC 
conjugate and counterstained with mounting media containing DAPI to show the location 
of the nuclei. Images were acquired using a fluorescent microscope (Figure 50), with 
quantitation of FITC fluorescence using Adobe Photoshop 7.0 (data expressed in Figure 
51). Figure 50 establishes that the wild-type (non-mutated) FLAG-topo IIα protein is 
Figure 49. Western blot of full-length FLAG-topo IIα. HeLa cells were transfected with plasmid 
containing FLAG-topo IIα plasmid via cationic lipid, and harvested after 20 hours. Protein 
extracts from 2.0 x 106 cells per lane were separated on SDA-PAGE gel, blotted onto 
nitrocellulose and probed with FLAG M2 antibody. Lane A is protein from cells transfected 
with non-mutated FLAG-topo IIα plasmid, lane B is FLAG-topo IIα 1054-1066, lane C 
transfected with FLAG-topo IIα plasmid 1017-1028, and lane D is a non-transfected control. 
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present in the nucleus of the cells plated at log density, whereas FLAG-topo IIα protein is 
located in the cytoplasm in cells plated at plateau density. Quantitation of fluorescence 
revealed a statistically significant shift (P=0.00001) for log cells with a 
nuclear:cytoplasmic ratio of 5.9:1, to a ratio of 0.42:1 in plateau cells (Figure 51) when 
using the wild-type FLAG-topoIIα plasmid. 
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Table 12.  Wild-type and Mutated Nucleotide Sequences of Putative Nuclear Export Signals. 
Wild-type sequence 1017-1028 
TTG GAT ATT CTA AGA GAC TTT TTT GAA CTC AGA CTT AAA TAT TAT 
L D I L R D F F E L R L K Y Y 
Mutated sequence 1017-1028 
AGC CTG GAC AAA GAT GCT GTT GCA GCA ATG GTC AGA AGA GCA  
 D I L R D A F E A R L K Y Y 
Wild-type sequence 1054-1065 
CGC TTT ATC TTA GAG AAA ATA GAT GGC AAA ATA ATC ATT GAA AAT 
R F I L E K I D G K I I I E N 
Mutated sequence 1054-1065 
CGC TTT ATC TTA GAG AAA GCA GAT GGC AAA GCA ATC ATT GAA AAT 
R F I L E K A D G K A I I E N 
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Mutated 1017-1028 
Mutated 1054-1066 
Figure 50. FLAG-topo IIα Immunofluorescence. Human multiple myeloma H929 cells 
were transfected by electroporation with full-length wild-type and mutated toto IIα and 
plated for 20 hours at log and plateau cell densities. Cytospins containing fixed cells 
were stained with FITC-labeled anti-FLAG M2 antibody (green), counterstained with 
DAPI for nuclear staining, and assayed by immunofluroescent microscopy.. 
Wild-type 
Wild-type 
Mutated 1017-1028 
Mutated 1054-1066 
FITC 
Log 
DAPI Merged FITC 
Plateau 
DAPI Merged 
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1053-1066 plateau 
1053-1066 log 
1016-1027 plateau 
1016-1027 log 
Wild-type plateau 
Wild-type log 
*p = 0.00001 
Nucleus 
Cytoplasm 
Figure 51. Quantitation of FLAG-topo IIα Immunofluoresence. Human myeloma H929 
transfected cells (n = 20) stained with anti-FLAG M2 monoclonal antibody-FITC 
conjugate were assayed for nuclear and cytoplasmic immunofluorescence. Quantitation 
of FITC fluorescence was performed using Adobe Photshop 7.0  program. Wild-type 
FLAG-topo IIα was export to the cytoplasm in cells at plateau density (P = 0.00001), 
whereas topo IIα mutated at the putative export sites, 1016-1027 and 1053-1066, did not 
demonstrate statistically significant levels of export to the cytoplasm. 
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13.9  Peptide ntNES1054-1066 and ntNES1017-1028 are Conserved. 
To determine if peptides NES1054-1066 and NES1017-1028 are conserved, a BLAST 
search of the SWISS PROT database was performed to identify homologous sequences in 
topo IIα. Tables 15 and 16 summarize a list of representative species containing 
homologous topo IIα sequences.  The data show that the characteristic spacing of 
hydrophobic residues in peptides NES1054-1066 and NES1017-1028 are highly conserved in a 
broad range of species.  For example, leucine residues appearing in human topo IIα NES 
are often substituted with the hydrophobic amino acids isoleucine or valine.  
Furthermore, Phe1054 and Ile1055 in peptide NES1054-1066 are highly conserved from 
mammals to the most primitive eukaryotic organism, Giardia lamblia, unlike Leu1056. 
This suggests that the presence of phenylalanine and isoleucine are critical for nuclear 
export of this peptide, and thus an omission of these two hydrophobic amino acids from 
the peptide sequence could explain why a previous report failed to identify NES1054-1066 
as the dominant nuclear export signal (Mirski et al., 2003) .  
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Table 13. Sequence Alignment of DNA Topoisomerase IIα NES1017-1028 
Homo sapiens (human) NES1017-1028 D I* L R D F F E L R L K 
Sus scrofa (pig), Mus musculus (mouse), 
Rattus norvegicus (rat) 
D I L R D F F E L R L K 
Cricetulus griseus (Chinese hamster) D I L  D F F E L R L K 
Gallus gallus (chicken) D I L   F F E L R L  
Saccharomyces cerevisia (yeast)  I L   F   V R L  
Aspergillus niger (fungus), Penicillium 
citrinum (fungus) 
D I L   F F  L R L  
Nicotiana tabacum (tobacco) D I L   F   V R L  
Encephalitozoon cuniculi (protozoan)  I L   F   L R L  
Bombyx mori (silkmoth)  I L R  F   L R L  
*Bold letters represent hydrophobic residues thought to be crucial for nuclear export. 
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Table 14. Sequence Alignment of DNA topo IIα NES1054-1066 
Homo sapiens (human)  NES 1054-1066 F I L E K I D G K I I I E 
Cricetulus griseus (Chinese hamster), 
Mus musculus (mouse), Rattus 
norvegicus (Rat) 
F I L E K I D G K I I I E 
Caenorhabditis elegans (nematode) F I L E K I D G K I V I E 
Saccharomyces cerevisiae (yeast) F I L  K I    I V I E 
Candida glabrata (yeast) F I   K I    L  I  
Aspergillus candidus (fungus) F I   K I    L I I  
Trichophyton rubrum (fungus) F I   K I  G  I V I  
Giardia lamblia (protist) F I   K I    I  I  
Bold letters represent hydrophobic residues thought to be crucial for nuclear export. 
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13.10  NES1054-1066 and NES1017-1028 Reside within a Putative Coiled-coil Domain 
We were interested in predicting the structural features of the region containing 
NES1054-1066 and NES1017-1028.  Each topo II monomer can be divided into three domains, 
an N-terminal domain that contains the ATP-binding region, the central domain 
containing the active site tyrosine residue, and the C-terminal domain that contains the 
nuclear localization sequences. Both of the NES are situated upstream of the bipartite 
NLS (Figure 52) and downstream of the active-site tyrosine residue (Tyr805). 
Furthermore, several CK-2 phosphorylation sites downstream of both NES have been 
identified in vitro and could be important for regulating the subcellular localization of 
topo IIα. Although NES1017-1028 alone is predicted to form an α-helix, we were interested 
in predicting the motif of the complete amino acid sequence stretching from NES1017-1028 
to NES1054-1066.  According to EMBOSS and Predict Protein, two programs designed to 
predict protein motifs, amino acids 1017-1066 are characterized by a high potential to 
form α -helices and also contain five 4-3 hydrophobic repeats, a typical feature of a 
coiled-coil motif. Such a repeating pattern of hydrophobic amino acids has been shown to 
form a hydrophobic core, which is critical for dimerization. In this manner, the 
hydrophobic amino acids are predicted to align on the same interface which facilitates 
DNA binding or protein-protein interactions. Interestingly, amino acids 1014-1057 in 
topo IIα have previously been shown to form a stable two-stranded α -helical coiled-coil 
in solution.  Furthermore, the Advanced Chemistry Development ChemSketch 5.12 
software was used to predict the 3-D structure of native and mutate peptides 1054-1066 
and 1017-1028.  The secondary structures of each peptide sequence was cleaned and 
then, visualized with the 3-D viewer.  Although each mutated peptide differed from their 
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native peptides by just two amino acids, figure 53 establishes that each mutated peptide 
appears more globular than the native peptide.  These results suggest that the native 
peptides may have more accessible binding sites available to bind CRM-1, whereas the 
mutated peptides are more compact with fewer extensions for CRM-1 binding.  These 
results, however, are limited to the microinjection data and do not necessarily reflect the 
tertiary structure of full-length topo IIα in living cells.  However, the results suggest that 
the larger amino acids such as isoleucine, leucine, and phenylalanine, have the potential 
to form extensions that would facilitate CRM-1 binding.  
 
13.11  Conclusions. 
 In order for topoisomerase targeted chemotherapy to function, the topoisomerase 
target must have access to the nuclear DNA.  Therefore, the nuclear export of 
topoisomerase IIα may contribute to drug resistance, and defining this mechanism may 
lead to methods to preclude this avenue of resistance.  We have identified nuclear export 
signals for topo IIα at amino acids 101701028 and 1054-1066 using FITC-labeled BSA-
export signal peptide conjugates microinjected into the nuclei of HeLa cells.  Functional 
confirmation of both signals was provided by transfectin of human myeloma cells with 
plasmids containing the gene for a full-length human FLAG-topoiosmerase fusion 
protein.  We futher showed that export by both signals was blocked by treatment of cells 
with leptomycin B, indicating that a CRM-1 dependent pathway mediates export.   
  
 
 189
    
  
     MEVSPLQPVN ENMQVNKIKK NEDAKKRLSV ERIYQKKTQL EHILLRPDTY IGSVELVTQQ 
  61 MWVYDEDVGI NYREVTFVPG LYKIFDEILV NAADNKQRDP KMSCIRVTID PENNLISIWN 
 121 NGKGIPVVEH KVEKMYVPAL IFGQLLTSSN YDDDEKKVTG GRNGYGAKLC NIFSTKFTVE 
 181 TASREYKKMF KQTWMDNMGR AGEMELKPFN GEDYTCITFQ PDLSKFKMQS LDKDIVALMV 
 241 RRAYDIAGST KDVKVFLNGN KLPVKGFRSY VDMYLKDKLD ETGNSLKVIH EQVNHRWEVC 
 301 LTMSEKGFQQ ISFVNSIATS KGGRHVDYVA DQIVTKLVDV VKKKNKGGVA VKAHQVKNHM 
 361 WIFVNALIEN PTFDSQTKEN MTLQPKSFGS TCQLSEKFIK AAIGCGIVES ILNWVKFKAQ 
 421 VQLNKKCSAV KHNRIKGIPK LDDANDAGGR NSTECTLILT EGDSAKTLAV SGLGVVGRDK 
 481 YGVFPLRGKI LNVREASHKQ IMENAEINNI IKIVGLQYKK NYEDEDSLKT LRYGKIMIMT 
 541 DQDQDGSHIK GLLINFIHHN WPSLLRHRFL EEFITPIVKV SKNKQEMAFY SLPEFEEWKS 
 601 STPNHKKWKV KYYKGLGTST SKEAKEYFAD MKRHRIQFKY SGPEDDAAIS LAFSKKQIDD 
 661 RKEWLTNFME DRRQRKLLGL PEDYLYGQTT TYLTYNDFIN KELILFSNSD NERSIPSMVD 
 721 GLKPGQRKVL FTCFKRNDKR EVKVAQLAGS VAEMSSYHHG EMSLMMTIIN LAQNFVGSNN 
 781 LNLLQPIGQF GTRLHGGKDS ASPRYIFTML SSLARLLFPP KDDHTLKFLY DDNQRVEPEW 
 841 YIPIIPMVLI NGAEGIGTGW SCKIPNFDVR EIVNNIRRLM DGEEPLPMLP SYKNFKGTIE 
 901 ELAPNQYVIS GEVAILNSTT IEISELPVRT WTQTYKEQVL EPMLNGTEKT PPLITDYREY 
 961 HTDTTVKFVV KMTEEKLAEA ERVGLHKVFK LQTSLTCNSM VLFDHVGCLK KYDTVLDILR 
1021 DFFELRLKYY GLRKEWLLGM LGAESAKLNN QARFILEKID GKIIIENKPK KELIKVLIQR 
1081 GYDSDPVKAW KEAQQKVPDE EENEESDNEK ETEKSDSVTD SGPTFNYLLD MPLWYLTKEK 
1141 KDELCRLRNE KEQELDTLKR KSPSDLWKED LATFIEELEA VEAKEKQDEQ VGLPGKGGKA 
1201 KGKKTQMAEV LPSPRGQRVI PRITIEMKAE AEKKNKKKIK NENTEGSPQE DGVELEGLKQ 
1261 RLEKKQKREP GTKTKKQTTL AFKPIKKGKK RNPWSDSESD RSSDESNFDV PPRETEPRRA 
1321 ATKTKFTMDL DSDEDFSDFD EKTDDEDFVP SDASPPKTKT SPKLSNKELK PQKSVVSDLE 
1381 ADDVKGSVPL SSSPPATHFP DETEITNPVP KKNVTVKKTA AKSQSSTSTT GAKKRAAPKG 
1441 TKRDPALNSG VSQKPDPAKT KNRRKRKPST SDDSDSNFEK IVSKAVTSKK SKGESDDFHM 
1501    DFDSAVAPRA KSVRAKKPIK YLEESDEDDL
Figure 52.The Complete Amino Acid Sequence of Human DNA Topo IIα (accession 
number NP 001058). The active-site tyrosine resiude (805) is indicated (*). NES1017-
1028. 1017DILRDFFELRLK1028 and NES1054-1066 1054FILEKIDGKIIIE1066 are shaded; 
bipartite NLS is single underscored; Ser/Thr phosphorylation sites are bold and 
underscored ; the predicted coiled-coil region is double underscored; the active-site 
tyrosine residue is indicated with a star, (   ).            
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Mutant sequence (1054-1065) 
RFILEKADGKAIIE  
Wildtype sequence (1054-1066) 
RFILEKIDGKIIIE  
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Figure 53. Predicted Tertiary Structure of Wild-type and Mutant Peptides. The 3-D 
structure of the wild-type and mutant peptides was determined using the Chem-Sketch 5.12 
3-D viewer. Arrows indicated amino acids protruding at or away from the viewer.  Figure 
53 continue on next page.  
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Wildtype sequence (1017-1028) 
LDILRDFFELRLK  
Mutant sequence (1017-1028) 
LDILRDAFEARLK
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Figure 53. Continued. The 3-D structure of the wild-type and mutant peptides was determined 
using the Chem-Sketch 5.12 3-D viewer. Arrows indicated amino acids protruding at or away from 
the viewer.   
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Chapter  Fourteen 
Discussion  
14.1 Previous Findings. 
It is well established that most cell lines display a differential sensitivity to topo II 
inhibitors, which depends on cell density (Sullivan 1986, 1987; Chow and Ross, 1987, 
Markovits, 1987). When non-transformed cell-lines reach confluence there is a 
concomitant decrease in drug sensitivity to topo targeting cytotoxic agents that has been 
attributed to an attenuation in the amount of topo IIα content (Sullivan, 1987).  However, 
in the tumor cell lines studied, confluence does not necessarily lead to a decrease in 
cellular topo II content, yet the cells are resistant (Sullivan 1986, 1987). We investigated 
several possible mechanisms of drug resistance in human myeloma and leukemia cell 
lines to explain the discrepancy in the cellular content of topo enzymes in transformed 
and non-transformed cell lines. 
 
14.2 Log and Plateau Cell Lines Drug Sensitivity Phenotype. 
Findings from this laboratory suggest that there are two general types of growth-
dependent mechanisms of drug resistance that are unrelated to prior drug exposure. The 
first is demonstrated by non-transformed Chinese hamster ovary and human Flow 2000 
fibroblasts cells lines which are 5-15 fold resistant to VP-16 in plateau-phase relative to 
log-phase cells (Table 7, page 122). This is due to an 80-90% reduction in total cellular 
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topo IIα protein (Figure 23, page 127), with a concomitant decrease in enzyme activity 
(data not shown). The second mechanism is seen in several hematological cell lines 
(mouse leukemia L1210, human myeloma RPMI-8226, human leukemia HL-60, human 
leukemia KG-1a, and human lymphoblastic leukemia CCRF cells), which show 
significant resistance to VP-16 at plateau phase (7.3-55-fold) (Table 7), but show no 
decrease in total cellular amounts of topo I, IIα, or IIβ protein when compared to log-
phase cells (Figure 23).   
Immunochemistry experiments demonstrated that in these cells, topo IIα is found 
in the nucleus of log-phase cells, but had a significant cytoplasmic distribution in plateau-
phase cells (Figure 24, page 129).  It appeared from this data that altered 
nucleocytoplasmic trafficking of topo IIα, but not topo I or topo IIβ, occurs in 
transformed cell lines at plateau-density. This was in contrast to other non-transformed 
cell lines that degrade topo IIα at plateau phase.  
 
14.3 Novel Human Myeloma Cell Line Models.  
We questioned whether the nuclear-cytoplasmic trafficking of topo IIα had a role 
in conferring altered drug sensitivity to topo targeting agents as well as cross-resistance 
to other non-topoisomerase associated cytotoxic agents.  Alterations in the subcellular 
localization of topo enzymes have been previously associated with a decrease in drug 
sensitivity, but the weight of the data describe alterations in the amount of activity of 
drug resistant cell lines as a result of a truncated enzyme that has lost its C-terminal NLS 
(Wessel et al., 1997).  There are two notable exceptions that correlate altered subcellular 
distribution of topo enzymes with altered drug sensitivity. First, multicellular spheroids 
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and Xenograft tumor cells are protected from etoposide-mediated DNA damage due to 
the cytoplasmic distribution of topo IIα (Oloumi et al., 2000).  Secondly, adhesion of 
human myelomonocytoid U937 cells to fibronectin by means of β1 integrins protects 
cells against mitoxantrone and etoposide mediated DNA damage and is accompanied by 
an altered sub-nuclear relocalization of topo IIβ to the nucleolus.  Thus, changes in the 
nuclear localization or binding properties of the nuclear pool of topo IIβ protein is 
suggested to have a role in cellular drug resistance to etoposide and mitoxantrone in these 
cells (Hazlehurst et al., 2001). 
The lack of data to describe the subcellular distribution of topo IIα, especially the 
nuclear export of the enzyme, as a predictor of drug responsiveness could be attributed to 
the unavailability of in vitro cell models to study the nucleo-cytoplasmic distribution of 
topo enzymes, that would otherwise make it possible to thoroughly investigate the role of 
topo trafficking in drug sensitivity. Molecular analysis of the topo gene has been largely 
unachievable because overexpression of topo IIα is lethal to cells, as well as topo IIα 
gene knockouts. Most reports are successful at transfecting cells with truncated topo or 
topo peptides (Ernst et al., 2000). In either case, the exogenous full-length topo is not 
expressed in the nucleus because of a missing C-terminal NLS. These experiments fail to 
correlate a cytoplasmic distribution of topo IIα with drug resistance because endogenous 
topo is still present in the nucleus to cause drug-induced DNA damage. Furthermore, the 
expression of an exogenous cytoplasmic topo makes it ineffectual at studying the nuclear 
export of the protein (since it never enters the nucleus). In addition to these laboratory 
complications, it has proved very difficult to culture cells from a plasma cell dyscrasia, 
such as multiple myeloma.  Much of our understanding of the biology of multiple 
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myeloma has been obtained by studying multiple myeloma derived cell lines. 
Unfortunately, human myeloma cell lines have proven difficult to transfect (refer to page 
162). 
We established an in vitro cell model system, referred to as accelerated-plateau, 
using established human myeloma cell-lines and overcame many of the experimental 
complications described above.  Since log and plateau-phase cells represent low and high 
cell densities relative to one another, we postulated that cell-cell contacts may trigger a 
cytoplasmic relocation of topo enzymes.  This model was used to describe the mechanism 
of growth dependent drug resistance described above (Table 9, page 135), and ultimately, 
to better characterize the mechanism of the nucleo-cytoplasmic trafficking of topo IIα 
(Figure 39, page 160).    
 We realize that the plateau density of cell cultures is far below the cell density 
existing in the tissues and biological fluids of patients. However, we consider that the 
changes that occur in the transition from the proliferative state in log culture to quiescent 
plateau densities are a reasonable model system to study the molecular mechanisms of 
acquiring drug resistance without a drug selection pressure.  
 
14.4 Log and Accelerated-plateau Drug Sensitivity Phenotype. 
Accelerated-plateau cells had a similar drug resistance phenotype as the natural-
plateau cells described above, but the accelerated-plateau cells were also analyzed for 
cross-resistance to a range of drugs with different mechanisms of cytotoxicity (Figure 5 
Table 11).  The accelerated-plateau cells were 10-fold resistant to VP-16, but less than 
1.5 fold resistant to Ara-c, taxol, BCNU, cis-platinum, and γ-irradiation. Similar results 
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were obtained in human myeloma RPMI-8226 cells. These data area not consistent with 
the multidrug resistance phenotype, but instead suggests that the observed drug resistance 
is specific for topo II interacting agents.  Furthermore, drug resistance to DNA 
crosslinking agents, such as cisplatinum and γ-irradiation, has been found to be inversely 
proportional (Gornati, 1997; Barret et al., 1994) to topo II amount as a result of enhanced 
DNA repair processes by topo II.  The drug resistance observed here, in the human 
myeloma cells, is not likely to be a result of enhanced DNA repair because there was 
minimal resistance to cisplatinum and γ-irradiation.  Furthermore, cells were 
hypersensitive to both cisplatinum and γ-irradiation at 16 h, suggesting that there was a 
decrease in the total cellular content of topo II enzyme.  However, Western blot analysis 
demonstrated minimal changes in the levels of topo protein after 16 hours, suggesting 
another mechanism exists for the observed hypersensitivity to the DNA crosslinking 
agents.  The cells grown at plateau-phase for 24 h continued to be hypersensitive to 
cisplatinum but, there was a 4-fold decrease in sensitivity to γ-irradiation.  Cell lines 
resistant to CDDP have not been found to be crossresistant to γ-irradiation, suggesting 
that there are different mechanism of resistance to γ-irradiation and cisplatinum (Caney et 
al., 2004).  For example, there may be different DNA repair processes for radiation 
induced DNA damage as compared CDDP induced DNA damage (Caney et al., 1999; 
Wilkins et al., 1996).  Furthermore, an association between the acetylation status of DNA 
histones and sensitivity to radiation has been previously reported (Zhang et al., 2004; 
Camphausen et al., 2004; Paoluzzi and Fig, 2004).  This suggests that histones may be 
hypoacetlyated in plateau-phase myeloma cells as compared to the log-growing cells. 
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Exposure to an HDAC inhibitor could sensitize the plateau-cells to γ-irradiation, by 
maintaining the acetylation of histone proteins.  
To elucidate other mechanisms conferring drug resistance to VP-16 and 
mitoxantrone, log and accelerated-plateau cells were examined for differences in cell 
cycle distribution, drug uptake, and subcellular distribution of topo protein.  No 
considerable difference was observed in the uptake of [3H-VP-16] between log and 
accelerated-plateau cells, suggesting that altered drug transport is unlikely to account for 
the observed drug resistance. Furthermore, cross-resistance to non-topoisomerase 
targeting agents would be expected, if plateau-phase human myeloma cells overexpressed 
MRP2 or MRP3 because both VP-16 and CDDP are substrates for MRP2 and MRP3. 
However, accelerated-plateau cells were not cross-resistant to CDDP.  Plateau-phase cells 
were minimally resistant to the non-topoisomerase targeting agents, providing additional 
support of the results from the drug uptake studies. Since flow cytometric analysis 
indicate that there are minimal changes in the levels of topo protein and in the number of 
cells in S-phase after 16 hours respectively, these cellular events are also not likely to be 
the principle mechanisms of drug resistance.  
 
14.5 Subcellular Distribution of Topo IIα. 
Immunofluorescence microscopy demonstrated that topo IIα was nuclear in log-
phase cells but had a cytoplasmic distribution in the accelerated-plateau cells at 16 h or 
24 h.  Cytoplasmic topo IIα was not a result of a C-terminally truncated protein that has 
lost the NLS, since there were single bands at the expected molecular weights for both 
topo IIα and topo IIβ by Western blot analysis.  The cytoplasmic distribution of topo IIα 
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observed in the accelerated-plateau cell model was similar to that observed in the natural-
plateau cells, but was observed in a shorter period of time (16 h for accelerated-plateau 
versus 4-5 days in natural-plateau cells).  This suggests that the nuclear-cytoplasmic 
trafficking of topo IIα is a function of time and stimulated by cell-cell contact. The ratio 
of topo I and II β did not change over the same period of time. Topo I remained nuclear 
in log, plateau, and accelerated-plateau cells.  Since Western blot analysis demonstrated a 
reduction of topo I content in the both 8226 and H929 accelerated-plateau cells (16-34% 
reduction; Figure 27, page 138), this suggests that topo I may be degraded by nuclear 
proteasomes or that its degradation in the cytoplasm is rapid, and thus its cytoplasmic 
location is below the threshold of immunofluorescence detection.  Topo IIβ was 
distributed approximately equally between the nuclear and cytoplasmic compartments in 
log and plateau cells. Therefore, the subcellular distribution of topo I or topo IIβ did not 
correlate with drug responsiveness. Rather, it appeared that an alteration in the 
subcellular localization of topo IIα could be the principle mechanism contributing to the 
decrease in drug sensitivity to topo II inhibitors.  
While it may appear unusual that DNA replication continues despite having a 
significant proportion of topo IIα in the cytoplasm, cells can survive with a 
predominantly cytoplasmic form of a catalytically active enzyme, which exists in several 
drug resistant cell lines.  For example, in the drug resistant human small cell lung 
carcinoma H69-VP cell line, a catalytically active yet truncated topo IIα enzyme is 
located in the cytoplasm while topo IIβ is expressed in the nucleus (Grue et al., 1998).  In 
these cells, chromosomal formation is dependent on cytosolic topo IIα entering the 
chromatin during mitosis when the nuclear membrane disappears rather than nuclear topo 
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IIβ performing the mitotic functions of topo IIα (Grue et al., 1998). Similar findings have 
been reported in drug resistant Chinese Hamster V511 cells that show minor alterations 
in cell growth despite having drastic reductions in the total amount topo IIα protein in 
both log growth and quiescence (Hashimoto et al., 1995).  The expression of topo IIβ 
remained constant and topo IIβ was presumed to compensate for topo IIα activity in the 
V511 cells.  This is supported by recent findings of HeLa cells transiently transfected 
with topo IIα or topo IIβ siRNA, which demonstrated that topo IIβ can partially substitute 
for topo IIα condensation and segregation in HeLa cells (Sakaguchi and Kikuchi, 2004).  
These findings could explain why there was only a minimal change in S-phase population 
of cells, but not a complete cessation of DNA replication. Western blot analysis of topo 
IIα protein in the nuclear and cytoplasmic compartments of log and accelerated-plateau 
H929 cells indicates that topo IIα was reduced by 25-50% (by densitometry) compared to 
the log cells (Figure 32, page 146).  Part of the topo IIα content appears to be degraded in 
both the nuclear and cytoplasmic compartments and was attributed to experimental 
artifacts.  Topo IIα degradation was likely to occur during the shearing of the nucleus 
from the cytoplasm as a similar degradation does not occur in the whole cells. Results of 
the comet assay confirmed that seeding cells at plateau density for 16 hours protects them 
from etoposide induced DNA damage and additional experiments demonstrated that 
etoposide treatment resulted in less DNA damage because there are fewer protein-drug-
DNA complexes in the cells seeded at plateau density than log-phase cells.  The data 
establishes that the nuclear-cytoplasmic trafficking of topo IIα mediates cellular drug 
resistance to topo inhibitors by reducing the amount of topo II in the nucleus and thus, 
reduces the number of enzyme-drug-DNA complexes formed.  A redistribution of a 
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population of topo IIα to the cytoplasmic compartment would have a similar effect as to 
drug sensitivity as an overall decrease in topo IIα content, by decreasing the amount of 
drug target in the nucleus.  Furthermore, these results may partially explain the 
hypersensitivity of accelerated-plateau cells to CDDP and γ-irradiation observed at 16 h.  
As previously mentioned, drug sensitivity to DNA crosslinking agents is inversely 
proportional to topo protein levels (Gornati, 1997; Barret et al., 1994). Although, the total 
cellular amount of topo IIα is not reduced, a shift from the nucleus to the cytoplasm could 
account for the observed drug sensitivity. 
Several mechanisms of drug resistance to topo inhibitors have been defined in 
vitro and include: (1) over expression of drug transport proteins (P-glycoprotein, 
multidrug resistance-associated protein, lung resistance-related protein, or breast cancer 
resistance protein), that result in either increased drug efflux or decreased drug uptake 
(Shustik et al., 1995), (2) a cell-cycle-dependent decrease in the amount of topo II protein 
(Sullivan et al., 1986, 1987), (3) the expression of a truncated protein that has lost its C-
terminal nuclear localization signal such that it remains in the cytoplasm (Wessel et al., 
1997), and (4) mutations in the topo gene that result in an enzyme with altered catalytic 
or cleavage activity (Matsumoto et al., 2001).  The data presented here demonstrates a 
fifth mechanism of drug resistance in vitro: (5) nucleocytoplasmic-trafficking of topo IIα 
is a mechanism of de novo drug resistance to topo inhibitors in human multiple myeloma 
cell lines (Engel and Turner et al., 2004; Engel et al., 2004; Valkov et al., 2000).  
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14.6 Clinical Relevance. 
The data establishes that a measurable difference in the nuclear and cytoplasmic 
distribution of topo IIα, a chief molecular target of commonly used anti-cancer therapy, 
occurs in human myeloma cell-lines at plateau densities.  The nuclear content of topo IIα 
is critical for topo targeting agents to be effective as cytotoxic agents because topo 
cleavage activity is necessary for drug-induced DNA damage to occur. The data 
presented here indicate that a cytoplasmic pool of topo IIα correlates with cellular drug 
resistance to etoposide (Engel et al., 2004; Valkov et al., 2000).  This is also supported by 
evidence that multicell spheroids and xenograft tumor cells are protected from etoposide-
mediated DNA damage due to the cytoplasmic distribution of topo IIα (Oloumi et al., 
2000).  These findings have potential clinical implications in the treatment of human 
myeloma as immunohistochemistry demonstrated that topo IIα has a cytoplasmic 
distribution in the malignant plasma cells obtained from the bone marrow aspirates of 
some multiple myeloma patients (Figure 36 and 38).   
The magnitude of cytoplasmic immunofluorescent staining of topo IIα was 
significantly more pronounced in the malignant plasma cells found in the clinical 
preparation than that observed in the human myeloma cells lines at plateau density.  
Many of the tumor cells demonstrated complete nuclear clearing of topo IIα that was less 
frequently observed in the cell lines. The plateau and accelerated-plateau cell models 
showed a shift (decrease) in the nuclear:  cytoplasmic ratio of topo IIα 
immunofluorescence in most cells, rather than complete nuclear clearing (ratios below 
1.0).  The data suggest that other physiological conditions besides cell-cell contact are 
involved in topo IIα trafficking that exist in the tumor microenvironment of the bone 
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marrow.  For example, the cell line models demonstrate a cytoplasmic distribution of 
topo IIα de novo, but the cytoplasmic distribution observed in the clinical preparations 
could be influenced by prior exposure to DNA damaging agents.  Multiple myeloma is 
characterized by karyotypic instability and many chromosomal aberrations are acquired 
after exposure to DNA damaging agents (refer to Appendix C on page 269 for a summary 
of hematological related chromosomal aberrations).  The amount of chromosomal 
aberrations correlates with disease stage and prognosis.  It is possible that certain 
chromosomes are susceptible to genetic translocations.  For example, many chromosomal 
gene translocations that are observed in hematological malignancies involve the 
nucleoporins (Nup) (Arai et al., 2000, 1997; Nakamura et al., 1996; Boer et al., 1998).  I 
have summarized a list of gene mutations that have been described in nucleoporins (refer 
to Table 8 on page 217 and all reference contained therein).  Thus, exposure to various 
chemotherapeutic agents could somehow disrupt the homeostasis of nucleo-cytoplasmic 
protein trafficking.  This is supported by evidence that multiple gene aberrations in 
Nup98 occur in some hematological disorders.  For example, Nup98 gene translocations 
have been reported in treatment related AML and myelodysplastic syndrome (MDS).  
Also, the chromosomal translocation t(11;20)(p15;q11) results in a Nup98/Topo I fusion 
protein in de novo acute myeloid leukemia (AML) (Potenza et al., 2004; Iwase et al., 
2003; Chen et al., 2003). These observations establish that a significant modulation 
occurs in topo I, which could theoretically alter topo enzyme stability, enzyme activity, 
and subcellular distribution.  Similar chromosomal translocations involving topo II have 
not been found.  Additional studies to analyze the subcellular distribution of topo II in 
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untreated patients compared to treated or relapsed patients combined with cytogenetic 
analysis are needed   
 
14.7 Topoisomerase IIβ as an Alternative Molecular Target in Human Myeloma. 
Another interpretation of the data is that topo IIβ could be an alternative 
molecular target in the treatment of human multiple myeloma. It is well documented that 
topo IIβ protein expression is rather constant over the cell cycle and less influenced by 
cell-cycle changes than topo IIα. Western blot analysis demonstrated no reduction in the 
total cellular content of topo IIβ in plateau-cells or accelerated-plateau phase cells when 
compared to log-phase cells. Topo IIβ was detectable in both the nuclear and cytoplasmic 
compartments of the plasma cell in clinical samples as well as, in the human myeloma 
cells lines. However, there was no measurable difference or shift in the amount of topo 
IIβ immunofluorescence detected in the cytoplasm at plateau density as compared to log 
density.  This suggests that the balance of topo IIβ nuclear import is influenced in the 
same manner or by cell-cell contact as observed with topo IIα.  Recently, microinjection 
studies identified an NES in topo IIβ (Mirski et al., 2003) and the data presented here 
demonstrates a possible shuttling of topo IIβ between the nucleus and cytoplasm. A 
determination of whether leptomycin B can shift the nuclear:cytoplasmic ratio of IIβ 
toward to the nucleus in plateau-phase cells could address the mechanism of topo IIβ 
trafficking.  Nevertheless, the data suggests the factors resulting in cytoplasmic 
distribution of topo IIα in tumor cells do not alter topo IIβ net trafficking in the same 
manner.  
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Several new cytotoxic agents that are specific for topo IIβ are being investigated 
for the effectiveness in the treatment of solid tumors that are refractory to topo II 
containing therapy (Hazeldine et al., 2005, 2002; Barthelmes et al., 2001; Gao et al., 
1999)  Many of these drugs are still in development and are derivatives of XK469, a 
topoisomerase IIβ selective poison that is reaching phase I clinical trials (Gatto and Leo, 
2003).  Tumors with large populations of cells in the G0/G1 phase are believed to be more 
sensitive to topo IIβ specific inhibitors because, unlike topo IIα, topo IIβ protein 
expression is not cell-cycle dependent. Thus, the low proliferative index of malignant 
plasma cells observed in multiple myeloma makes topo IIβ an attractive molecular target.  
Furthermore, XK469 results in upregulation of the topo IIα protein (Mensah-Osman et 
al., 2002).  Based on these findings a plausible regimen for multiple myeloma patients 
would contain a topo IIβ specific cytotoxic agent (ex. XK469) combined with a nuclear 
export inhibitor (leptomycin B) followed by a topo II targeting cytotoxic agent (i.e..., 
etoposide).  Theoretically, the topo IIβ specific cytotoxic agent would induce cell death 
via topo IIβ activity while also elevating the cellular content of topo IIα protein.  A 
nuclear export inhibitor would be necessary to inhibit the export of topo IIα from the 
nucleus and thus, provide a molecular target in the nucleus for etoposide mediated DNA 
damage to occur.  This sequence could only be effective if topo IIα activity and levels 
remained sufficient to induce DNA damage.  Inhibitors of the proteasome represent a 
new class of cytotoxic agents with promising results in the treatment of hematological 
malignancies.  A proteasome inhibitor may be useful for maintaining the total cellular 
content of topo protein.   
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Sequestering proteins in the nucleus is gaining acceptance as a potential 
mechanism for inducing apoptosis in cancer cells (Yashiroda and Yoshida, 2003).  One 
recent study treated human chronic myelogenous leukemia cells with a tyrosine kinase 
inhibitor (STI571) to induce the nuclear import of BCR-Abl, a chimeric oncoprotein that 
activates mitogenic and anti-apoptotic cell signaling pathways when it is in the cytoplasm 
of cells (Vigneri and Wang, 2001).  The cells were then exposed to leptomycin B to block 
the export of BCR-Abl into the cytoplasm, thus trapping the protein in the nucleus. A 
general weakness of this drug combination is that leptomycin B inhibits all CRM-1 
mediated nuclear protein trafficking, but in vitro the drug combination selectively killed 
transformed cells expressing BCR-Abl chimera.  Furthermore, a phase I clinical trial of 
LMB demonstrated that the drug caused profound anorexia and malaise in patients 
(Newlands et al., 1996).  The clinical trials with LMB were discontinued but, the 
discovery that CRM is the molecular target of LMB instigated new efforts to reevaluate 
LMB for potential use in chemotherapy.  Safer leptomycin B analogues are currently 
being developed and investigated for their antitumor activity (Kau and Silver, 2003).  
Further investigations into the mechanisms of topo trafficking are needed to develop 
drugs specific for topo that may be less toxic in humans. 
 
14.8 Nuclear Content of Topo IIα is a Determinate of Topo II Drug Cytotoxicity. 
There has been one report to describe the role of the nuclear-cytoplasmic 
trafficking of topo IIα in de novo drug resistance (Oloumi et al., 2000).  The weight of 
the data has been limited to measuring the total cellular content of topo protein found 
either in drug-resistant cell lines (Mirski et al., 2000’ Davis et al., 1998; Kusumoto et al., 
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1996; Chen and Beck, 1995;) or in clinical specimens (Bauman et al., 1997).  Traditional 
practice has relied heavily on in vivo topo quantification as a prognostic indicator 
(Schrader et al., 2004; Lohri et al., 1997).  As such, there have been numerous reports to 
describe a correlation between topo protein expression with a positive response to topo 
inhibitors (Lohri et al., 1997; Kaufmann, et al., 1994).  However, there is a growing 
awareness in both scientific and clinical forums that monitoring the subcellular 
distribution of topo is also important when predicting drug responsiveness (Oloumi et al., 
1993). This is supported by several reports unable to explain alterations in drug 
sensitivity to topo targeting agents with alterations in either topo mRNA, topo protein 
expression or activity, or P-gp expression (Yamazaki et al., 1997; Davis et al., 1998; 
Yamazaki et al., 1997; Boege et al., 1993).  For example, eight breast epithelial cell lines, 
including six derived from breast cancers, were analyzed for mechanisms of drug 
resistance to camptothecin and etoposide (Davis et al., 1998). Drug resistance to 
camptothecin was attributed to low levels of topoisomerase I and activity. However, topo 
II levels and activity did not correlate with drug sensitivity or resistance to etoposide.  
These cells were analyzed for alterations in S-phase, doubling time, expression of mdr-1, 
p53, Bcl-2 and Bax proteins, but none of these parameters correlated with drug resistance 
to etoposide (Davis et al., 1998).  Only one cell line (BT47 cells) exhibited a high bcl-
2/Bax ratio and mutant p53 protein that was believed to contribute to decreased 
sensitivity to etoposide. The BT47 cells also displayed slow growth characteristics 
similar to that observed in the human myeloma cell line models, but the subcellular 
distribution of topo enzyme was not investigated in any of the cells explored. A shift 
toward the cytoplasm in the nucleo-cytoplasmic shuttling of topo II could have similar 
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effects as an overall decrease in protein levels, by decreasing the amount of active 
enzyme in the nucleus.  A similar study was performed that analyzed 14 unselected 
human lung cancer cell lines, including small-cell lung cancer and non-small cell lung 
cancer, for drug sensitivity to doxorubicin and etoposide, two topo II targeting agents 
(Yamazaki et al., 1997).  There was variation in drug sensitivity to etoposide and 
doxorubicin in all cell lines, but neither topo IIα content nor enzyme activity correlated 
with observed drug resistance. Other cellular parameters were not investigated, including 
the subcellular distribution of topo IIα.  This could be significant because a shift in the 
subcellular distribution of topo IIα would not be detectable by Western blot of topo II 
protein in whole cells. Furthermore, the observation of cytoplasmic topo IIα in patient 
samples described here suggests that there is a clinical role for the nucleo-cytoplasmic 
trafficking of topo that could explain de novo drug resistance previously described in 
other tumor types.  Thus, examining the nuclear and cytoplasmic content of topo protein 
by immunocytochemistry, especially topo IIα, is an important factor to consider when 
attempting to explain cellular drug resistance in the laboratory and clinical preparations. 
 
14.9 Possible Roles of Cytoplasmic Topo II. 
One of the potential consequences of exporting a pool of topo IIα to the 
cytoplasm is a decrease in sensitivity to topo inhibitors. This could result from 
cytoplasmic topo IIα serving as a drug sink by trapping VP-16 in this compartment.  This 
is supported by data demonstrating that the binding of VP-16 to topo II can occur in the 
absence of DNA (Burden et al., 1996). For this to occur, the amount of drug binding to 
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topo IIα would need to be sufficient to result in a decrease in drug- induced DNA 
damage. 
One question that has not been addressed is whether topo IIα is recruited to the 
cytoplasm to perform a specific function.  If topo II were acting on cytoplasmic 
substrates, there are at least two theoretical possibilities. First, topo II could be involved 
in maintaining the secondary structure of RNA or be involved in splicing RNA.  To date, 
there has been no direct evidence of topo II binding RNA.  A second possibility is that 
topo IIα could be recruited to the cytoplasm as an early apoptotic event.  I have 
hypothesized that a link exists between the calcium/calmodulin pathway and nuclear-
cytoplasmic trafficking of topoisomerase IIα during apoptosis in chapter 15, page 220.. 
 
14.10 Topoisomerase IIα Contains Two Functional Nuclear Export Signals. 
One question that we addressed was whether the cytoplasmic distribution of topo 
IIα was a result of increased nuclear export or decreased nuclear import. Identification of 
the direction and mechanism of transport across the nuclear membrane could lead to a 
better understanding of how to regulate the levels of active enzyme in the nucleus and 
thus, sensitize cells to topo inhibitors.  Human topo I (Mo et al., 2000), IIα (Mirski, et al., 
1999), and IIβ (Mirski, et al., 1999) have NLS that target them into the nucleus, but only 
recently has the mechanism of nuclear-export of these proteins been investigated (Mirski 
et al., 2003).  Sumoylation followed by redistribution of topo I from the nucleoli to the 
nucleoplasm in response to topotecan or camptothecin exposure has been reported (Mo et 
al., 2002; Rallabhandi et al., 2002).  The lack of data describing the shuttling of topo 
enzymes may be because topo is usually reported to occur in the nucleus of cells and a 
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cytoplasmic distribution of topo IIα has usually been ascribed to the expression of a 
truncated protein that has lost its C-terminal NLS (Mirski, et al., 2000). However, 
proteins that appear predominately nuclear may still shuttle between the nucleus and the 
cytoplasm if the rate of nuclear import is greater than the rate of nuclear export. Thus, 
demonstrating that a protein shuttles between the nucleus and cytoplasm requires 
defining the specific conditions that will shift the steady state kinetics toward nuclear 
export (Table 15).  Many conditions have been shown in vitro to alter the shuttling of 
proteins between the nucleus and cytoplasm, including changes in the cell-cycle and 
oxidative stress (Miyamoto et al., 2004; Kodiha et al., 2004; Greber and Gerace, 1995).  I 
have created a list of molecular and biochemical agents that have been demonstrated to 
alter specific transport pathways for different proteins.  This table demonstrates that 
certain cellular conditions or exogenous agents can induce a shift in the nuclear-
cytoplasmic trafficking of specific proteins.  In the accelerated-plateau cell model used in 
these experiments, it is likely that intensive cell-cell contact initiates a signal that induces 
the export of topo IIα to the cytoplasm. This is supported by the findings of others that a 
cytoplasmic distribution of topo IIα occurs in the outer-proliferating cells of multicell 
spheroids in Xenograft tumors when compared to monolayers formed by the same cells 
(Oloumi et al., 2000).   
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Table 15.  Inhibitors of the Nuclear-cytoplasmic Transport Pathway 
Biochemical Agent or MolecularFactor Target Mechanism 
Wheat germ aggultinin 
(Duverger et al., 1995) 
N-Acetylglucosamine 
moieties expressed on 
nucleoporins 
Non-specifically blocks protein 
import by binding sugar moieties 
on nucleoporins 
Anti-FG repeat antibodies 
(Snow et al., 1987) Importins/Nucleoporins 
Blocks importins from docking to 
the NPC 
Trichostatin A 
(Chen et al., 2001) NF-kB Blocks NF-kB import 
Cyclosporin A 
(Liu et al., 1991) Cyclophilin, NFAT 
Blocks NFAT import; 
cyclosporin-cyclophilin complex 
binds calcinuerin and inhibits 
dephosphorylation of NFAT 
3, 5–Bistrifluoromethyl pyrazoles 
(Trevillyan et al., 2001) NFAT 
Blocks NFAT import 
independently of calcinuerin 
Leptomycin B  
(Wolff et al., 1997) 
Myxobacterial cytotoxins (Ratjadones) 
(Koster et al., 2003) 
Chromosome region 
maintenance protein 1 (Crm-
1) 
Blocks CRM1 mediated nuclear 
export 
Arylene bis(methylketone) compounds 
(Dubrovsky et al., 1995) 
Pre-integration complex 
(PIC) 
Blocks import of HIV viral 
genome 
Arginine-rich RNA molecules (ARM) 
(Fineberg et al., 2003) HIV-1 Rev 
BSA molecules with ARM 
peptides block HIV-1 Rev protein 
import 
Transfected importin-β binding domain 
(Kutay et al., 1997); importin-β P446L 
mutant protein (Timinszky et al., 2002) 
Importin-β 
Dominant negative competitive 
inhibitor of importin α/β mediated 
import 
Cellular Stress:    UV radiation 
   Oxidative stress 
   Heat shock 
(Miyamoto et al., 2004; Kodiha et al.,  
  2004) 
Ran gradient Blocks nuclear export of importin-α  
Wortmannin 
(Arcaro and Wymann, 1993) 
Phosphatidylinositl-3 kinas 
(PI3 kinase) 
Blocks nuclear-cytoplasmic 
trafficking regulated by PI3kinase 
phosphorylation 
Okadaic acid 
Calyculin A 
(Elrick and Docherty, 2001) 
Phosphatase inhibitors Blocks some phosphorylation dependent trafficking. . 
Peptide Aptamers 
(Colas et al., 2000) 
Peptide containing a NLS or 
NES directed against any 
protein; may also contain 
ubiquitin. 
Redirects protein to the nucleus 
(NLS) or cytoplasm (NES);  
modify any protein with 
ubiquitin. 
Energy Regenerating System and 
 Ran Mix  
(Timinszky et al., 2002) 
Ran gradient Energy source for continued nuclear-cytoplasmic shuttling. 
Thapsigargin 
(Greber and Gerace, 1995) Calcium pump inhibitor 
Blocks signal-mediated protein 
import 
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14.11 Nuclear Transport and Oncogenesis. 
Alterations in nucleo-cytoplasmic protein transport are strongly implicated in a 
number of human diseases that include several autoimmune disorders (Wesierska-Gadek 
et al., 1996) and human cancers (Kau et al., 2004).  The data presented in this 
investigation describes a mechanism of drug resistance observed in human myeloma and 
leukemia cell lines that involves alterations in the subcellular distribution of topo IIα.  
The data presented herein suggests that alterations in the nuclear-cytoplasmic trafficking 
of topo IIα may have a role in cellular drug resistance in human myeloma and leukemia 
cell lines.  Several genetic abberations in the nuclear-cytolasmic transport machinery 
have been described in human leukemia and myeloma cells to date (Lam and Aplan, 
2001).  At least 17 chromosomal rearrangements in acute and chronic leukemia involve 
nucleoporin genes (Table 16) (Cronshaw and Matunis, 2004).  Nucleoporin 98 (Nup98) is 
implicated in 15 of those chromosomal rearrangements (Slape and Aplan, 2004; 
Takeshita, et al., 2004).  Furthermore, chromosomal translocations involving Nup98 and 
DNA topo I have been observed in some patients with therapy related acute myeloid 
leukemia, and in one patient with de novo AML (Iwase et al., 2003; Chen et al., 2003).  
Leukemias associated with nucleoporin gene rearrangements have been reported to be 
more refractory to therapeutic intervention. (Kakazu et al., 2001) suggesting that these 
gene rearrangements are involved in drug sensitivity.  Nup98 gene rearrangements have 
also been implicated in therapy related myelodysplasia (MDS) (Ahuja, et al., 1999), a 
group of bone marrow disorders that resemble hematologic malignancies.  MDS is 
characterized by the clonal expansion of stem cells and is most prevalent in individuals 
over 60 years of age.  Nup gene rearrangements in multiple myeloma have not been 
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reported.  In addition to the Nup family of proteins, the major vault protein (MVP) 
referred to as the lung resistance related protein (LRP), has been associated with 
decreased sensitivity to chemotherapy in multiple myeloma.  The MVP is a 
ribonucleoprotein complex that localizes to the nuclear pore complexes (Chugani et al., 
1993).  Results of a clinical study showed that expression of MVP in myeloma patients 
was associated with the multidrug resistance phenotype not mediated by MDR-1/P-gp 
(Rimsza et al., 1999).  Collectively, these studies illustrate the underlying role of nucleo-
cytoplasmic trafficking and the NPC in oncogenesis.  Furthermore, the significance of 
Nup98/topo I fusion proteins in conferring altered drug sensitivity represent one area of 
research yet to be explored  
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Table 16. Nucleoporin (NUP)  Gene Rearrangements Associated with Hematological Malignancies* 
Nucleoporin Gene 
Rearrangement FUSION GENE 
Protein 
Characteristics Disease References 
t(7;11)(p15;p15) NUP98/HOXA9 Homeodomain transcription factor 
AML, CML, 
MDS 
Nakamura et al., 
1996 
t(2;11)(q31;p15) NUP98/HOXD13 Homeodomain transcription factor AML Arai et al., 2000 
t(1;11)(q23;p15) NUP98/PMX1 Homeodomain transcription factor MDS/AML 
Nakamura et al., 
1999 
t(7;11)(p15;p15) NUP98/HOXA11 Homeodomain transcription factor CML, AML Suzuki et al., 2002 
t(11;12(p15;q13) NUP98/HOXC11 Homeodomain transcription factor AML Gu et al., 2003 
t(7;11)(p15;p15) NUP98/HOXA13 Homeodomain transcription factor AML 
Taketani et al., 
2002 
t(2;11)(q31;p15) NUP98/HOXD11 Homeodomain transcription factor AML Terui et al., 2003 
t(11;12)(p15;q13) NUP98/HOXC13 Homeodomain transcription factor AML 
Panagopoulos et 
al., 2003 
inv11(p15;q22) NUP98/DDX10 RNA helicases AML, MDS Arai et al., 1997 
t(11;20)(p15;q11) NUP98/TOP1 DNA topo I 
de novo AML; 
 t-AML, t-
MDS; 
polycethemia 
vera 
Potenza et al., 
2004 
Iwase et al., 2003 
Chen et al., 2003 
t(10;20;11)(q24;q11;p15) NUP98/TOP1 DNA topo I t-MDS Panagopoulos et al., 2002 
t(4;11)(q21;p15) NUP98/RAP1GDS1 Nucleotide exchange factor T-ALL Hussey et al., 1999 
t(10;11)(q25;p15) NUP98/ADD3 Membrane-cytoskeleton T-ALL 
Lahortiga et al., 
2003 
t(5;11)(q35;p15) NUP98/NSD1 SET domain AML La Starza et al., 2004 
t(8;11)(p11.2;p15) NUP98/NSD3 SET domain AML Rosati et al., 2002 
t(6;9)(p23;q34) NUP214/DEK DNA binding AML, MDS Boer et al., 1998 
t(6;9)(p23;q34) NUP214/SET 
Nucleosome 
assembly protein 
family 
AML Saito et al., 2004 
*Reviewed in reference Lam and Aplan, 2001. 
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Chapter Fifteen 
Future Considerations 
 
15.1 Phosphorylation 
 Phosphorylation has also been shown to be important in regulating the 
subcellular localization of many proteins and could have a role in topo IIα trafficking 
(Harreman et al., 2004).  This is suggested by the finding that the outer proliferating cells 
of multi-cell spheroids contain a cytoplasmic pool of topo IIα and have a 10-fold 
decrease in the phosphorylation state of the enzyme when compared to monolayers 
containing nuclear topo IIα (Oloumie et al., 2000).  Phosphorylation has been extensively 
investigated for yeast DNA topo IIα and to a lesser extent in topo IIβ.  Phosphorylation 
 
Table 17. Phosphorylation Sites in DNA Topoisomerase IIα Established In vitro 
Kinase Residue Reference 
PKC Serine 29 Wells et al., 1995 
Presumed to be  
Casein Kinase 1 or 2  Serine 1106 Chikamori et al., 2003 
Casein Kinase 2 Serine 1377 Serine 1525 Wells et al., 1994 
Casein Kinase 2 Threonine 1343 Daum and Gorbsky, 1998 Ishida et al., 1996 
Casein Kinase 2 Serine 1469 Escarguiel et al., 2000 
One or more proline 
directed kinases 
 
Serine 1213 
Serine 1247 
Serine 1354 
Serine 1361 
Serine 1393 
Wells and Hickson, 1995 
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events in topo II in human cells is less well characterized (Austin and Marsh, 1998) 
Several serine residues in topo IIα are phosphorylated in vitro by CK2 and PKC (Table 
17). Many of the phosphorylation sites are located near the NLS in the carboxyl terminus 
(Figure 52, page 192).  For topo IIα, the phosphorylation status at S29, S1213, S1247, 
S1354, S1361, S1393 vary throughout the cell cycle.  In contrast, phosphorylation at 
S1377, S1525, and T1343 remains constant throughout the cell cycle (Austin and Marsh, 
1998).  To predict additional protein kinase recognition motifs, the complete amino acid 
sequence was entered into Scansite, a computer algorithm developed at Massachusetts 
Institute of Technology. Scansite 2.0 uses a library of phosphorylation data to predict 
phosphorylation sites and protein-protein binding domains in any protein (Obenauer et 
al., 2003). 
 
Table 18. Predicted Phosphorylation Sites in DNA Topoisomerase IIα 
Kinase Group Amino Acid Residue Recognition Sequence 
Src SH3  Proline 887 MDGEEPLPMLPSYKN 
Protein kinase C Serine 1426 TAAKSQSSTSTTGAK 
Protein kinase C Threonine 193 YKKMFKQTWMDNMGR 
Calmodulin dependent kinase IIγ Serine 230 LSKFKMQSLDKDIVA 
Calmodulin dependent kinase IIγ Threonine1279 TKTKKQTTLAFKPIK 
Casein kinase 2 Serine 1337 LDSDEDFSDFDEKTD 
Casein kinase 2 Serine 1106 DEEENEESDNEKETE 
   
 216
The computer program can recognize 62 protein kinase or protein binding motifs that 
includes Ser/Thr or Tyr kinases and SH2 and SH3 binding domains.  Figure 32 is the 
graphical output showing predicted phosphorylation sites that have not been reported in 
the literature. Table 18 summarizes the protein kinase recognition sequences identified 
under high stringency.  As expected, topo IIα has recognition motifs for protein kinase C, 
casein kinase 2 and proline dependent Ser/Thr kinases. Several in vitro studies have 
reported similar phosphorylation occurrences by these kinases, albeit different amino acid 
residues  
 
15.2 Calmodulin Dependent Kinases  
Calmodulin dependent kinase-IIγ (CaMK-IIγ) is one unexpected result in the 
Scansite report. CamK-IIγ belongs to the family of calmodulin dependent kinases 
(CaMK).  Calmodulin is a cytosolic protein that responds to intracellular calcium levels 
by activating various calcium-calmodulin dependent enzymes, such as calmodulin 
dependent kinases (CaMK) (Tombes et al., 1995).  There are six different CaM kinases 
but, only CaMK I and CaMK II are consistently expressed in proliferative cells (Tombes 
and Krystal, 1997).  CaMK II was originally believed to be encoded by a single gene.  
For example, CaMK-IIγ has for different isozymes, IIγB, IIγC, IIγG, and IIγH, generated 
by alternative splice sites.  In one study, panels of human tumor and non-tumor cell lines 
were examined for expression of all CaMK-II protein isoforms (Tombes and Krystal, 
1997).  The tumor cell lines included several human breast cancer cell lines, colon 
adenocarcinoma, human neuroblastoma, and CCRF-CEM lymphoblastic leukemia cells, 
whereas NIH 3T3 mouse fibroblasts, mammary epithelia, and mouse embryo fibroblasts 
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were the non transformed cell lines examined.  The tumor cell lines expressed an entirely 
different spectrum of CaMK-II isozymes than adult neuronal tissue.  All tumor cell lines 
(including the neural derived cells) lacked CamK-IIα and expressed several alternative 
splice variants.  CaMK- IIγG and IIγH were preferentially expressed in tumor cell lines 
as compared to undifferentiated fibroblasts.  This data establishes that CaMK-IIγ is 
expressed in a variety of human cancer cell lines, including the hematological cell line, 
CCRF-CEM. Thus, it is possible that CaMK-IIγ is expressed in other hematological cell 
lines such as, human myeloma H929 cells. Expression of CaMK-IIγ in H929 cells would 
be significant if, topo IIα is regulated by CaMK-IIγ phosphorylation. 
Identification of a CaMK phosphorylation site in topo IIα could be significant 
factor in regulating topo IIα subcellular distribution for several reasons.  First, topo IIα 
has been shown to be hypophosphorylated in drug resistant cell lines in a calcium 
dependent manner (Grabowski et al., 1998; Aoyama et al., 1998; Ganapathi et al., 1996). 
Secondly, the complete amino acid sequence for topo IIβ was entered into Scansite but, 
does not have a calmodulin dependent kinase recognition motif even when the protein 
was scanned under low stringency. This is significant because topo IIβ subcellular 
localization is not altered by cell-density in the same manner as topo IIα suggesting that 
different cellular conditions can regulate the differential localization of the two enzymes.  
Thirdly, calcium levels present in the ER cisternae have been reported to regulate 
nuclear-cytoplasmic trafficking of proteins such that, when calcium levels are low, the 
NPC restricts the nuclear cytoplasmic trafficking of proteins (Greber and Gerace, 1995).  
It has been suggested that calcium stores signal the NPC when the cell senses stress such 
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as, oxidative stress, DNA damage, or proteins unfolding in the ER.  Thus, there could be 
a link between NPC trafficking and early apoptotic events.  
There is increasing evidence that calcium signaling pathways are intimately 
involved with apoptotic regulatory pathways.  BCL-2, Bax, Bak, and Bid are apoptotic 
regulatory proteins that exert their effect in part by regulating calcium mobilization 
between the ER and mitochondria. Bax, Bid, and Bcl-2 localize in the ER, the central 
intracellular calcium stores of the cells. BCL-2 mediates the release of ER calcium pools, 
which results in a concomitant increase in mitochondrial calcium uptake (Oakes et al., 
2003; Foyouzi-Youssefi et al., 2000). Bax and Bak, promote apoptosis in part by 
increasing calcium transfer from the ER to the mitochondria, which results in cytochrome 
c release during apoptosis (Nutt et al., 2002).  Bax and Bid have also been shown to 
localize on the nuclear envelope and move from the cytoplasm to the mitochondria in 
response to camptothecin exposure (Gajkowska et al., 2004).  This data suggests that 
camptothecin may initiate apoptosis in a via Bax and Bid in a calcium dependent manner. 
Calcium release from the ER may be linked with oxidative stress, which has been 
one physiological condition demonstrated to modulate NPC mediated protein trafficking.  
This is significant because the tumor microenvironment can contribute to hypoxia. For 
example, solid tumors that are resistant to topo II containing chemotherapy usually have 
regions of low oxygen, which are not observed in normal tissue (Tomida and Tsuruo, 
1999).  Although multiple myeloma is not considered a solid tumor, the disease is 
characterized by anemia, which has been shown to induce or hasten hypoxia (Sordet et 
al., 2004; Mittelma, 2003).  Furthermore, when Bid is expressed in hypoxic cells, it 
results in increased sensitivity to the topoisomerase II inhibitor etoposide (Erler et al., 
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2004).  Downregulation of Bid was attributed to the decrease sensitivity to etoposide; 
however, the subcellular localization of topo II enzymes was not investigated.  Likewise, 
the total amount of Bcl2, Bid and Bax were not investigated in the natural-plateau or 
accelerated-plateau human myeloma cell line models.  Thus, topo IIα could be regulated 
by calmodulin dependent kinase activity such that, when calcium is released from the ER 
under conditions of stress, topo becomes phosphorylated and degraded. In another study, 
proteasomes were found to accumulate in the nucleus of cells grown under stress 
conditions (glucose starvation) (Ogiso et al., 2002). This could partially explain how 
tumor cells evade etoposide toxicity and yet, maintain topo II content for cell division- by 
sequestering topo IIα in the cytoplasm away from the nuclear proteasomes.   
Furthermore, repetitive hypoxia, which could be prevalent in multiple myeloma patients 
who are chronically exposed to DNA damaging agents, could select for drug resistant 
cells (Weinmann et al., 2004).  
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Chapter Sixteen 
 Concluding Remarks 
 
Resistance to chemotherapeutic drugs is a major obstacle in the treatment of 
leukemia and myeloma. We have reported that resistance to topo IIα poisons, such as VP-
16 is found to increase dramatically with concurrent increases in cell density.  The high-
cell density of myeloma cells in the bone marrow may mimic the high-density plateau 
phase conditions that we established in vitro, and thus  these cells may export 
endogenous topo IIα. from the nucleus to the cytoplasm in vivo. In order for topo targeted 
chemotherapy to function, topoisomerase must have access to the nuclear DNA. Thus, 
the nuclear export of topo IIα must be added to the list of potential mechanisms of 
resistance to topo poisons. It is unique in that it does not require drug exposure and may 
mimic the high cell density microenvironment seen in the bone marrow of patients with 
multiple myeloma. Further defining this mechanism, and possibly modulating export, 
may lead to methods to preclude this avenue of resistance. Clinical drug resistance is 
likely to be a multifactorial phenomeon and enhancing drug activity of available agents 
will likely require a multifaceted approach. 
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Appendix A:  The Complete Amino Acid Sequence for Human DNA Topoisomerase I 
 
  1 MSGDHLHNDS QIEADFRLND SHKHKDKHKD REHRHKEHKK EKDREKSKHS NSEHKDSEKK 
 61 HKEKEKTKHK DGSSEKHKDK HKDRDKEKRK EEKVRASGDA KIKKEKENGF SSPPQIKDEP  
121 EDDGYFVPPK EDIKPLKRPR DEDDADYKPK KIKTEDTKKE KKRKLEEEED GKLKKPKNKD  
181 KDKKVPEPDN KKKKPKKEEE QKWKWWEEER YPEGIKWKFL EHKGPVFAPP YEPLPENVKF  
241 YYDGKVMKLS PKAEEVATFF AKMLDHEYTT KEIFRKNFFK DWRKEMTNEE KNIITNLSKC  
301 DFTQMSQYFK AQTEARKQMS KEEKLKIKEE NEKLLKEYGF CIMDNHKERI ANFKIEPPGL  
361 FRGRGNHPKM GMLKRRIMPE DIIINCSKDA KVPSPPPGHK WKEVRHDNKV TWLVSWTENI 
421 QGSIKYIMLN PSSRIKGEKD WQKYETARRL KKCVDKIRNQ YREDWKSKEM KVRQRAVALY  
481 FIDKLALRAG NEKEEGETAD TVGCCSLRVE HINLHPELDG QEYVVEFDFL GKDSIRYYNK 
541 VPVEKRVFKN LQLFMENKQP EDDLFDRLNT GILNKHLQDL MEGLTAKVFR TYNASITLQQ  
601 QLKELTAPDE NIPAKILSYN RANRAVAILC NHQRAPPKTF EKSMMNLQTK IDAKKEQLAD  
661 ARRDLKSAKA DAKVMKDAKT KKVVESKKKA VQRLEEQLMK LEVQATDREE NKQIALGTSK  
721 LNYLDPRITV AWCKKWGVPI EKIYNKTQRE KFAWAIDMAD EDYEF 
 
Figure 54. The Complete Amino Acid Sequence for Human DNA Topoisomerase I. 
(accession number NP 001059). The NLS is underlined. 
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Appendix B: The Complete Amino Acid Sequence for Human DNA Topoisomerase IIβ 
 
   1 MAKSGGCGAG AGVGGGNGAL TWVNNAAKKE ESETANKNDS SKKLSVERVY QKKTQLEHIL    
  61 LRPDTYIGSV EPLTQFMWVY DEDVGMNCRE VTFVPGLYKI FDEILVNAAD NKQRDKNMTC   
 121 IKVSIDPESN IISIWNNGKG IPVVEHKVEK VYVPALIFGQ LLTSSNYDDD EKKVTGGRNG   
 181 YGAKLCNIFS TKFTVETACK EYKHSFKQTW MNNMMKTSEA KIKHFDGEDY TCITFQPDLS  
 241 KFKMEKLDKD IVALMTRRAY DLAGSCRGVK VMFNGKKLPV NGFRSYVDLY VKDKLDETGV 
 301 ALKVIHELAN ERWDVCLTLS EKGFQQISFV NSIATTKGGR HVDYVVDQVV GKLIEVVKKK  
 361 NKAGVSVKPF QVKNHIWVFI NCLIENPTFD SQTKENMTLQ PKSFGSKCQL SEKFFKAASN 
 421 CGIVESILNW VKFKAQTQLN KKCSSVKYSK IKGIPKLDDA NDAGGKHSLE CTLILTEGDS  
 481 AKSLAVSGLG VIGRDRYGVF PLRGKILNVR EASHKQIMEN AEINNIIKIV GLQYKKSYDD  
 541 AESLKTLRYG KIMIMTDQDQ DGSHIKGLLI NFIHHNWPSL LKHGFLEEFI TPIVKASKNK 
 601 QELSFYSIPE FDEWKKHIEN QKAWKIKYYK GLGTSTAKEA KEYFADMERH RILFRYAGPE  
 661 DDAAITLAFS KKKIDDRKEW LTNFMEDRRQ RRLHGLPEQF LYGTATKHLT YNDFINKELI  
 721 LFSNSDNERS IPSLVDGFKP GQRKVLFTCF KRNDKREVKV AQLAGSVAEM SAYHHGEQAL  
 781 MMTIVNLAQN FVGSNNINLL QPIGQFGTRL HGGKDAASPR YIFTMLSTLA RLLFPAVDDN 
 841 LLKFLYDDNQ RVEPEWYIPI IPMVLINGAE GIGTGWACKL PNYDAREIVN NVRRMLDGLD  
 901 PHPMLPNYKN FKGTIQELGQ NQYAVSGEIF VVDRNTVEIT ELPVRTWTQV YKEQVLEPML   
 961 NGTDKTPALI SDYKEYHTDT TVKFVVKMTE EKLAQAEAAG LHKVFKLQTT LTCNSMVLFD  
1021 HMGCLKKYET VQDILKEFFD LRLSYYGLRK EWLVGMLGAE STKLNNQARF ILEKIQGKIT 
1081 IENRSKKDLI QMLVQRGYES DPVKAWKEAQ EKAAEEDETQ NQHDDSSSDS GTPSGPDFNY 
1141 ILNMSLWSLT KEKVEELIKQ RDAKGREVND LKRKSPSDLW KEDLAAFVEE LDKVESQERE 
1201 DVLAGMSGKA IKGKVGKPKV KKLQLEETMP SPYGRRIIPE ITAMKADASK KLLKKKKGDL 
1261 DTAAVKVEFD EEFSGAPVEG AGEEALTPSV PINKGPKPKR EKKEPGTRVR KTPTSSGKPS 
1321 AKKVKKRNPW SDDESKSESD LEETEPVVIP RDSLLRRAAA ERPKYTFDFS EEEDDDADDD 
1381 DDDNNDLEEL KVKASPITND GEDEFVPSDG LDKDEYTFSP GKSKATPEKS LHDKKSQDFG 
1441 NLFSFPSYSQ KSEDDSAKFD SNEEDSASVF SPSFGLKQTD KVPSKTVAAK KGKPSSDTVP 
1501 KPKRAPKQKK VVEAVNSDSD SEFGIPKKTT TPKGKGRGAK KRKASGSENE GDYNPGRKTS 
1561 KTTSKKPKKT SFDQDSDVDI FPSDFPTEPP SLPRTGRARK EVKYFAESDE EEDDVDFAMF 
1621 N 
Figure 55.  The Complete Amino Acid Sequence for Human DNA Topoisomerase IIβ 
(accession Number NP 001059). Nuclear export signal (NES) is double-underscored. A 
specific nuclear localization signal has not been identified in topo IIβ, but the C-terminus 
is important for targeting the enzyme to the nucleus (Mirski e al., 2003). 
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Appendix C: Gene Rearrangements in Hematological Malignancies 
 
Table 19.Oncogenes and Fusion Proteins in Hematological Malignacies* 
Oncogene Symbol Functional Product Diseases 
Abelson Murine Leukemia 
Viral Oncogene Homolog 1 ABL1 
A nuclear and cytoplasmic non-receptor 
tyrosine kinase activity implicated in cell 
differentiation, cell division, and cell adhesion.  
When expressed as Philadelphia 
translocation its activity is 
associated with CML 
Acute Myeloid Leukemia-1 AML-1 
Transcription factor (activator) for various 
hematopoietic specific genes. Expressed during 
differentiation and hematopoesis. 
Associated with acute non-
lymphocytic leukemia. 
Acute Myeloid Leukemia-1 / 
Myeloid Translocation Gene 8 AML1/MTG8 
Fusion protein as a result of t(8;21). Proposed 
role in preventing cell differentiation and thus, 
propagating leukemic blast cells 
Associated with de novo acute 
myeloid leukemias 
Receptor Tyrosine Kinase AXL Receptor tyrosine kinase.  Hematopoietic cancers 
B-cell CLL / Lymphoma 2 BCL2 
B-cell leukemia/lymphoma protein is localized 
in the inner mitochondrial membrane. Blocks 
programmed cell death. 
Associated with leukemias; 
linked with follicular lymphoma 
when overexpressed as a result 
of the t(14;18) translocation. 
Breakpoint Cluster Region BCR 
GTPase activating protein for RAC1 and 
CDC42; exhibits serine/threonine kinase 
activity 
Translocations t(9;22) BCR-
ABL and  
t(4;22) PDGFRA-BCR 
associated with CML 
Breakpoint Cluster Region / 
Abelson Murine Leukemia 
Viral Oncogene Homolog 1 
BCR/ABL 
Fusion protein with constitutive tyrosine kinas 
activity as a result of 9:22 chromosomal 
translocation.  
CML, ALL 
Cyclin D1 CCND1 
Important for cell cycle regulation; 
Dysregulation of cyclin D1 associated with 
t(11;14) 
Multiple myeloma 
*Huret, J.-L. et al., 2003. Atlas of Genetics and Cytogenetics in Oncology and Haematology. [online] 
http://www.infobiogen.fr/services/chromcancer/ (accessed 2004). 
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Appendix C: (Continued) 
Table 19 continued. 
 
DEK Oncogene / Nucleoporin 
214D 
DEK/CAN 
DEK is  ubiquitous protein expressed in the 
nucleus of cells and interacts with histones.; 
fusion protein formed as a result of t(6;9) 
translocation. 
Associated with poor prognosis 
in AML. 
Transcription Factor 3 / pre-B-
cell leukemia transcription 
factor 1 
E2a/Pbx1 
Chimeric transcription factor (activator) 
resulting from t(1;19) chromosomal 
translocation. 
pre-B-cell Acute Lymphoblastic 
Leukemia 
Erythroblastosis Virus E26 
Homolog ETS-1 
Transcription factor involved in extracellular 
matrix remodeling; cell migration; tumor 
invasion 
Lymphomas 
Monocytic leukemia 
Fibroblast Growth Factor 3 FGFR3 Receptor for acidic and basic fibroblast growth factors. 
Chromosomal translocation 
t(4;14) implicated in multiple 
myeloma 
Homeobox-11 HOX-11 Homeobox protein; DNA binding protein Found to be deregulated in acute lymphoblastic T-cell leukemia 
Interluekin-3 IL-3 Cytokine involved in cell survival, proliferation, and differentiation. 
Overexpression of protein 
associated with acute pre B-cell 
leukemia 
Lymphoid Blast Crisis LBC guanine nucleotide exchange factor Myeloid leukemias 
Lymphocyte Specific Kinase LCK src family tyrosine kinase critical for T-cell development and activation T-cell lymphoma 
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Appendix C (Continued) 
Table 19 continued. 
Lymphoblastic Leukemia 
Derived Sequence 1 Lyl-1 Basic helix-loop-helix protein.  
Involved in T-cell ALL through 
t(7:19) which involves Lyl-1 and 
T-cell receptor beta chain genes. 
Mixed Lineage Leukemia MLL 
Transcription factor involved in maintenance of 
HOX gene expression by hematopoietic stem 
and progenitor cells 
Associated with poor prognosis 
in acute myeloid leukemia 
 
Mixed Lineage Leukemia / 
Lymphoid Nuclear Protein 4 
MLL/LAF4 Fusion protein resulting from t(4;11) translocation.  
70-80% of all ALL and 50-60% 
of AML infants; Reported in 
secondary leukemias after topo II 
inhibitors; poor prognosis 
Musculoaponeurotic 
Fibrosarcoma MAF 
Transcription factor; overexpression implicated 
in cell proliferation and pathological 
interactions with bone marrow stroma. 
Multiple myeloma 
Myeloblastosis Myb  
A family of DNA binding proteins containing 
tandem repeats of a helix-turn-helix motif. 
Expression in hematopoietic cells is necessary 
fo proliferation. 
Chromosomal aberrations at the 
6q breakpoint linked with colon 
carcinoma, leukemias, and 
lymphomas 
Myeloctyomatosis  c-Myc 
Transcription factor involved in cell cycle 
regulation, apoptosis, metabolism, cell 
differentiation, and cell adhesion. 
Overexpressed in most 
hematogenic malignancies. Most 
well characterized in Burkitts 
lymphoma. 
Myosin, heavy polypeptide 11, 
smooth muscle  / Core-binding 
factor beta subunit 
MYH11/CBFB 
CBFB is a transcription factor which master-
regulates a host of genes specific to hemtopoesis 
and osteogenesis. Pericentric inversion 
Inv(16)(p13;q22) fuses CBFB with MYH11 
Acute Myeloid Leukemia 
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Table 19 continued. 
Nucleophosmin1 / 
Anaplasticlymphoma kinase NPM/ALK 
ALK is a receptor tyrosine kinase; The t(2;5) 
translocation results in a fusion protein with 
NPM; accumulates in the nucleoli of neoplastic 
cells. 
Non-Hodgkin’s lymphomas; 
Anaplastic lymphoma; Large cell 
lymphomas 
pre-B cell Leukemia 
Transcription Factor 3  Pbx1/E2A 
fusion protein that activates WNT-16 
expression. WNT-16 expression contributes to 
t(1;19) pre-B ALL 
Acute pre B-cell leukemia 
PIM1 Oncogene PIM-1 serine/threonine kinase T-cell lymphoma 
Promyelocytic Leukemia / 
Retinoic Acid Receptor alpha 
 
 PML/RAR 
 
PML is a RING finger and nuclear matrix 
associated phosphoprotein. Functions in growth, 
transformation and tumor suppressor activity. 
Fusion with RAR may abrogate the corepressor 
function. 
 
Acute premyelocytic leukemia 
Reticuloendotheliosis  REL Transcription factor; role in differentiation and lymphopoiesis. 
Gene amplification associated 
with Hodgkin’s lymphoma 
Suppressor of variegation, 
Enhancer of zeste and Trithroax 
/ Nucleoporin 214 
 SET/CAN 
CAN is a nucleoporin that may serve as a 
docking site in receptor mediated nuclear 
import; Fusion protein resulting from t(6;9) 
translocation.  
Acute myeloid leukemia 
Stem Cell Leukemia SCL 
Transcription factor; t(1:14) in leukemia cell 
lines results in deletion between delta chain 
diversity regions 
Acute T-cell leukemia 
Transforming Acidic Coiled-
coil Containing Gene 3 TACC3 
Centrosomal proteins that can interact with 
microtubules. 
t(4;14) implicated in Multiple 
myeloma. 
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